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GENERAL INTRODuCTION
1. Inflammation
Inflammation is the body’s way of responding to disturbances in homeostasis. 
Depending on the triggering event and the site of inflammation, the inflammatory response 
has different physiological purposes and pathological consequences (Figure 1) [1]. 
Inducers of inflammation are either foreign molecules or molecules derived from the 
body itself (self-molecules). These molecules, of which a selection is listed in Table 1, 
often contain highly conserved molecular patterns that are recognized by specific 
receptors that are expressed by cells of the immune system, but also by other cell types. 
Receptor binding of these molecularly conserved patterns leads to the production and 
secretion of inflammatory mediators that alter tissue functionality such that the tissue 
adapts to the harmful insult and homeostasis can be restored [1]. 
Foreign molecules Self molecules
Inammatory 
inducer
Physiological 
reaction
Pathological 
consequences
INFLAMMATION
Tissue injuryInfection
Fibrosis, metaplasiaInammation, tissue 
damage and sepsis
“New” homeostatic
environment
“New” homeostatic
environment
“New” homeostatic
environment
Development of
autoimmune diseases
Tissue stress and malfunction
Adaptation and restorationHost defense against infection Tissue repair
Figure 1. Inducers of inflammation. 
Inducers of inflammation are either foreign molecules or molecules derived from the body itself (self-
molecules) and can have different physiological purposes and pathological consequences. Modified 
from Medzhitov [1].
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2. The systemic inflammatory response syndrome and the compensatory anti-
inflammatory response syndrome
The systemic inflammatory response syndrome (SIRS) is a complex host response 
inflicted by a variety of clinical insults, such as severe hemorrhage, ischemia-reperfusion 
injury, pancreatitis, and sepsis [2]. SIRS is characterized by (a) hyperthermia or 
hypothermia; (b) tachycardia; (c) tachypnea or hyperventilation; (d) leukocytosis; and 
(e) excessive production of pro-inflammatory mediators, of which a selection is listed in 
Table 2 [3]. The incidence of SIRS in the Western world is high and is even expected 
to increase in the near future [4,5]. SIRS occurs in more than one third of all in-hospital 
patients, in 50% of all intensive care unit (ICU) patients, and in 80% of all surgical ICU 
patients [4,5]. In developing countries the incidence of SIRS is even higher than in the 
Western world [6]. 
The SIRS-associated uncontrolled and excessive production of pro-inflammatory 
mediators can lead to multiple organ dysfunction syndrome (MODS) and death. Anti-
inflammatory mediators, of which a selection is also listed in Table 2, are produced 
nearly concomitantly with the initial production of pro-inflammatory mediators [7,8]. 
The production of anti-inflammatory mediators is known as the compensatory anti-
inflammatory response syndrome (CARS) and is essential to control SIRS (Figure 2) 
[8,9]. Initially, the pro- and anti-inflammatory responses take place locally in the affected 
Table 1. A selection of inducers of inflammation.
Foreign molecules (pathogen-
associated molecular patterns)
Reference Self-molecules (danger-associated 
molecular patterns)
Reference
Cell membrane-derived Cell and tissue-derived
peptidoglycan 95,96 lipoprotein 97
zymosan 98 heat shock protein 99
lipopolysaccharide 96 high-mobility group box 1 100
mannan 101
Plasma-derived
Intracellular-derived complement 102
bacterial and viral nucleic acid 104,105 Hageman factor 103
Secreted factors Extra cellular matrix-derived
super antigen 106 collagen 107
pore forming exotoxin 108 hyaluronan 109
proteases 110 fibronectin 111,112
fMLP 113
fMLP, formyl-methionyl-leucyl-phenylalanine.
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Table 2. A selection of pro- and anti-inflammatory cytokines that are involved in SIRS and CARS.
Inflammatory cytokines Origin Target Reference
Pro- Anti-
IL-1β monocytes,macrophages,
keratinocytes
macrophages, lymphocytes, 
fibroblasts, endothelial cells
114-116
IL-1RA endothelial cells, 
myeloid cells, hepatocytes
myeloid cells, hepatocytes 117-121
IL-2 T-cells T-cells 122,123
IL-4 T-cells, mast cells B-, T-cells 124-127
IL-6 IL-6 T-cells, macrophages,
endothelial cells
B-, T-cells,  hepatocytes 128,129
IL-6SR monocytes, macrophages,
T-cells
T-cells,
endothelial cells
128
IL-10 monocytes, macrophages,
T-cells
monocytes, macrophages,
T-cells
130,131
IL-12 NK-, T-cells NK-, T-cells 132
IL-13 T-cells phagocytes 133,134
IL-18 macrophages NK-, T-cells 135
IL-22 NK-, T-cells fibroblasts 136,137
IL-23 T-cells T-cells 138
LT-α T-cells endothelial cells,
T-cells
139
TNF-α monocytes, macrophages monocytes, macrophages, 
hepatocytes
140
TNF-SRI stromal cells, 
myeloid cells, 
B- and T- cells
stromal cells,
myeloid cells, B- and T- cells
7,141-144
TNF-SRII stromal cells,
myeloid cells,
B- and T- cells
stromal cells,
myeloid cells, B- and T- cells
7,141-144
TGF-β monocytes, dendritic cells,
T-cells, fibroblasts,
epithelial cells
 fibroblasts, endothelial cells, 
epithelial cells
145-148
IFN-γ lymphocytes monocytes, macrophages 149
Abbreviations: IL, interleukin; TNF, tumor necrosis factor; SR, soluble receptor; IFN, interferon; RA, 
receptor antagonist; LT, lymphotoxin. 
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tissue and can be viewed as a battle between opposite forces. When the level of 
mediators is correctly balanced, homeostasis is restored. However, in case of excessive 
production of pro-inflammatory mediators in the affected tissue, systemic spillover of 
pro-inflammatory mediators can occur that affects other organs and induces pathology. 
When CARS is too strong and anti-inflammatory mediators are detected systemically, 
a profound state of immune paralysis can develop that makes the individual highly 
susceptible to infections [8,9].
2.1 Immune cells and acute systemic inflammation 
Systemic spillover of pro-inflammatory mediators activates endothelial cells as well 
as other cells, including neutrophils and monocytes [10]. Subsequently, these cells start 
producing inflammatory mediators that activate other leukocytes, such as NK-, T-, and 
B-lymphocytes, leading to an uncontrolled and massive production of inflammatory 
mediators (Figure 3) [11,12]. Thereafter, leukocytes migrate from the circulation into 
vital tissues. 
The extravasation process of leukocytes requires a multistep cascade of adhesive 
and migratory events that are mediated by three classes of adhesion molecules, the 
selectins, integrins and adhesion receptors of the immunoglobulin super family. The 
extravasation process of leukocytes can be divided into five sequential stages: (a) 
Figure 2. Schematic representation of SIRS and CARS following a severe clinical insult. 
Nearly concomitant with the initial production of pro-inflammatory mediators starts the production of 
anti-inflammatory mediators. The balance between pro- and anti-inflammatory mediators determines 
the inflammatory status of the individual.
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selectin-mediated leukocyte attraction; (b) integrin-mediated intravascular crawling; 
(c) firm arrest of leukocytes to the endothelium; (d) chemokine-induced leukocyte 
activation; and finally (e) transendothelial migration [13,14]. Subsequently, through a 
chemokine gradient, leukocytes migrate to the inflamed loci, where they release their 
contents that affect local cell and tissue function [10,13,15]. Depending on the intensity 
of this response, the tissue is either completely shut down or an attempt is made to 
restore homeostasis, with some pathological changes [16]. 
Only a small percentage of SIRS patients die during the initial stage of inflammation, 
as a result of severe tissue dysfunction and destruction [10,17]. The primary tissues 
affected during the initial stage of SIRS are sequentially lungs, gut, liver, kidneys, 
and eventually the central nervous system [18]. Most patients that survive the hyper-
inflammatory response enter a protracted stage of immunosuppression that has been 
termed immune paralysis [19]. 
2.2 Immune cells and immune paralysis 
Immune paralysis is the inability to generate an immune response against foreign 
molecules and molecules derived from the body itself [20,21]. Several cellular 
mechanisms, such as the generation of regulatory T-lymphocytes and myeloid 
suppressor cells contribute to this process [22,23]. However, the most important 
contributing mechanism is apoptosis-induced depletion of immune cells, including 
antigen presenting cells (APC), B-, and T-lymphocytes (Figure 4) [24,25]. It is not 
only the apoptosis-induced loss of immune cells that contributes to immune paralysis. 
Apoptosis also induces anergy in surviving cells, as ingestion of apoptotic bodies 
by phagocytes reduces the expression of co-stimulatory molecules, such as CD80, 
CD86 and CD40L, on these cells [26]. Furthermore, phagocytosis of apoptotic bodies 
stimulates the production of anti-inflammatory cytokines, such as IL-10 and TGF-β, by 
these cells [20]. Anti-inflammatory cytokine production can also be induced through 
direct cell contact with apoptotic cells [27]. In addition, apoptosis-induced loss of gastro-
intestinal epithelial cells increases gut permeability with consequent translocation of 
microbial flora from the intestine into the circulation [28]. This, in combination with the 
inability of the immune system to respond appropriately against invading pathogens, 
increases the susceptibility to sepsis and septic shock [12,17,20]. Recent studies 
show that the prevention of immune cell apoptosis improves survival in a murine poly-
microbial induced sepsis model [20]. 
In summary, apoptotic depletion of immune cells is a key pathological process 
that dampens the pro-inflammatory response which, in combination with the 
immunosuppressive effect of apoptotic cells, can induce a profound state of immune 
paralysis that is a major cause of morbidity and mortality.
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2.3 Danger recognition and molecular pathways involved in inflammation 
Specific cell membrane-bound and secreted receptors initiate inflammatory 
responses as these receptors survey the host for potential danger [29]. These receptors 
are highly conserved throughout evolution and are referred to as pattern recognition 
receptors (PRR), of which a selection is listed in Table 3 [29]. PRR recognize a series 
of molecularly preserved patterns that are expressed on micro-organisms (pathogen-
associated molecular patterns (PAMP)) and on intracellular proteins, DNA and RNA 
derived from dying host cells (danger-associated molecular patterns (DAMP)) [30]. In 
addition, phagocytosis of apoptotic cells can lead to the release of large amounts of 
DNA and RNA, which can interact with intracellular PRR [31].
Most PRR are expressed on extracellular and intracellular membranes of many 
cell types [29]. Cell membrane-bound PRR, such as most Toll-like receptors (TLR) 
and C-type lectins, are involved in the recognition of extracellular pathogens, while 
intracellular PRR are involved in the recognition of intracellular pathogens [29,32]. 
Intracellular PRR such as TLR-3, TLR-7, TLR-8, TLR-9, RNA helicase family (RLR), 
retinoic acid inducible gene protein 1 (RIG-1), and melanoma differentiation-associated 
gene 5 (MDA5) are involved in the recognition of different groups of RNA viruses and 
intracellular bacteria [33,34]. The nucleotide oligomerization-binding (NOD)-domain-
like receptor (NLR) family consists of a group of intracellular PRR that include NLR-
domain leucine rich repeat and pyrin domain-like receptors (NALP), IL-1β-converting 
enzyme (ICE)-protease activating factor (IPAF), and neuronal apoptosis inhibitor factors 
(NAIP) [30]. NLR survey the cytoplasm for the presence of intracellular pathogens [33]. 
Recently it was shown that NOD2 recognizes cytoplasmic viral RNA by triggering the 
activation of interferon-regulatory factor 3 (IRF-3) and the subsequent production of 
interferon (IFN)-β [35]. Secreted PRR are involved in the opsonization of invading 
micro-organisms and comprise amongst others the complement factors C3a and C1q, 
as well as the lipopolysaccharide (LPS)-binding protein (LBP) [36,37]. 
PAMP or DAMP recognition by PRR, such as by TLR, activates several intracellular 
signaling cascades, in which adaptor molecules are key players [38]. The most 
Figure 3. Activation of host defense by pro-inflammatory cytokines. 
Upon DAMP or PAMP recognition by endothelial cells and immune cells these cells become activated 
and secrete cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-12, and IL-18. 
Subsequently these cytokines activate T-, and natural killer (NK)-cells, and neutrophils. The activated 
T- and NK-cells produce interferon (IFN)-γ and together with IL-12, they induce the activation of CD4+ 
Th1 cells, characterized by the production of IFN-γ, IL-2 and lymphotoxin (LT)-α. In addition, these 
mediators enhance the bactericidal activity in immune cells through the production of TNF-α, radical 
oxygen intermediates (ROI), and radical nitrogen intermediates (RNI), and increased MHC expression. 
IFN-γ inhibits the activation of CD4+ Th2 cells, which can produce and secrete amongst others IL-4, IL-5, 
and IL-10. The latter is a potent inhibitor of Th1-derived cytokines. Modified from Netea et al. [11].
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Figure 4. Impact of apoptosis on immune function. 
Apoptosis-induced depletion of immune cells impairs the host anti-microbial defenses. In addition to 
the immune cell depletion, apoptosis also induces anergy in surviving cells as ingestion of apoptotic 
bodies by phagocytes shifts their pro-inflammatory state to an anti-inflammatory phenotype or these 
cells become anergic. CTL, cytotoxic T lymphocytes; FDC, follicular DC. Modified from Hotchkiss et al. 
[20].
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Table 3. A selection of pattern recognition receptors and their ligands.
Pattern receptor  recognition Ligand Reference
TLR TLR-1 triacyl lipoproteins 150
TLR-2 lipoproteins, 97
PG, 95,96
zymosan, 98
hsp, 99
hyaluronan, 109
HCMV, HSV-1 151
TLR-3 dsRNA,
poly I:C
104
TLR-4 LPS 96
hsp 99,152
fibrinogen 112
fibronectin 111,112
TLR-5 flagellin 153
TLR-6 lipoteichoic acid 154
zymosan 98]
TLR-7 ssRNA 105
TLR-8 ssRNA 105
TLR-9 demethylated CpG 155
TLR-10 unknown 156
TLR-11 profilin 157
TLR-12 unknown 158
TLR-13 unknown 158
NLR NAIP1 anthrax lethal toxin 159,160
NAIP2 muramyldipeptide 161
NAIP3 bacterial RNA 160
NAIP4 unknown 162
NOD1 murodipeptide 163
NOD2 mitochondria 35
viral ssRNA 35
RLR RIG-1 5’-triphosphate ssRNA 164
poly I:C 164
MDA5 MHV
poly I:C
165
164
Complement C3 OH-groups on carbohydrates
and proteins
36
C1q immune complexes 36
Others LBP LPS 37
Abbreviations: TLR, Toll-like receptor; NOD, nucleotide oligomerization-binding; NLR, NOD-domain-like 
receptor; RIG-1 retinoic acid inducible gene-1; RLR, RIG-1-like receptor; NAIP, NLR-domain leucine 
rich repeat and pyrin domain-like receptors; MDA5, melanoma differentiation-associated gene 5; MHV, 
murine hepatitis virus; PG, peptidoglycan; LPS, lipopolysaccharide; hsp, heat shock protein; ds, double 
stranded; ss, single stranded; RNA, ribonucleic acid; HCMV, human cytomegalovirus; HSV-1, herpes 
simplex virus type-1; LBP, LPS-binding protein; CpG, cystine purine repeat in DNA. 
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important adaptor molecules in TLR signaling are myeloid differentiation primary 
response protein 88 (MyD88), TIR domain-containing adaptor protein (TIRAP), MyD88 
adaptor-like (MAL), and TIR domain-containing adaptor-inducing IFN-β (TRIF) [38]. 
TLR mostly signal in a MyD88-dependent manner, with the exception of TLR-3 which 
signals through TRIF [39]. Recruitment of adaptor molecules to PRR leads to the 
initiation of intracellular signaling cascades that activate multiple transcription factors 
(discussed below), followed by transcriptional activity of a variety of inflammatory genes 
that encode cytokines, chemokines and adhesion molecules [40]. Together, these 
inflammatory molecules orchestrate the inflammatory response [40].
Based on the mode of action and function, the transcription factors downstream of 
PRR signaling can be divided into three categories [41]. The first category of transcription 
factors, which comprises nuclear factor (NF)-κB and IRF, are constitutively expressed 
by all cell types and are retained in an inactive form in the cytoplasm [42,43]. Activation 
of these transcription factors occurs by post-translational modifications, such as 
phosphorylation and inactivation of inhibitor molecules, after which they translocate into 
the nucleus to control gene transcription [41,44]. The second category of transcription 
factors, to which CCAAT/enhancer-binding protein (C/EBP)-δ belongs, regulate the 
waves of gene activation that occur after the primary response and they do so over a 
prolonged period of time [45,46]. The third category comprises transcription factors, 
such as PU.1 and runt-related transcription factor (RUNX)-1, that are well known for 
their role in hematopoiesis, but upon PRR activation these transcription factors can 
also enhance the transcriptional activity of transcription factors belonging to the first 
category [47-49]. 
Collectively, PRR activation initiates several intracellular signaling cascades that 
activate multiple transcription factors, which can initiate the transcription of genes that 
shape the inflammatory response. 
3. Sepsis and septic shock
The term sepsis originates from the Greek word sepo, meaning decomposition of 
animal or vegetable organic matter in the presence of bacteria or putrefaction [50]. 
Nowadays, sepsis is defined as SIRS with a suspected or proven infection [51]. In 
clinical routine diagnostics it may, however, be difficult to detect the pathogen in blood 
or other body materials [52]. This makes the differential diagnosis between infectious 
and noninfectious SIRS, as well as the decision for a successful treatment strategy, 
difficult [52,53]. Therefore, a lot of research is performed to identify biomarkers that 
can discriminate between infectious and non-infectious SIRS. Several biomarkers with 
varying degrees of specificity and sensitivity to discriminate between infectious and 
noninfectious SIRS have been described. These include procalcitonin (PCT), C-reactive 
protein (CRP), soluble CD14, LBP, differential blood cell count and extracellular 
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phospholipase A2 [7,54-58]. However, the multi-factorial character of SIRS, as it 
depends amongst others on the nature of the inciting agent and the inflammatory 
status of the patient, makes the identification of one biomarker to discriminate between 
infectious and non-infectious SIRS difficult [7-9,19,59,60]. This means that a panel of 
markers should be used to discriminate between infectious and noninfectious SIRS. 
Despite great improvements in our knowledge on the pathobiological processes 
involved in SIRS and sepsis, as well as the identification of several biomarkers, the 
incidence of sepsis still increases [17]. A shift in bacterial species that cause sepsis is 
thought to contribute to this. During the last decade the incidence of Gram-positive sepsis 
steadily increased, while before the 1980s Gram-negative bacteria were responsible 
for most cases of sepsis [17,61]. Nowadays, the most commonly isolated Gram-
positive pathogens from septic patients are Staphylococcus aureus and Streptococcus 
pneumoniae, while the most common Gram-negative pathogens are Escherichia coli, 
Klebsiella species and Pseudomonas aeruginosa [61]. 
Annually, in the United states more than 200.000 people die from sepsis [17]. Only 
a small percentage of septic patients will die from SIRS [17]. The majority of septic 
patients that survive the initial insult, subsequently develop a profound state of immune 
paralysis that is manifested by the inability to eradicate the primary infection and/or 
the development of secondary infections [19]. This is also the phase in which most 
septic patients die [20]. The fact that many of the pathogens responsible for the fatal 
secondary infections, such as Stenotrophomonas species, Acinetobacter species, and 
Candida albicans, are not particularly virulent in individuals with a normal, competent 
immune system highlights the severe degree of immunosuppression that can occur in 
patients with SIRS and sepsis.
4. Treatment of infectious and non-infectious SIRS
The standard care for sepsis is the intravenous administration of a broad spectrum 
of antibiotics that eradicate the inciting organism. This treatment should be reevaluated 
daily to optimize efficacy, prevent antibiotic resistance, and avoid toxicity [62]. Over 
the last decades several anti-inflammatory therapeutics, such as corticosteroids, have 
been investigated in infectious and noninfectious SIRS. The results from these studies 
show that corticosteroids can inhibit the inflammatory response and pathology during 
a noninfectious SIRS, while during an infectious SIRS corticosteroid treatment did not 
improve survival. Despite this fact, it is not uncommon that clinicians treat sepsis patients 
with corticosteroids, such as hydrocortisone at a dose of 200-300 mg/day, for seven 
days [18]. Also activated protein C, which exerts anti-coagulant, anti-inflammatory, and 
fibrinolytic effects, is used to treat septic patients [18]. Furthermore, hyperglycemia is 
common in septic patients and there is evidence that maintaining blood glucose levels 
within 4.4-6.1 mmol/L can reduce morbidity and mortality [18]. However, maintaining 
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the blood glucose concentration at such a level is difficult and therefore hypoglycemic 
events can occur. 
Other therapeutics have also been investigated and were focused on reducing 
systemic and local inflammatory responses with monoclonal antibodies that neutralize 
cytokine activity or inhibit inflammatory mediator production. Although such studies 
showed a remarkable survival improvement in LPS-models of septic shock in animals 
[63,64], no such beneficial effect on survival was observed in the murine poly-microbial 
induced sepsis model [65-67] as well as in clinical trials involving septic patients [68-70]. 
Therefore, more studies are needed to investigate and understand the effectiveness of 
anti-inflammatory therapies on morbidity and mortality during sepsis and septic shock. 
5. Pregnancy and immunoregulation 
Pregnancy remains to some extent an immunological enigma; the fetus inherits 
histocompatibility antigens from the father and yet coexists within the mother’s uterus 
in harmony throughout pregnancy. However, when fetal tissues are grafted onto a 
third party they do induce an immunological response [71-73]. This suggests that the 
maternal immune system is regulated in such a way that immune responses against the 
fetal tissues are prevented to facilitate pregnancy success [74,75]. 
During pregnancy, the maternal immune response shifts from a type-1 (cell-mediated) 
response towards a type-2 (humoral) response [76]. This shift is most pronounced 
at the maternal-fetal interface, but it may also modulate systemic immunity to some 
extent. Consequently, during pregnancy symptoms of type-1 associated autoimmune 
diseases (e.g. rheumatoid arthritis and multiple sclerosis) decline, but they return to pre-
pregnancy levels post-partum. In contrast, symptoms of systemic lupus erythematosus, 
which is considered as a type-2 associated autoimmune disease in which the principal 
pathology is autoantibody driven, may flare up during pregnancy [76]. Also, as a 
result of the pregnancy-associated immunoregulation, the susceptibility to certain 
pathogens, including Listeria monocytogenes, Toxoplasma gondii, Leishmania major, 
and Plasmodium species increases [77-80]. Likely, a particular pregnancy-associated 
hormonal environment contributes to the shift in immunity [76,81].
Characteristic for human pregnancy is the production of the hormone human 
chorionic gonadotropin (hCG) by syncytiotrophoblasts in the placenta [82]. hCG is a 
member of the glycoprotein hormone family to which also belong luteinizing hormone 
(LH), follicle stimulating hormone (FSH), and thyroid stimulating hormone (TSH) [83]. 
Hormones from this family consist of similar heterodimeric structures of an identical 
α-subunit, but a unique β-subunit that confers the hormonal biological specificity [84]. 
It has been recognized that hCG, besides its endocrine function, has profound 
immunosuppressive effects [78-80,85-87]. There is also evidence that hCG-derived 
peptides have immunoregulating properties [see below].
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5.1 hCG-derived oligopeptides
During pregnancy, hCG exists in a variety of forms in serum and urine. These 
forms include heterodimeric hCG and its separate α and β subunits, but also nicked 
hCG and hCG β core, which both consist of a β-chain with a defective loop 2 [88-
90]. It has been demonstrated that a 400-2000 Dalton fraction from pregnancy urine 
prevented the onset of autoimmune diabetes in nonobese diabetic (NOD) mice [77,91]. 
In addition this fraction was able to reverse established pancreatic inflammation in 
these mice [91]. Considering these data it has been hypothesized that oligopeptides 
originating from loop 2 cleavage of the β-chain of hCG have immunoregulatory activity 
[92]. Therefore, based on known preferential cleavage sites within the loop 2 sequence 
MTRVLQGVLPALPQVVC (Figure 5) seven different oligopeptides (MTR, MTRV, 
LQG, LQGV, VLPALP, VLPALPQ, and VVC) were synthesized, as well as two alanine 
replacement variants of LQGV, namely AQGV and LAGV [92,93]. Several of these 
synthetic oligopeptides were tested in different animal models that are characterized 
by excessive immune activation [93,94]. In this thesis the immunoregulatory effects of 
the oligopeptides LQGV, VLPALP, AQGV, and LAGV were further explored in in vivo 
models associated with infectious and noninfectious inflammation. Also mechanistic 
studies of LQGV were explored in in vivo, ex vivo, and in vitro experimental settings. 
6. Aim of the thesis
The overall aim of this thesis was to examine the anti-inflammatory effects of LQGV, 
VLPALP, AQGV, and LAGV in animal models associated with SIRS. Infectious as well 
as non-infectious animal SIRS models were used. The underlying mechanisms, by 
which LQGV can exert anti-inflammatory activity were also investigated. Chapter II 
demonstrates the effects of high dose treatment with LQGV, VLPALP, and AQGV (50 
mg/kg BW) on early innate immune activation in a L. monocytogenes infection model in 
mice. In chapter III the in vivo effects of the same high dose of LQGV (50 mg/kg BW) on 
leukocyte subpopulations was investigated. In chapter IV mechanistic studies on the 
mode of action of LQGV (5 and 50 mg/kg BW) were explored by using an in vivo LPS-
induced shock model in mice and ex vivo murine adrenal gland cultures. In chapter V 
the effects of LQGV, AQGV, and LAGV (5 mg/kg BW) was explored on hemorrhagic 
shock and resuscitation induced inflammation and subsequent liver damage in rats. 
Chapter VI demonstrates the effect of LQGV (5 mg/kg BW) in a polymicrobial sepsis 
model in mice. This study explores whether LQGV treatment is of additive value to 
the standard treatment in sepsis (antibiotics and fluid administration). Chapter VII 
demonstrates the effect of high, median, and low dose dexamethasone treatment on 
mortality and inflammation in a polymicrobial sepsis model in mice. Also the effect of low 
dose dexamethasone treatment in combination with antibiotics and fluid administration 
was explored. Chapter VIII, the general discussion of the experimental work of this 
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Figure 5. Structure of β-hCG with loop 2 (left) and the amino acid sequence of loop 2 (right). 
Adapted from Lapthorn et al. [90]. Arrows indicate the preferential cleavage sites in loop 2.
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thesis, deals with the implications of the studies in the context of available literature. 
Also suggestions are made for future research in this area.
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ABSTRACT
Background: Synthetic human chorionic gonadotropin (hCG)-related oligopeptides 
are potent inhibitors of pathogenic inflammatory responses induced by in vivo 
lipopolysaccharide exposure or hemorrhagic shock-induced injury. In this study, we 
tested whether hCG-related oligopeptide treatment similarly altered inflammatory 
responses and innate host defenses in mice during experimental Listeria monocytogenes 
infection.
Methods: Mice were infected with L. monocytogenes and treated with hCG-related 
oligopeptides (LQGV, VLPALP, AQGV) or phosphate-buffered saline. Subsequently, 
mice were analyzed for bacterial loads, cytokine and chemokine responses, and 
inflammatory cell infiltrates in target organs.
Results: Oligopeptide administration increased bacterial numbers in spleen and 
liver at 6 h after infection. Simultaneously, CXCL1/KC and CCL2/MCP-1 plasma levels 
as well as neutrophil numbers in spleen, blood, and peritoneal cavity decreased. In 
contrast, at 18 h after infection, systemic tumor necrosis factor-α, interleukin-12p70, 
interleukin-6, and interferon-γ levels increased statistically significantly in oligopeptide-
treated mice compared to controls, which correlated with increased bacterial numbers.
Conclusion: These data show that treatment with hCG-related oligopeptides (LQGV, 
VLPALP, AQGV) inhibits early innate immune activation by reducing initial chemokine 
secretion following infection. This leads to bacterial overgrowth with subsequent 
enhanced systemic inflammation. Our data underscore the importance of early innate 
immune activation and suggests a role for hCG-derived oligopeptides at the placenta 
that increases the risks to L. monocytogenes infections.
INTRODuCTION
Listeria monocytogenes is an intracellular bacterium with a predilection for causing 
invasive infection in individuals with compromised host defenses [1]. It is also a model 
pathogen used for understanding innate and adaptive immune responses to bacterial 
infection [1]. Innate immune receptors, such as Toll-like receptors and nucleotide 
oligomerization-binding domain-like receptors, mediate the earliest recognition of 
L. monocytogenes components and trigger signaling pathways that induce specific 
chemokine and cytokine responses [2-4]. Chemokines are critical for directing cellular 
recruitment to infected tissues, and cytokines, such as interferon-γ (IFN-γ), tumor 
necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-12 are crucial for eradicating 
L. monocytogenes through activation of NK cells and organ-specific phagocytes [5-6]. 
Accordingly, mice lacking key chemokines, cytokines, or their cognate receptors and 
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downstream signaling proteins are highly susceptible to L. monocytogenes infection 
[7-11].
Pregnancy is one condition that increases the risk of invasive listeriosis [1]. Pregnancy 
transiently biases immune responses of the maternal host toward a type 2 (humoral) 
and away from a type 1 (cell-mediated) phenotype [12]. This shift is most pronounced at 
the maternal-fetal interface, but it may also modulate systemic immunity to some extent. 
Consequently, pregnancy has deleterious effects on the outcome of infections such as 
leishmaniasis, malaria, toxoplasmosis, and listeriosis [13-16]. In addition, autoimmune 
diseases such as systemic lupus erythematosus, in which the principal pathology is 
autoantibody production, tends to flare up during pregnancy, whereas rheumatoid 
arthritis is ameliorated in the maternal host [17]. 
The pregnancy hormone human chorionic gonadotropin (hCG) exerts endocrine 
as well as immunosuppressive functions [18]. Recently, we demonstrated that hCG 
induces dendritic cells to differentiate towards a tolerogenic phenotype [19]. In addition, 
hCG was observed to decrease IFN-γ production and prevent the onset of autoimmune 
diabetes in nonobese diabetic mice [20]. Remarkably, the anti-diabetic effect was not 
due to native hCG, but resided in a 400-2000 Da peptide fraction that likely originated 
from proteolytic degradation of loop 2 of β-hCG [21]. On the basis of preferential 
cleavage sites within loop 2 of β-hCG, we developed and tested the activity of synthetic 
oligopeptides in experimental inflammation [22-24]. These studies demonstrated that 
the oligopeptides LQGV and AQGV (alanine substitution) reduced proinflammatory 
cytokine levels, reduced adhesion molecule expression, and diminished granulocytic 
infiltration into the liver following hemorrhagic shock and the kidney following ischemia 
& reperfusion, [22-23]. In addition, the oligopeptide VLPALP reduced lipopolysaccharide 
(LPS)-induced mortality as effectively as did the 400-2000 Da hCG-derived peptide 
fraction [25]. 
To gain more insight into the effects of hCG-related oligopeptides on innate immune 
responses during infection with live bacteria, we tested the extent to which hCG-related 
oligopeptides altered host defenses in experimental L. monocytogenes infection in 
mice. Our data suggest that treatment with hCG-related oligopeptides impairs innate 
immune responses against L. monocytogenes by inhibiting chemokine responses and 
subsequent cellular recruitment to infected organs. This results in delayed bacterial 
clearance and more aggressive bacterial propagation. These data underscore the 
importance of early activation of innate immune responses following L. monocytogenes 
infection. 
hCG-related peptides and L. monocytogenes
37
MATERIALS AND METHODS 
Animals
Specific pathogen-free C57BL/6 mice (Jackson Laboratory and Harlan) were 8–16 
wk of age when used in experiments and allowed food and water ad libitum. Experiments 
were approved by the local animal care and use committees.
Bacteria
Inocula of live L. monocytogenes (strain EGD) and heat killed L. monocytogenes 
(HKLM) were prepared as described elsewhere [26]. 
L. monocytogenes infection model
Mice were infected by intravenous injection of 2.0–5.5 log10 colony-forming units 
(CFU) wild-type L. monocytogenes or 7.0 log10 CFU of the L. monocytogenes Δhly 
mutant DP-L2161 [27]. The hCG-related oligopeptides VLPALP, LQGV, and AQGV (GL 
Biochem Shanghai) were dissolved in PBS and intraperitoneally injected (50 mg/kg 
body weight) starting 24 h before infection and continued every 24 h thereafter. PBS-
treated mice served as controls. Mice were euthanized at fixed time points.
Tissue collection and evaluation of bacterial CFus 
Peritoneal lavage was performed with ice-cold PBS. Liver, spleen and bone marrow 
were isolated aseptically at necropsy. Blood was collected from the submandibular 
vein into EDTA-containing tubes (Greiner, Bio-one) and plasma was obtained by 
centrifugation (3000 rpm; 10 min), immediately frozen and stored at -80°C until assayed. 
Liver and spleen were divided into sections for evaluation of bacterial CFUs or for flow 
cytometric analysis. Sections were weighed, homogenized and bacterial CFUs were 
quantified as described elsewhere [26]. CFUs bacteria in blood, peritoneal washings 
and bone marrow cell suspensions were determined similarly. Results were expressed 
as mean (± standard error of the mean) log10 CFUs bacteria per gram tissue, per mL 
blood, per mL peritoneal fluid, or per femur. 
In vitro stimulation of splenocytes
Uninfected mice were injected intraperitoneally with PBS or LQGV (50 mg/kg); after 
18 h, splenocytes were isolated and cultured at a density of 106 cells/mL in Roswell Park 
Memorial Institute medium containing antibiotics and 5% fetal calf serum. Cells were 
stimulated with HKLM (103-108) or LPS (100 ng/mL) and supernatants were collected 
after overnight incubation for cytokine level measurements.
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Evaluation of cytokines and chemokines in plasma and culture supernatant
Levels of TNF-α, IL-6, IL-12p70, IL-10 and CCL2/MCP-1 were determined in plasma 
by means of cytometric bead array (BD Biosystems) as described elsewhere [22]. 
CXCL1/KC in plasma, TNF-α and IL-6 levels in culture supernatant were determined 
by means of enzyme-linked immunosorbent assay according to the manufacturer’s 
instructions (R&D Systems Europe). Results are expressed as mean (± standard error 
of the mean) pg/mL.
Flow cytometric analysis 
Flow cytometric analysis was performed on blood, peritoneal lavage, bone marrow 
and spleen cell suspensions, as described elsewhere [26]. Briefly, cells were incubated 
with monoclonal antibodies directed against Ly6C (ER-MP20 [28]), Ly6G (1A8), and 
CD11b (M1/70) (BD PharMingen) for 30 min, washed 3 times with PBS/0.5%BSA/20mM 
sodium-azide, and fixed with 1% paraformaldehyde (weight per volume). Monocytes 
are defined as CD11b-positive, Ly6C-positive and Ly6G-negative. Neutrophils were 
defined as CD11b-positive, Ly6C-positive and Ly6G-positive. Flow cytometric analysis 
was performed on a FACSCalibur (BD Biosciences, San Jose, CA, USA). Data were 
analyzed using Flow-Jo software (version 7.5.4; TreeStar).
Statistical analysis 
Statistical analysis was performed using SPSS software (version 15; SPSS). 
Differences between groups were analyzed with Kruskal-Wallis statistical test. If this 
resulted in p < 0.05, a Dunn’s Multiple Comparison post-test was performed and a p < 
0.05 was considered statistically significant. Correlation coefficients were determined 
with Pearson’s correlation analyses with significance set at a p < 0.05.
RESuLTS
Association between hCG-related oligopeptide treatment and increased bacterial 
numbers after lethal infection 
To assess the effects of LQGV, VLPALP and AQGV during L. monocytogenes 
infection, oligopeptide-treated and control mice were infected with 4 log10 CFUs bacteria 
(1-3 median lethal dose) and then bacterial loads in target organs were measured.
In the spleens of PBS-treated mice, the mean bacterial load increased from 4.2 log10 
CFUs of bacteria at 6 h after infection to 7.4 log10 at 72 h after infection. By comparison, 
for each oligopeptide, CFUs of bacteria were statistically significantly higher in 
oligopeptide-treated mice than those in control mice at 6 h after infection. Moreover, at 
each time point, splenic CFUs were statistically significantly higher in the LQGV-treated 
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mice (p < 0.01) and AQGV-treated mice (p < 0.05) compared with PBS-treated mice 
(Figure 1A).
There was a mean of 3.8 log10 CFUs detected in the livers of PBS-treated mice at 
6 h after infection, which increased to a mean of 7.6 log10 CFUs at 72h after infection. 
As also found in the spleen, CFUs of bacteria in the liver were statistically significantly 
higher in oligopeptide-treated (p < 0.05) mice at 6, 18, and 72h after infection than in 
PBS-treated mice (Figure 1B). 
Bacteria were not detected in blood and bone marrow of PBS-treated mice until 
48h and 72h after infection, respectively. In contrast, bacteremia was noted by 18h 
after infection in oligopeptide-treated mice, with LQGV-treated mice always showing the 
highest bacterial load in the blood (Figure 1C). In bone marrow, bacteria were present 
at 18 h after infection in LQGV-treated mice, and by 48h after infection in VLPALP-
treated mice and AQGV-treated mice. LQGV-treated mice and AQGV-treated mice had 
the highest bacterial load in bone marrow at 72 h after infection (Figure 1D). 
Effect of LQGV treatment during sublethal challenge with wild-type 
L. monocytogenes and infection with avirulent L. monocytogenes mutants 
Because LQGV treatment consistently produced the highest bacterial loads during 
lethal wild-type infection, subsequent experiments tested the effect of this oligopeptide 
in 2 different models of sublethal infection. First, mice were infected with 2.0 log10 CFUs 
wild-type L. monocytogenes (0.01 median lethal dose) and bacterial loads in organs 
were quantified as before. As also found in lethal infection, LQGV treatment resulted 
in statistically significantly increased bacterial loads in the spleen (p < 0.01) and liver 
Figure 1. Increased bacterial loads as a result of hCG-related oligopeptide treatment after lethal 
Listeria monocytogenes challenge.
Phosphate-buffered saline (PBS; control), or one of the oligopeptides (VLPALP, LQGV, or AQGV) was 
administered intraperitoneally daily starting 24 h before infection with 4 log10 colony-forming units (CFUs) 
of bacteria. Mice were killed at the indicated time and CFUs of bacteria in tissues were quantified. 
Results are presented as CFUs of bacteria in (A) spleen (log10/g), (B) liver (log10/g), (C) blood (log10/mL), 
and (D) bone marrow (log10/femur) from the indicated treatment groups at 6, 18, 48, 72h after infection. 
Results shown are from one representative experiment out of three (n = 4 mice/group). * p < 0.05, # p < 
0.01 compared with PBS-treated mice. 
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(p < 0.01) at 72 h after infection compared to PBS treatment. Furthermore, 3.0 log10 
CFUs of bacteria were detected in bone marrow from LQGV-treated mice, whereas 
bone marrow from PBS-treated mice remained sterile (Figure 2A). In a second set of 
experiments, mice were infected with 7.0 log10 CFU of avirulent Δhly L. monocytogenes 
mutants that do not produce listeriolysin O or escape phagosomes and are eliminated 
rapidly. As found before, there were greater numbers of bacteria in spleens and livers of 
LQGV-treated mice at 6 and 18 h after infection compared to PBS treated mice (Figure 
2B). Collectively, these data suggest that LQGV impairs host defenses against bacterial 
infection in general, rather than acting specifically against mechanisms triggered by 
bacteria that access the cytosol. 
Figure 2. Increased bacterial loads as a result of LQGV treatment following a sub-lethal 
L. monocytogenes challenge or infection with avirulent ∆hly L. monocytogenes mutants.
(A) Results for infection with wild-type L. monocytogenes. Phosphate-buffered saline (PBS) or LQGV was 
administered intraperitoneally daily starting 24h before infection with 2 log10 colony-forming units (CFUs) 
of wild type L. monocytogenes. CFUs of bacteria in spleen, liver and bone marrow were quantified at 
72h after infection (B) Results for infection with ∆hly L. monocytogenes mutants. PBS or LQGV were 
administered intraperitoneally daily starting 24h before infection with 7 log10 ∆hly L. monocytogenes 
mutants. CFUs of bacteria in spleen and liver were measured at 6 and 18 h after infection (n = 4 mice/ 
group). * p < 0.05, ** p < 0.01 compared with PBS-treated mice. 
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Decrease of in vitro cellular responsiveness to HKLM and LPS by LQGV treatment 
in uninfected mice 
Next, we tested the extent to which LQGV treatment impaired the ability of cells to 
generate proinflammatory cytokines. For this, uninfected mice were treated with PBS 
or LQGV. After 18 h splenocytes were isolated and stimulated in vitro overnight with 
varying amounts of HKLM or 100 ng/mL LPS. The results showed that HKLM induced 
dose-dependent production of TNF-α and IL-6 by splenocytes from both groups of 
mice (Figure 3). However, splenocytes from LQGV-treated mice produced statistically 
significantly less TNF-α and IL-6 than did cells from control mice (p < 0.05). Similar 
results were obtained when splenocytes were stimulated in vitro with LPS (Figure 3).
Inhibition of early neutrophil accumulation during L. monocytogenes infection by 
oligopeptide treatment
Subsequent experiments tested the degree to which treatment with LQGV, VLPALP, 
or AQGV impaired cellular recruitment following infection. For this, we analyzed 
neutrophil and monocyte numbers in spleen, blood, and peritoneal cavity in PBS-treated 
or oligopeptide-treated mice at steady state and after infection. The percentages of 
neutrophils in blood, spleen, and peritoneal cavity were increased over steady state at 
6 h after infection in PBS-treated mice. Interestingly, treatment with each oligopeptide 
resulted in lower neutrophil counts in each compartment at 6 h after infection as well as 
Figure 3. Impaired production of proinflammatory cytokines displayed by splenocytes from 
LQGV-treated mice.
Uninfected mice were treated with phosphate-buffered saline (PBS) or LQGV. After 18 h splenocytes 
were isolated and subsequently cultured in vitro overnight with increasing amounts of heat killed Listeria 
monocytogenes (HKLM) or 100 ng/ml lipopolysaccharide (LPS). Concentrations of tumor necrosis 
factor (TNF)-α (A) and interleukin (IL)-6 (B) in culture supernatants were measured by enzyme-linked 
immunosorbent assay. Data depicted are from one representative experiment out of three (n = 4 mice/ 
group). U.S., unstimulated. * p < 0.05 LQGV-treated cells compared with PBS-treated cells. 
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Figure 4. Inhibition of the initial mobilization of neutrophils by synthetic hCG-related oligopeptides 
during L. monocytogenes infection.
(A) Dot plots showing representative flow cytometric profiles from the spleen, blood and peritoneal 
cavity from mice 6 h after infection with 4 log10 CFUs of L. monocytogenes and from uninfected mice. 
CD11b positive cells were selected, and monocytes and neutrophils were analyzed on plots of Ly6C 
vs. Ly6G. Monocytes were defined as CD11b-positive, Ly6C-positive, and Ly6G-negatieve. Neutrophils 
were defined as CD11b-positive, Ly6C-positive, Ly6G-positive. Neutrophil (upper box) and monocyte 
(lower box) windows are shown. (B) Quantification of percentages of neutrophils in spleen, blood, and 
peritoneal lavage. (C) Neutrophil numbers in spleen and peritoneal cavity. Data are given as mean ± SEM 
from four mice per group from one representative experiment out of three with similar findings. 
* p < 0.05 oligopeptide-treated groups compared with PBS-treated control, or PBS-treated compared 
with uninfected mice.
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at 18 h after infection, with the exception of the peritoneal cavity (Figure 4A and B). At 18 
h after infection, the percentage and absolute numbers of neutrophils in the peritoneal 
lavage decreased in all mice compared to 6 h after infection, but this decrease was 
not as marked in oligopeptide-treated mice as in PBS-treated mice (Figure 4B and C). 
In contrast to the results with neutrophils, monocyte populations were not altered in 
any of the oligopeptide treated groups (data not shown). These data suggest that the 
previously demonstrated increase in bacterial loads in target organs could be due to 
inhibition of neutrophil accumulation.
Alteration of systemic cytokine and chemokine levels upon hCG-related 
oligopeptide treatment during L. monocytogenes infection
Next, we tested whether reduced mobilization of inflammatory cells in vivo correlated 
with inhibition of systemic proinflammatory chemokine and cytokine levels. At 6 h after 
infection, plasma concentrations of CCL2/MCP-1 and CXCL1/KC increased significantly 
in PBS-treated mice compared to uninfected mice (CCL2/MCP-1: 148 pg/mL vs 20 pg/
mL, respectively; p < 0.05) and (CXCL1/KC: 1086 pg/mL vs 215 pg/mL, respectively; 
p < 0.05 (Figure 5)). Although oligopeptide-treated mice also showed increased CCL2/
MCP-1 levels at 6 h after infection, both CCL2/MCP-1 and CXCL1/KC levels were 
statistically significantly lower in oligopeptide-treated mice than the levels found in PBS-
treated mice (p < 0.05). Increased concentrations of TNF-α, IL-12p70, IL-6, and IFN-γ 
were first detected in plasma at 18 h after infection in all mice and were statistically 
significantly higher in oligopeptide-treated (p < 0.05) mice than in PBS-treated mice 
(Figure 5). At 18h after infection, CCL2/MCP-1 and CXCL1/KC levels further increased 
in all mice to comparable levels. These data demonstrate that elevation of systemic 
levels of chemokines precedes the elevation of systemic levels of pro-inflammatory 
cytokines and that administration of LQGV, VLPALP or AQGV initially inhibits the early 
chemokine response.
Determination of chemokine and cytokine plasma levels by bacterial load
To explain the apparent contradiction between depression of early chemokine levels 
but enhanced proinflammatory cytokine levels following oligopeptide treatment, we 
hypothesized that increased levels of proinflammatory cytokines at 18 h after infection 
were related to increased bacterial loads in target organs at this time point. To test this, 
mice were infected with increasing amounts of bacteria (4 log10, 5 log10, 5,5 log10 CFUs) 
and cytokine and chemokine plasma levels were measured at 18 h after infection. 
The results revealed a statistically significant, positive correlation between increasing 
amounts of infecting bacteria with higher plasma levels of TNF-α, IL-12p70, IL-6, IFN-γ, 
CCL2/MCP-1, and CXCL1/KC (Figure 6A) as well as greater bacterial loads in vivo 
(Figure 6B). These data support a causal relationship between bacterial load and the 
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concentration of inflammatory mediators in plasma. Moreover, statistically significant 
correlations between TNF-α, IL-12p70, IL-6, and IFN-γ plasma levels with splenic CFUs 
were observed at 18 h after infection in LQGV-treated mice, VLPALP-treated mice, 
and AQGV-treated mice. In contrast, this correlation did not hold for CCL2/MCP-1 and 
CXCL1/KC (Figure 6C). These data indicate that the increased cytokine levels in plasma 
at 18 h after infection in LQGV-treated mice, VLPALP-treated mice and AQGV-treated 
mice are caused by the increased bacterial load at this time point.
Figure 5. Massively increased levels of cytokines as a result of treatment with LQGV, VLPALP, or 
AQGV following lethal challenge with L. monocytogenes.
Phosphate-buffered saline (PBS), VLPALP, LQGV, or AQGV was administered intraperitoneally daily 
starting 24 h before infection with 4 log10 CFUs of L. monocytogenes. Mice were killed at fixed time 
points. Plasma levels of tumor necrosis factor α (TNF)-α, interleukin 12 (IL-12p70), interleukin 6 (IL-6), 
interferon γ (IFN-γ), CCL2/MCP-1 and CXCL1/KC in different experimental groups were determined at 
6 and 18 h after infection. Data depicted are from one representative experiment out of three with similar 
findings (n = 4 mice/group). B.D., below detection limit. * p < 0.05 oligopeptide-treated groups compared 
with PBS-treated controls, or PBS-treated compared with uninfected mice.
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DISCuSSION
Innate immune responses against L. monocytogenes are characterized by the early 
mobilization of neutrophils and monocytes, as well as the production of proinflammatory 
cytokines and chemokines [29]. In this study we show that hCG-related oligopeptides 
inhibit innate immune activation during L. monocytogenes infection, which results in 
overwhelming bacterial propagation and excessive inflammation. In addition, we 
demonstrate that a systemic chemokine response manifested by increased plasma 
concentrations of CCL2/MCP-1 and CXCL1/KC precedes similar elevations of 
Figure 6. Positive correlation between systemic cytokine and chemokine levels and bacterial 
load.
Mice were infected with 4 log10, 5 log10, or 5.5 log10 colony-forming units (CFUs) of wild type 
L. monocytogenes. Mice were killed at 18h after infection and plasma levels of tumor necrosis factor α 
(TNF)-α, interleukin 12 (IL-12p70), interleukin 6 (IL-6), interferon γ (IFN-γ), CCL2/MCP-1 and CXCL1/
KC in different experimental groups were determined. (A) Mean ± (standard error of the mean) plasma 
concentrations of TNF-α, IL-12p70, IL-6, IFN-γ, CCL2/MCP-1 and CXCL1/KC determined from groups of 
4 mice. Statistical differences between groups of mice are shown (* p < 0.05, ** p < 0.01). (B) Correlation 
analysis between plasma cytokine/chemokine concentrations and CFUs of bacteria in spleens of 
mice infected with different inocula. Statistical significance was determined by Pearson’s correlation 
analyses. (C) Correlation analysis between plasma levels and splenic CFUs in different experimental 
groups determined at 18h after infection. Data depicted are from one representative experiment out of 
three (n = 4 mice/group). 
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proinflammatory cytokines. These observations are in line with other studies showing 
MyD88-independent production of CCL2/MCP-1 in the spleen within 6 h of infection 
[30]. Inhibition of this early response leads to a more aggressive infection as was also 
found in our studies [30]. These data underscore the importance of the magnitude and 
rapidity with which innate immune activation follows L. monocytogenes infection. 
Neutrophil migration to infected foci is important for controlling bacterial growth locally 
and for preventing bacterial dissemination [31]. In this study we show that treatment 
with hCG-related oligopeptides reduced neutrophil accumulation in blood, spleen, and 
peritoneal cavity after L. monocytogenes infection. Reduced neutrophil recruitment is 
likely related to diminished CXCL1/KC production, as reflected by decreased plasma 
levels and splenic mRNA levels (data not shown) at 6 h after infection. Consequently, 
bacterial numbers increased more rapidly in spleen and liver, and were detected earlier 
in blood and bone marrow than in control mice. These data are in line with previous 
studies demonstrating that both reduced neutrophil migration and neutrophil depletion 
lead to overwhelming bacterial propagation in L. monocytogenes infection and in cecal 
ligation and puncture models [13,32-33]. CCL2/MCP-1 regulates monocyte recruitment 
during the initial stage of inflammation [34]. We observed decreased CCL2/MCP-1 
levels upon treatment with hCG-related oligopeptides, but we found no significant effect 
on monocyte recruitment. This may be explained by preserved expression of other 
monocyte-attracting chemokines, such as CCL7/MCP-3 [35]. 
Neutrophil recruitment to infected organs, IFN-γ production by NK cells, and TNF-α 
and IL-6 production by monocytes, macrophages, and TNF-α and inducible nitric oxide 
synthase producing dendritic cells are all essential features of the innate immune 
response against L. monocytogenes [29]. In this study we found that LQGV treatment of 
uninfected mice impaired the ability of splenocytes to produce TNF-α and IL-6 in vitro in 
response to HKLM or LPS stimulation. This suggests that LQGV interferes with innate 
immune receptor-mediated activation, although the mechanisms involved are not yet 
clear. In contrast to decreased cytokine production in vitro, IFN-γ, TNF-α, IL-6, and IL-
12p70 plasma levels increased dramatically when mice were treated with hCG-related 
oligopeptides prior to L. monocytogenes infection. These increased plasma levels 
correlated statistically significantly with splenic bacterial numbers, suggesting a causal 
relationship between bacterial load in target organs and the magnitude of the systemic 
inflammatory response. This notion was confirmed experimentally by infecting mice with 
increasing doses of L. monocytogenes as well as by in vitro data from HKLM stimulation 
of splenocytes. LQGV clearly impaired the ability of splenocytes to produce TNF-α and 
IL-6 upon HKLM stimulation. Nevertheless both TNF-α and IL-6 increased markedly 
when cells were stimulated with greater amounts of HKLM, and they exceeded cytokine 
levels produced by splenocytes from PBS-treated mice stimulated with a lower dose of 
HKLM. This mimics the in vivo situation of oligopeptide-treated mice having a higher 
hCG-related peptides and L. monocytogenes
47
bacterial burden than PBS-treated mice and supports the notion that the increased 
cytokine levels detected in vivo in oligopeptide-treated mice are due to greater bacterial 
loads. In sublethal L. monocytogenes infection, LQGV treatment also was associated 
with increased bacterial numbers in spleen and liver, as well as greater bacterial 
numbers in the bone marrow. The latter finding is significant because the bone marrow 
was sterile in control mice. This underscores the strong immunosuppressive capacity 
of LQGV in mice. These data show that the early innate immune activation is important 
for the initial infiltration of phagocytes at sites of infection to control L. monocytogenes 
growth locally, a response that is fully active within the first 6 h after infection [36]. This 
rapid response also is essential for limiting bacterial dissemination to other organs or 
compartments, such as the bone marrow.
An alternative explanation for increased bacterial numbers following oligopeptide 
treatment could be a reduced capacity of resident effector cells to kill bacteria 
immediately following infection. Although we cannot fully exclude this possibility, we 
consider it to be less likely, because after cellular invasion, virulent bacteria escape 
from phagosomes in a listeriolysin O-dependent fashion, then replicate intracellularly 
and infect neighboring cells [37-38]. L. monocytogenes Δhly mutants lack listeriolysin O 
and are easily eradicated by the immune system [27]. Our results showed decreasing 
CFUs of Δhly mutants in spleen and liver of LQGV-treated mice similar to PBS-treated 
mice, but with delayed kinetics. This finding suggests that LQGV treatment does not 
significantly impair bacterial internalization and killing by effector cells. More rapid 
bacterial replication following treatment with hCG-related oligopeptides therefore is 
likely due to decreased chemokine production and subsequent reduced neutrophil 
recruitment, although formally we cannot exclude that LQGV interferes with bactericidal 
activities. Our data are in line with other studies demonstrating that treatment with 
hCG preparation also reduces chemokine production during thioglycolate-induced 
inflammation [39].
Pregnant women are prone to placental infection with L. monocytogenes, which 
typically occurs during later stages of pregnancy [1,29,40]. During the third pregnancy 
trimester, increased nicked β-hCG and β-core fragment levels occurr in urine and 
plasma, as compared to the first trimester [41]. At present we are unable to detect 
hCG-derived oligopeptides in blood or urine. However, the relative amounts of nicked 
β-hCG and β-core fragments can be detected [42], providing an indirect estimate for 
the concentration of hCG-derived oligopeptides. We postulate that high amounts of 
smaller fragments, including LQGV and VLPALP, may be liberated from the loop 2 
region during the third trimester of pregnancy. This could cause not only local immune 
suppression at the placenta, which is needed to prevent fetal allograft rejection, but 
also could make the host more prone to placental L. monocytogenes infection later 
in pregnancy. Interestingly, placentas of humans and guinea pigs are much more 
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susceptible to infection with L. monocytogenes compared with mouse placentas [43-45]. 
The explanation for differential susceptibility to L. monocytogenes infection is unclear 
but has been related to structural similarities between human and guinea pig placentas, 
whereas the mouse placenta is more different [43,46-47]. Alternatively, a placental 
immunological environment in humans and guinea pigs that is more permissive for 
growth of L. monocytogenes than in mice could explain this differential susceptibility. 
Interestingly, βCG-derived oligopeptides could contribute to such an immunological 
environment in humans and guinea pigs, since both species produce the βCG subunit 
and share 63% homology, whereas mice lack the βCG gene and thus do not produce 
βCG. Clearly, more studies on animal models of pregnancy with L. monocytogenes 
infection are needed to unveil the precise role of CG-related oligopeptides during 
pregnancy.
Elsewhere, we reported that LQGV and AQGV attenuated life-threatening 
inflammation and organ damage associated with hemorrhagic shock and renal 
ischemia & reperfusion [22-23]. In addition, we show that VLPALP treatment reduced 
mortality upon LPS injection [25]. Although the exact mechanism of action of LQGV, 
VLPALP, and AQGV is (are) not yet known, our current study suggests that suppressive 
effects on innate immune responses have contributed to beneficial outcomes found in 
these models. These data show that hCG-related oligopeptides have strong immune 
suppressive activity, which provides the underlying foundation for phase I trials as 
currently performed in humans.
In summary, we demonstrate that a chemokine response precedes the pro-
inflammatory cytokine and cellular response in L. monocytogenes infection. This 
chemokine response is essential for rapid cellular recruitment to prevent further 
progression of infection. Furthermore, this study reveals that the synthetic hCG-related 
oligopeptides LQGV, VLPALP, and AQGV inhibit early innate immune responses with 
subsequent increased bacterial propagation. Our data underscore the importance of 
early innate immune activation following bacterial infection and suggest that hCG-
derived oligopeptides at the placenta could increase host susceptibility to certain 
infections, e.g. L. monocytogenes. 
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ABSTRACT
Neutrophils are the first cells to respond to an injury by migrating from the circulation 
into the inflammatory site. Previously, we showed that LQGV impaired neutrophil 
recruitment during a Listeria monocytogenes infection in mice. In other studies LQGV 
administration was found to reduce hepatic and renal E-selectin expression during 
hemorrhagic shock and renal ischemia reperfusion injury, respectively. This may account 
for the reduced neutrophil accumulation at the site of inflammation due to the LQGV 
treatment. However, the mechanisms of action that contributed to this reduced neutrophil 
accumulation were not studied. Therefore, in the present study we explored the effect 
of LQGV on neutrophil viability and neutrophil-endothelial cell interactions in vivo and 
in vitro. LQGV administration at a dose of 50 mg/kg body weight to naive C57BL/6 
mice was associated with a transient increase in the number of apoptotic neutrophils 
in the blood. These apoptotic neutrophils reduced the heat-killed L. monocytogenes 
driven TNF-α and IL-6 production by splenocytes from untreated C57BL/6 mice in vitro. 
LQGV also reduced O2
- activity by PMA activated neutrophils as well as in the cell free 
cytochrome C assay. Collectively these data suggest that LQGV induces a transient 
reduction in the number of circulating neutrophils by apoptosis, possibly by reducing 
their O2
- activity. This may have contributed to the inhibition of innate immune activation 
by LQGV as described in our L. monocytogenes infection study.
INTRODuCTION
Neutrophils play a central role in the early antibacterial host defense system [1]. 
Listeria monocytogenes is an intracellular bacterium that can cause invasive infection 
in individuals with compromised host defenses [2]. Upon L. monocytogenes infection, 
activated neutrophils transmigrate from the circulation into vital organs where they 
produce and secrete pro-inflammatory mediators, reactive oxygen species (ROS; 
including O2
-, OH- and H2O2) and proteases in order to eliminate the invading pathogen 
[3,4]. However, excessive ROS production results in damage to cellular structures, 
including lipids, proteins, and DNA [5,6]. Also neutrophil-derived proteases, such as 
elastase and matrix metalloproteinases, cause tissue damage [7,8]. These processes 
are in part responsible for the loss of organ integrity and contribute to multiple organ 
failure during a severe L. monocytogenes infection [3,9,10]. 
Previously, we found that oligopeptides related to the primary structure of 
human chorionic gonadotropin (hCG) reduced the inflammatory response upon 
lipopolysaccharide (LPS) injection, ischemia-reperfusion injury, and L. monocytogenes 
infection [11-14]. In these models administration of hCG-related oligopeptides was 
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found to be associated with reduced adhesion molecule expression and neutrophil 
accumulation at the site of inflammation [11-13]. These data suggest that these 
oligopeptides may have inhibited neutrophil accumulation by means of reducing 
adhesion molecule expression. We can, however, not exclude the possibility that other 
mechanisms, such as redistribution to other organs or apoptosis-induced depletion, 
also contributed to the reduction of neutrophil accumulation at inflammatory sites 
[11,12]. Therefore, in this study we explored the effect of LQGV on neutrophil viability 
and neutrophil-endothelial cell interactions in naive mice.
Here we demonstrate that LQGV induces apoptosis of circulating blood neutrophils. 
Furthermore, LQGV can reduce O2
- activity, which may have accounted for the pro-
apoptotic effect. Such LQGV-induced apoptotic neutrophils impaired the capacity of 
splenocytes from untreated mice to produce cytokines upon overnight stimulation with 
heat-killed L. monocytogenes (HKLM). Collectively, these data suggest that LQGV-
induced neutrophil apoptosis may have contributed to the early inhibition of innate 
immune activation as found in our study on severe L. monocytogenes infection [14]. 
MATERIALS AND METHODS 
Animals
Specific pathogen-free C57BL/6 male mice (Harlan, Horst, The Netherlands), aged 
8–12 wk, were used in experiments that were approved by the local Animal Experiments 
Committee. 
Tissue collection, in vitro splenocyte stimulation and cytokine analysis
Mice were intra-peritoneally (ip) injected with 200 µL LQGV (50 mg/kg BW; GL 
Biochem Shanghai, China) or PBS and euthanized at the indicated time points. Blood 
was obtained by cardiac puncture and collected in EDTA-tubes (Greiner, Bio-one, 
Alphen aan den Rijn, The Netherlands). Spleen and lungs were isolated and collected 
in PBS. Plasma was obtained by centrifugation (3000 rpm; 10 min), immediately frozen 
and stored at -20°C until assayed. Splenocytes were isolated and cultured (106 cells/ml) 
overnight in the presence or absence of apoptotic neutrophils in a 1:1 cell ratio in RPMI 
medium containing 5% FCS, antibiotics, and with or without 7log10 HKLM [14]. Culture 
supernatants were collected and TNF-α and IL-6 levels were determined by ELISA 
(R&D Systems Europe, Abingdon, UK).
Flow cytometric analysis 
Flow cytometric immunophenotyping was performed on leukocytes as described 
previously [15]. Briefly, cells were incubated with 5% normal mouse serum (Sanquin 
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Reagents, The Netherlands). Neutrophils were visualized with anti-Ly6C (ER-MP20 
[16]) and anti-Ly6G (1A8) mAbs. T-cell subsets were detected using anti-CD3 (145-
2C11), anti-CD4 (RM4-5), and anti-CD8α (53-6.7) mAbs. B-cells with anti-CD19 (ID3), 
and anti-IgM (R6-60.2) (BD PharMingen, Breda, The Netherlands). Neutrophils (Ly6G-
pos, Ly6C-pos) were subsequently labeled with Annexin V and 7-AAD, according to 
the manufacturers protocol (BD PharMingen, Breda, The Netherlands). Early apoptotic 
neutrophils (Annexin V positive and 7AAD negative) and late apoptotic neutrophils 
(Annexin V positive and 7AAD positive) were analyzed on a FACSCanto (BD Biosciences, 
San Jose, CA, USA). Data were analyzed using Flow-jo software (TreeStar, Ashland, 
OR, USA).
Neutrophil isolation
Neutrophils were isolated as described [17]. Briefly, neutrophils were isolated through 
ficoll centrifugation (lymphocyte separation media; ICN Biomedicals, Zoetermeer, The 
Netherlands) followed by hypotonic lysis of erythrocytes. The neutrophil-rich sample 
was analyzed for cell number by a Coulter counter (Beckman Coulter, Woerden, The 
Netherlands). From naive mice, neutrophils were isolated and subsequently cultured 
overnight to generate apoptotic neutrophils. From LQGV-treated mice, neutrophils were 
isolated at one hour after LQGV administration. Both isolated neutrophil populations 
were co-cultured as described above. Apoptosis was confirmed by flow cytometric 
staining for Annexin V and 7-AAD, according to manufacturers protocol (BD PharMingen, 
Breda, The Netherlands).
Isolation of pulmonary endothelial cells
Pulmonary endothelial cells were isolated as described [18]. Briefly, lungs were 
cut with two scalpels into smaller sections, which were subjected to collagenase III 
digestion (Sigma-Aldrich, Zwijdrecht, The Netherlands). The obtained cell suspension 
was washed three times with PBS and cultured in a culture flask in M199 medium 
containing FCS, endothelial growth supplement, heparin, and antibiotics [19]. Every 
other day the medium was replaced. Endothelial cells were used up to maximum 
passage six. 
Adhesion assay
Mouse pulmonary endothelial cells (passage 2 - 6) were plated into 96 wells plates 
followed by two to three days incubation at 37°C, after which a monolayer was present 
as confirmed by light microscopy, as described elsewhere [17,19]. One hour after PBS 
or LQGV administration, neutrophils (1×106 cells/ml) were isolated and labelled with 
calcein-AM (Molecular Probes, Leiden, The Netherlands). The labelled neutrophils 
(100µl) were added to the endothelial cell monolayer. Thereafter, plates were centrifuged 
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for 1 minute at 80 × g, incubated for 1 hour at 37°C, and washed twice with medium to 
remove non-adherent neutrophils. The remaining fluorescence per well was measured 
on a plate reader using 485 nm excitation and a 530 nm emission filter. Neutrophil 
adherence was expressed as the percentage increase in cell number as compared with 
the wells where no neutrophils were added.
Lactate dehydrogenase (LDH) analysis
LDH levels were determined at the Erasmus MC clinical chemistry diagnostic facility 
according to standard procedures.
Superoxide anion detection in a cell free system
Superoxide anion (O2
-) production was measured with the cytochrome C reduction 
assay as described [20]. Briefly, a cytochrome C (Sigma-Aldrich, Zwijdrecht, The 
Netherlands) solution was prepared in Hanks’ Balanced Salt Solution (HBSS; Invitrogen, 
Molecular Probes, Carlsbad, CA). This cytochrome C solution was added to a cuvette, 
to which either superoxide dismutase (SOD; positive control), HBSS (negative control) 
or different dosages of LQGV were added. Subsequently, xanthine-oxidase was added 
after which the optical density was measured in time for a total of 90 seconds. Hereafter, 
hypoxanthine was added to the cuvette to initiate the reaction between xanthine-oxidase 
and hypoxanthine that leads to O2
- production. The cuvette was measured in time for 
a total of 30 measurements, and each measurement lasted for 30 seconds. All buffers 
were pH 7.4 during the reaction. The cuvette was measured on a spectrophotometer 
(Shimadzu, Tokyo, Japan ) at 550 nm and results are expressed as extinctions. 
Extracellular superoxide anion detection
Extracellular O2
- production was measured using lucigenin (bis-N-methylacridinium; 
Sigma-Aldrich, Zwijdrecht, The Netherlands), which yields a chemiluminescent 
signal in the presence of superoxide anion. SOD (50 U/ml) was used as control for 
O2
- neutralization. Neutrophils were suspended in HBSS containing Mg2+ and Ca2+ 
(Invitrogen, Molecular Probes, Carlsbad, CA) and seeded in triplo into 96 wells U-bottom 
plates (GreinerBio, Alphen a/d Rijn, The Netherlands) that already contained HBSS 
with different dosages of LQGV. Subsequently, cells were stimulated with 500 ng/ml 
phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, Zwijdrecht, The Netherlands). 
After adding lucigenin and PMA to the cells, chemiluminescence was immediately 
measured using a 96 wells luminometer (LUMIstar Galaxy, BMG, LABTECH, Offenburg, 
Germany). Each well was measured in time for a total of 70 measurements, and each 
measurement lasted for 10 seconds. Results are expressed as O2
- production (average 
counts per minute (cpm)).
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad software, 
CA, USA). Intergroup differences were analyzed with Mann-Whitney statistical test and 
p < 0.05 was considered statistically significant. For survival analysis, a Kaplan-Meier 
analysis followed by a log rank test was performed.
RESuLTS
LQGV treatment decreases the blood neutrophil numbers 
In order to investigate the effect of a single LQGV injection on circulating leukocyte 
populations, C57BL/6 mice were treated with LQGV (50 mg/kg BW) and flow cytometric 
analysis was performed on blood. To this end, we quantified T-cells (Figure 1A), B-cells 
(Figure 1B), neutrophils (Figure 1C), and monocytes (Figure 1D). LQGV treatment 
caused a significant reduction of neutrophil numbers as compared to PBS treatment at 
one hour (3.4x108 cells/L vs 6.2 x108 cells/L; p < 0.05) and at three hours (2.5x108 cells/L 
vs 5.6x108 cells/L; p < 0.05) after treatment. T-cell, B-cell, and monocyte numbers were 
not affected by LQGV.
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
2.5
0 1 3 6 24
0.0
0.2
0.4
0.6
0.8
PBS
LQGV
0 1 3 6 24
0.0
0.1
0.2
0.3
x1
05
 
ce
lls
/m
l
x1
05
 
ce
lls
/m
l
T-cells B-cells
Neutrophils Monocytes
Time (hrs) Time (hrs)
A B
C D
* *
Figure 1. LQGV treatment transiently decreases blood neutrophil numbers.
Mice were treated with LQGV (50mg/kg BW) or PBS and at 1, 3, 6, and 24 hours after treatment 
the numbers of (A) T-cells, (B) B-cells, (C) neutrophils and (D) monocytes in blood were determined. 
Data depicted are from 8 mice per group. * means p < 0.05.
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LQGV does not affect the adhesive capacity of neutrophils to endothelial 
cells 
The reduced neutrophil numbers that were observed upon LQGV administration 
(50 mg/kg BW) might be due to increased adhesion to endothelial cells. Therefore, we 
analyzed neutrophil adhesion to endothelial cells in vitro. Blood neutrophils, isolated 
at 30 and 60 minutes after in vivo LQGV administration, were co-cultured with primary 
pulmonary endothelial cells. This revealed no significant differences between the 
adherent capacity of neutrophils from LQGV-treated and PBS-treated mice (Figure 2).
 
LQGV treatment is associated with increased systemic LDH levels and 
neutrophil apoptosis 
Since LQGV did not affect the adherent capacity of neutrophils to endothelial cells, 
we next examined neutrophil apoptosis. First, we determined LDH levels in plasma, as 
a marker for cell damage. In untreated mice, the LDH plasma levels were approximately 
34 ± 4 IU/L. Upon LQGV (50 mg/kg BW) treatment, the LDH plasma levels increased 
significantly as compared to PBS treatment at 40 minutes (75 IU/L vs 42 IU/L) and 
at 60 minutes (98 IU/L vs 48 IU/L; p < 0.05) (Figure 3A). Next, we performed flow 
cytometic analysis on the blood neutrophils at 30 and 60 minutes after either PBS or 
LQGV administration. The populations of annexin-V and 7-AAD positive neutrophils 
from LQGV-treated mice were significantly larger (p < 0.05) than those from PBS-
treated mice and naive mice at 60 minutes after LQGV-administration (Figure 3B). 
This indicates increased neutrophil apoptosis upon LQGV treatment.
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Figure 2. LQGV treatment does not affect the adherent capacity of neutrophils to endothelial 
cells. 
Neutrophils were isolated from the blood of mice at 30 and 60 minutes after PBS or LQGV administration 
and subsequently used in the endothelial cell adhesion assay. 
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LQGV decreases superoxide anion production
Neutrophil viability is regulated by several mechanisms, one of which is the regulation 
of intracellular ROS levels, such as O2
- [21]. We investigated the effect of LQGV on 
PMA-stimulated neutrophils. This revealed that LQGV dose dependently reduced 
extracellular O2
- levels upon PMA stimulation (Figure 4A). Also in a cell free system, O2
- 
levels were reduced when LQGV was added to the assay, again in dose dependently 
(Figure 4B).
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Figure 3. LQGV treatment is associated with increased systemic LDH levels and increased 
numbers of apoptotic neutrophils. 
(A) LQGV treatment is associated with increased LDH levels in plasma. (B) Quantification of 
apoptotic blood neutrophil numbers after LQGV treatment. Early apoptotic neutrophils were 
defined as Annexin V positive and 7-AAD negative. Late apoptotic neutrophils were defined 
as Annexin V positive and 7-AAD positive. Data depicted are from 4 mice per group. * means 
p < 0.05.
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LQGV-induced apoptotic neutrophils are anti-inflammatory.
It has been recognized that apoptotic neutrophils exert anti-inflammatory activity upon 
TLR activation [22,23]. We examined whether apoptotic neutrophils obtained one hour 
after in vivo LQGV administration (50 mg/kg BW) or obtained after overnight culture in 
vitro reduced the responsiveness of splenocytes from naïve mice to HKLM stimulation. 
This revealed that LQGV-induced apoptotic neutrophils as well as apoptotic neutrophils 
generated by overnight culture impaired the capacity of splenocytes from untreated 
mice to produce TNF-α (Figure 5A) and IL-6 (Figure 5B) upon HKLM stimulation.
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Figure 4. LQGV reduces O2
- levels. 
(A) Blood neutrophils stimulated with PMA in the presence of LQGV showed a dose dependent reduction 
of extracellular O2
- formation. (B) Adding LQGV to a cytochrome C reduction assay leads to a dose 
dependent inhibition of hypoxanthine/oxidase-induced cytochrome C reduction. Superoxide dysmutase 
(SOD).
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Figure 5. LQGV-induced apoptotic neutrophils reduce cytokine secretion. 
Splenocytes from naïve mice were unstimulated or stimulated with HKLM in the presence of neutrophils 
from LQGV-treated mice or overnight (ON) cultured neutrophils. (A) TNF-α and (B) IL-6 levels were 
determined in culture supernatant by ELISA. US, unstimulated. * means p < 0.05.
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DISCuSSION
Multiple organ dysfunction syndrome (MODS) is an often fatal complication of SIRS. 
Although the exact mechanisms involved are not completely known yet, studies in 
which neutrophils were depleted prior to the onset of SIRS showed a reduced MODS 
[24-26], indicating that neutrophils are a contributing factor. However, in case of an 
infection neutrophil depletion leads to an enhanced susceptibility to the infectious agent, 
due to the hosts inability to clear the pathogen [27]. Previously, we found that LQGV 
(50 mg/kg BW) enhanced the susceptibility of mice to a L. monocytogenes infection 
[14]. In this model, neutrophils play an important role. In our current study, we describe 
that  high dose (50 mg/kg BW) LQGV-treatment of C57BL/6 mice specifically induces 
neutrophil apoptosis, probably through reducing O2
- activity. In addition, we show that 
these apoptotic neutrophils exert anti-inflammatory activity when co-cultured with naive 
splenocytes and stimulated overnight with HKLM.
Neutrophil viability is tightly regulated by intracellular ROS levels [28]. Is has been 
demonstrated that SOD injection reduces intracellular O2
- levels in neutrophils, leading 
to caspase-3 activation and subsequent apoptosis [21,29]. We found that LQGV has 
the ability to reduce O2
- activity and such a process may have contributed to the LQGV-
induced neutrophil apoptosis. LQGV, however, did not affect the viability of monocytes, 
probably because intracellular ROS levels do not regulate monocyte viability [30,31]. 
Neutrophils are the first cells to be recruited to the inflammatory foci [2]. This 
extravasation process can be divided into five sequential stages: (a) selectin-
mediated leukocyte sticking; (b) integrin-mediated intravascular crawling; (c) firm 
arrest of leukocytes to the endothelium; (d) chemokine-induced leukocyte activation 
and migration over the endothelium; and finally (e) transendothelial migration through 
a chemokine gradient [32,33]. Previously, we found that LQGV treatment reduced 
E-selectin expression in the liver, which was associated with reduced hepatic neutrophil 
accumulation [12]. Although our previous study may suggest a decreased migration 
of neutrophils into the liver [12], our current data show that high dose (50 mg/kg BW) 
LQGV-treatment induces a transient neutropenia, which may also have contributed to 
this reduced accumulation. We cannot exclude that other granulocytes, for instance 
eosinophils and mast cells, of which the viability is also tightly regulated by intracellular 
ROS levels, are also transiently reduced by apoptosis [34].
The LQGV-induced apoptotic neutrophils reduced the capacity of splenocytes from 
untreated mice to secrete TNF-α and IL-6 to HKLM stimulation. Such effects of apoptotic 
neutrophils may have contributed to the decline in inflammatory cytokines (e.g. TNF-α 
and IL-6) that we found in mice infected with L. monocytogenes [14]. 
In conclusion, we show that high dose (50 mg/kg BW) LQGV-treatment of C57BL/6 
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mice induces neutrophil apoptosis, possibly by neutralization of intracellular O2
- levels. 
Both the transient depletion of neutrophils and the anti-inflammatory activity of apoptotic 
neutrophils may have contributed to the inhibition of early innate immunity during a 
L. monocytogenes infection in mice [14]. More studies are needed to investigate these 
effects of LQGV on neutrophil viability, ROS production and inflammation. 
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ABSTRACT
The systemic inflammatory response syndrome (SIRS) is a complex host response 
to a variety of clinical insults, generally leading to severe pathology. The human 
chorionic gonadotropin β-chain related tetrapeptide LQGV reduces hemorrhagic 
and LPS-induced SIRS, while its mechanisms of action are not yet fully understood. 
Through the combination of in vivo, in vitro and ex vivo approaches we demonstrate that 
LQGV actively stimulates corticosterone production in mice and thereby suppresses 
in vivo TLR-4 directed inflammation upon LPS administration. Blocking in vivo 
glucocorticosteroid receptor signaling reduced the pro-survival effect of LQGV. Also 
upon multiple TLR activation by heat killed Listeria monocytogenes, splenocytes from 
LQGV-treated mice produced significantly less TNF-α and IL-6, which was absent after 
in vitro blockage of the glucocorticosteroid receptor. Using adrenal gland and adrenal 
cell line cultures, we show that LQGV stimulates corticosterone production. Moreover, 
by using specific pharmacological inhibitors of the adrenocorticotropic hormone and 
luteinizing hormone receptors as well as of cyclic AMP signaling, we demonstrate 
that LQGV stimulates the ACTH-receptor. These data show that the β-hCG-related 
tetrapeptide LQGV stimulates adrenal glucocorticosteroid production through activation 
of the adrenocorticotropic hormone-receptor with consequent glucocorticoid receptor 
activation and immunosuppression in C57BL/6 mice.
 
INTRODuCTION
Pregnancy is characterized by specific control of the maternal immune system, which 
is necessary to prevent rejection of the fetal allograft [1]. Consequently, during pregnancy 
symptoms of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis 
decline, while susceptibility to intracellular pathogens such as Listeria monocytogenes, 
Toxoplasma goundii, Leishmania major and Plasmodium species increases [1-4]. 
The exact mechanisms that modulate the immune system during pregnancy are largely 
unknown, but most likely specific hormonal changes are involved [5].
Human chorionic gonadotropin (hCG) is a human pregnancy hormone that, besides 
its endocrine functions, also influences the functionality of the immune system [6-9]. 
In addition to intact hCG several other isoforms of hCG exist during pregnancy [10]. 
It is well recognized that loop 2 of β-hCG is nicked by leukocyte elastase-like proteases, 
generating hCG β-core and several nicked β-hCG forms [11,12]. These molecules can 
be detected in serum and urine, especially in the late second and third pregnancy 
trimester [10]. It was postulated that, besides the generation of hCG β-core and nicked 
β-hCG, small breakdown products of three to seven amino acids long are generated 
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from loop 2 of β-hCG, and that such small peptides can exert immunomodulatory effects 
[9,13,14].
The systemic inflammatory response syndrome (SIRS) is a complex host response 
that may be inflicted by a variety of insults, such as severe trauma-hemorrhage, 
ischemia-reperfusion injury, pancreatitis, sepsis and septic-shock [15]. SIRS is 
characterized by excessive production of pro-inflammatory mediators, such as IL-1, 
IL-6, TNF-α, CCL2, CXCL1, and CXCL2 [16,17]. High levels of these pro-inflammatory 
mediators contribute to severe organ damage and multiple organ dysfunction syndrome 
[18]. Recently, we demonstrated that the synthetic β-hCG-related tetrapeptide LQGV 
reduces hemorrhagic shock associated inflammation and liver damage, prevents LPS-
induced mortality in mice, and ameliorates the early chemokine response following 
L. monocytogenes infection [19-21]. However, the regulatory mechanism by which 
LQGV exerts anti-inflammatory effects remains elusive.
Endogenous glucocorticosteroid production and function are crucial in the control 
and resolution of inflammation [22-24]. In line with this, administration of synthetic 
glucocorticosteroids is commonly used in clinical settings to control inflammation [22]. 
Also specific activation of endogenous glucocorticosteroid production by the adrenal 
glands has been postulated as a way to control an inflammatory event  [25].  An increase 
in circulating cortisol (of which the rodent analogue is corticosterone) is observed during 
the late second and third pregnancy trimester, the phase that the highest degree of 
proteolytic cleavage of β-hCG occurs. Therefore, we examined whether the β-hCG-
related tetrapeptide LQGV exerts anti-inflammatory effects through the stimulation of 
glucocorticosteroid receptor (GR) signaling and glucocorticosteroid production.
By using combined in vivo, in vitro and ex vivo approaches we demonstrate that 
LQGV exerts anti-inflammatory effects through GR activation, via stimulation of 
corticosterone production by the adrenal glands. This LQGV-induced corticosterone 
production is mediated through specific adrenocorticotropic hormone (ACTH)-receptor 
activation and subsequent cAMP-signaling. 
MATERIALS AND METHODS 
Animals
Specific pathogen-free C57BL/6 male mice (Harlan, Horst, The Netherlands), 
aged 8–12 wk, were used in the experiments that were approved by the local Animal 
Experiments Committee. 
Lipopolysaccharide-induced shock 
Mice were injected intraperitoneally (ip) either with 200 µl LQGV (50 mg/kg BW 
dissolved in PBS; purity 99,2%; GL Biochem Shanghai Ltd., China) or PBS (as 
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control), directly followed by a second ip injection with 500 µl of the GR antagonist 
mifepristone (RU38486; 10 mg/kg BW, dissolved in dimethylsulfoxide; Sigma Aldrich, 
Zwijndrecht, The Netherlands) or vehicle. The next day, mice were challenged with a 
lipopolysaccharide (LPS) injection (30 mg/kg BW of Escherichia coli strain 0111:B4; 
Sigma Aldrich, Zwijndrecht, The Netherlands). The survival was scored every 12 hours 
for three days.
Adrenalectomy 
Adrenalectomy (ADX) was performed as described [26], after which mice acclimatized 
for seven days before start of the experiment. All mice postoperatively received 0.9% 
NaCl solution as drinking water. 
Ex vivo adrenal gland culture
Complete adrenal glands were isolated and cultured as described [27,28]. Briefly, 
300 µl RMPI medium containing antibiotics, 5% FCS, and LQGV (50, 5, 0.5 µg/ml) or 
PBS was added to the adrenal gland culture for six hours. The cAMP-blocker H-89 
(10 µM; Biomol, Plymouth, USA), the ACTH-blocker corticotropin-inhibiting peptide CIP 
(10-6 mM, 10-7 mM, 10-8 mM or 10-9 mM; Phoenix Pharmaceutics INC, Phoenix, USA) 
and the luteinizing hormone (LH)-receptor antagonist Antide (100 µM; Sigma Aldrich, 
Zwijndrecht, The Netherlands) were added 5 minutes before LQGV stimulation. Culture 
supernatants and adrenal glands were collected and stored at -80 ºC until assayed.
In vitro stimulation of LHR-Y1-cells
The murine LH-receptor-transfected Y1-adrenal cells (LHR-Y1-cells; kindly provided 
by Dr. Bill Moyle; University of Medicine and Dentistry of New Jersey) were cultured 
as described [29]. The cAMP-blocker H-89 (10 µM), ACTH-blocker CIP (10-6 mM), 
and LH-receptor antagonist Antide (100µM), were added 5 minutes before addition of 
recombinant hCG (300 U/ml; Sigma  Aldrich, Zwijndrecht, The Netherlands) or LQGV 
(5 or 50 µg/ml). Cells and supernatants were collected and stored at -80 ºC until 
assayed.
In vitro stimulation of splenocytes and cytokine analysis
ADX and non-ADX mice were ip injected with 200 µL LQGV (50 mg/kg BW) or PBS. 
Thirty minutes later 500 µl of the GR antagonist mifepristone or vehicle was administrated 
ip. Mice were euthanized 18 hours later; blood was collected by cardiac puncture and 
splenocytes were isolated and stimulated as described [21]. Plasma was obtained by 
centrifugation (3000 rpm; 10 min), immediately frozen and stored at -80°C until assayed. 
In addition, splenocytes (106 cells/ml) from untreated mice (mice that neither received 
LQGV nor PBS) were isolated and cultured overnight in the presence of plasma from 
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either LQGV- or PBS-treated mice or with culture media from either LQGV or PBS 
stimulated adrenal glands, with or without 7 log10 heat killed Listeria monocytogenes 
(HKLM) [21], and with or without mifepristone (0.3 µg/ml). Culture supernatants were 
collected and TNF-α and IL-6 levels were determined by ELISA (R&D Systems Europe, 
Abingdon, UK).
Corticosterone quantification 
Corticosterone levels in plasma (obtained between 3:00 and 4:00 pm) and culture 
supernatant were determined by ELISA (IBL, Hamburg, Germany).
Evaluation of mRNA expression levels by real-time quantitative (RQ)-PCR
RNA was isolated using the GenElute RNA kit (Sigma Aldrich, Zwijndrecht, The 
Netherlands). CYP11B1 (encoding 11-β-hydroxylase) gene expression levels were 
determined by RQ-PCR using an Applied Biosystems 7900 PCR machine (Foster City, 
CA, USA). The expression levels were quantified by normalization against the mRNA 
levels of the household gene ABL [30]. Primers and probes used are available upon 
request. 
Statistical analysis 
Statistical analysis was performed using SPSS version 15 software (SPSS Inc., 
Chicago, Ill). Intergroup differences were analyzed using Mann-Whitney statistical test 
and p < 0.05 was considered statistically significant. For survival analysis, a Kaplan-
Meier analysis followed by a log rank test was performed. Correlation coefficients were 
determined with Pearson’s correlation analyses with significance set at a p < 0.05.
RESuLTS
LQGV reduces LPS-induced mortality via GR activation
Previously, we demonstrated that LQGV protected BALB/c mice against LPS-
induced mortality [19]. Here, we found that LQGV administration 24h prior to LPS 
injection significantly (p < 0.05) improved the three day survival from 20% to 60% in 
C57BL/6 mice (Figure 1). This pro-survival effect of LQGV was completely reversed 
when mice received the GR antagonist mifepristone in combination with LQGV 
(Figure 1). These data indicate that the pro-survival effect of LQGV in this model is 
dependent on GR activation.
In vivo LQGV treatment reduces the in vitro responsiveness of splenocytes to 
L. monocytogenes antigens
Next we examined how LQGV treatment activated the GR in immune cells. Hereto 
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splenocytes from untreated mice were stimulated with HKLM (which activates multiple 
pattern-recognition receptors and evokes a stronger inflammatory response than LPS 
[21]), in the presence of LQGV (50 µg/ml). HKLM stimulation induced TNF-α and 
IL-6 production by splenocytes, which was not affected by addition of LQGV to the 
cultures (Figure 2A and B). In contrast, splenocytes obtained from mice 18h after LQGV 
(50 mg/kg BW) administration produced significantly less TNF-α (p < 0.01) and IL-6 
 (p < 0.05) upon HKLM stimulation than splenocytes from PBS-treated mice (Figure 2C 
and D). This suppressive effect of LQGV was completely reversed when LQGV-treated 
mice also received mifepristone (Figure 2C and D). These data demonstrate that LQGV 
does not directly stimulate GR activity in splenocytes nor that it directly interferes with 
cytokine production and secretion, but suggests that the immunosuppressive effect of 
LQGV is established through an in vivo released secondary mediator that stimulates 
the GR.
LQGV induces the systemic release of an immunosuppressive mediator
Next, we determined whether LQGV induced the systemic release of an 
immunosuppressive mediator that acts through the GR. Hereto, plasma was obtained 
from mice 18 hours following PBS or LQGV injection. Plasma from both LQGV- and 
PBS-treated mice inhibited HKLM-induced TNF-α production by naïve splenocytes in 
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Figure 1. Mifepristone injection abolishes the LQGV pro-survival effect. 
Mice were ip injected with either 200 µl LQGV (50 mg/kg BW) or PBS, directly followed by a second ip 
injection with 500 µl mifepristone (10 mg/kg BW) or vehicle. The next day, mice were challenged with an 
LPS injection. Survival was scored every 12 hours. Data depicted are from 19 mice per group. * p < 0.05 
for LQGV + vehicle treatment  compared with LQGV + mifepristone treatment, or PBS + vehicle.
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a dose dependent manner (Figure 3A). When a total volume of 30% (v/v) plasma was 
added to the culture, plasma from LQGV-treated mice reduced HKLM-induced TNF-α 
(p < 0.01) and IL-6 (p < 0.05) production to significantly lower levels than observed 
with plasma from PBS-treated mice (Figure 3B and C). Addition of mifepristone to the 
cultures completely reversed the immunosuppressive effect of plasma from LQGV-
treated mice (Figure 3B and C). Collectively, these data suggest that the reduced 
capacity of splenocytes to respond to HKLM antigens, as displayed after in vivo LQGV 
administration, is established through the systemic release of a GR activating factor.
The immunosuppressive effect of LQGV is abolished by adrenalectomy
To examine the role of the adrenal glands in LQGV-induced immunosuppression, 
splenocytes from both LQGV- and PBS-treated ADX mice were stimulated with HKLM. 
Removal of the adrenal glands completely abolished the immunosuppressive effect 
of LQGV (Figure 4A), as reflected by the TNF-α and IL-6 levels detected in culture 
supernatants. Also plasma from LQGV-treated ADX mice did not reduce the HKLM-
induced TNF-α and IL-6 production by splenocytes from untreated mice (Figure 4B). 
These data demonstrate that the adrenal glands are involved in establishing the 
immunosuppressive effect of LQGV. 
LQGV stimulates adrenal corticosterone production 
The previous experiments suggest that LQGV induces the release of an adrenal-
derived immunosuppressive mediator that exerts its action through the GR. Therefore, 
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Figure 2. In vivo LQGV administration reduces HKLM-induced TNF-α and IL-6 production by 
splenocytes.
Splenocytes from untreated mice were stimulated overnight with 7log10 HKLM in the presence of 50 µg/
ml LQGV whereafter TNF-α (A) and IL-6 (B) levels in culture supernatants were determined by ELISA. 
In other experiment, mice were treated with LQGV (50 mg/kg BW) or PBS, in combination with or without 
mifepristone, 18h later splenocytes were isolated and cultured overnight with 7log10 HKLM, whereafter 
TNF-α (C) and IL-6 (D) levels in culture supernatants were determined by ELISA. Data depicted are 
from 5 mice per group. US, unstimulated. * means p < 0.05 and ** means p < 0.01.
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we determined plasma corticosterone levels at different time points following LQGV 
administration. Corticosterone plasma levels were significantly higher at one hour 
(0.265 µMol/L vs 0.074 µMol/L; p < 0.05), at six hours (0.664 µMol/L vs 0.055 µMol/L; 
p < 0.05), and at twenty-four hours (0.406 µMol/L vs 0.050 µMol/L; p < 0.05) in LQGV-
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Figure 3. LQGV induces the release of an immunosuppressive mediator in plasma.
Mice were treated with LQGV (50 mg/kg BW) or PBS, and 18h later plasma was obtained and used 
in increasing amounts (v/v) in overnight cultures of splenocytes from untreated mice stimulated with 
7log10 HKLM. Thereafter TNF-α levels in culture supernatants were determined by ELISA. Data depicted 
are from 4 mice per group (A). In other experiments, mice were treated with LQGV or PBS, and 18h 
later plasma was isolated and 30% (v/v) was used in an overnight stimulation of splenocytes from 
untreated mice with 7log10 HKLM in combination with or without mifepristone. TNF-α (B) and IL-6 (C) 
levels in culture supernatants were determined by ELISA. Data depicted are from 7 mice per group. US, 
unstimulated. * means p < 0.05 and ** means p < 0.01.
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treated mice than in PBS-treated mice (Figure 5A). Ex vivo stimulation of complete 
adrenal glands revealed that LQGV dose dependently and significantly (p < 0.05) 
induced corticosterone secretion (Figure 5B). Recombinant hCG and the irrelevant 
tetrapeptide EPPE did not stimulate adrenal corticosterone secretion (data not shown). 
Next, we examined whether the adrenal gland culture media affected HKLM-induced 
TNF-α and IL-6 production by splenocytes. Splenocytes were isolated from untreated 
mice and stimulated with HKLM in the presence of culture media from adrenal glands 
stimulated with either LQGV or PBS. Culture media obtained from LQGV-stimulated 
adrenal glands inhibited HKLM-induced TNF-α production in a dose dependent manner 
(Figure 5C). When a total of 8% (v/v) adrenal gland culture medium was added to the 
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Figure 4. Adrenalectomy abolishes the immunosuppressive effect of LQGV.
ADX mice were treated with LQGV (50 mg/kg BW) or PBS, and 18h later splenocytes were obtained 
and cultured overnight with 7log10 HKLM. TNF-α and IL-6 levels in culture supernatants were determined 
by ELISA (A). In other experiments, ADX mice were treated with LQGV or PBS, 18h later plasma was 
isolated and 30% (v/v) was used in an overnight stimulation of splenocytes from untreated non-ADX 
mice with 7log10 HKLM and TNF-α and IL-6 levels in culture supernatants were determined by ELISA 
(B). Data depicted are from 5 mice per group. * means p < 0.05.
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Figure 5. LQGV activates the adrenal glands to secrete corticosterone.
Mice were treated with LQGV (50 mg/kg BW) or PBS and plasma corticosterone levels were determined 
at 0, 1, 6 and 24 hours after treatment. Plasma corticosterone levels in LQGV-treated mice increased 
and peaked at 6h after which the levels slowly declined (A). Data depicted are from 8 mice per time 
point. Adrenal glands from naïve mice were ex vivo stimulated with either 0.5, 5, or 50 µg/ml LQGV and 
corticosterone levels in supernatant were determined. * means p < 0.05 (B). Culture supernatant collected 
from ex vivo adrenal gland stimulation was used in increasing amounts (v/v) in overnight stimulation of 
splenocytes from untreated mice with 7log10 HKLM. Thereafter, TNF-α levels in culture supernatants were 
determined by ELISA. Data depicted are from 4 mice per group. * means p < 0.05  and ** means p < 0.01 
(C). Culture supernatant (8% (v/v)) was added to an overnight stimulation of splenocytes from untreated 
mice with 7log10 HKLM and TNF-α (D) and IL-6 (E) concentrations in culture supernatants were measured 
by ELISA. Data depicted are from 7 mice per group. US, unstimulated. * means p < 0.05 and ** means 
p < 0.01. 
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culture, supernatant from LQGV-stimulated adrenal glands reduced the HKLM-induced 
TNF-α (p < 0.05) (Figure 5D) and IL-6 (p < 0.05) (Figure 5E) production to significantly 
lower levels than observed with supernatant from PBS-stimulated adrenal glands. This 
effect was completely abolished when mifepristone was co-added to the cultures (Figure 
5D and E). These data suggest that LQGV activates the adrenal glands to synthesize 
and secrete corticosterone, which reduces the in vitro responsiveness of splenocytes 
to HKLM.
LQGV activates the adrenal ACTH-receptor 
Next, we determined the mRNA expression levels of 11-β-hydroxylase, the enzyme 
that converts deoxycorticosterone to corticosterone. LQGV dose dependently enhanced 
the mRNA expression levels of 11-β-hydroxylase (Figure 6A), which correlated positively 
and significantly (r = 0.426; p < 0.05) with the corticosterone levels detected in the culture 
media (Figure 6B). The cAMP-blocker H-89 and ACTH-receptor blocker CIP completely 
abolished the LQGV-induced corticosterone release, while this was not observed when 
the LH-receptor antagonist  Antide was added to the organ culture (Figure 6C). Moreover, 
CIP inhibited the LQGV-induced increase of 11-β-hydroxylase mRNA expression in a 
dose dependent manner (Figure 6D). H-89, LH-receptor antagonist, and CIP alone did 
not affect the basal adrenal 11-β-hydroxylase mRNA expression levels (data not shown). 
These data suggest that LQGV activates the adrenal glands to actively synthesize and 
secrete corticosterone through an ACTH-receptor activated cAMP-signaling cascade.
LQGV activates the ACTH-receptor on the murine adrenal cell line LHR-Y1
To further study the specificity of LQGV for the ACTH-receptor, we examined the 
effects of LQGV on ACTH-receptor and LH receptor activation by using the adrenal 
cell line LHR-Y1 (in which the LH-receptor has been cloned [29]). These cells were 
stimulated with recombinant hCG or LQGV in the presence or absence of H-89, CIP 
or LH receptor antagonist. In line with previous observations [31,32], recombinant hCG 
increased the corticosterone levels and the 11-β-hydroxylase mRNA expression levels. 
This increase was inhibited by H-89 and the LH receptor antagonist (Figure 7A and B). 
LQGV dose dependently increased the corticosterone levels and the 11-β-hydroxylase 
mRNA expression levels, which were reduced by H-89 and CIP, but not by the LH 
receptor antagonist Antide (Figure 7A and B). In addition, mRNA expression levels of 11-
β-hydroxylase correlated positively and significantly with corticosterone levels detected 
in supernatants (Figure 7C). The irrelevant tetrapeptide EPPE did not increase the 11-
β-hydroxylase mRNA expression (data not shown). These results demonstrate that 
LQGV induces 11-β-hydroxylase mRNA expression through ACTH-receptor induced 
cAMP signaling.
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Figure 6. LQGV activates the adrenal ACTH-receptor. 
Adrenal glands were ex vivo stimulated with either 0.5, 5, or 50 µg/ml LQGV or with a combination of 
50 µg/ml LQGV with either the cAMP-blocker (H-89), LH-receptor antagonist (LHR) or ACTH-receptor 
antagonist (CIP) and 11-β-hydroxylase mRNA expression levels were determined (A). Correlation 
analysis between adrenal 11-β-hydroxylase mRNA expression levels and corticosterone levels with 
different LQGV stimuli. Statistical significance was determined by Pearson’s correlation analyses (B). 
Adrenal glands were stimulated with 50µg/ml LQGV alone or in combination with either the cAMP-
blocker (H-89), LH-receptor antagonist (LHR) or ACTH-receptor antagonist (CIP) and corticosterone 
levels in supernatant were determined (C). Adrenal glands were ex vivo stimulated with PBS or 50 µg/ml 
LQGV in combination with either 10-9 mM, 10-8 mM, 10-7 mM or 10-6 mM CIP. 11-β-hydroxylase mRNA 
levels were determined (D). Data depicted are from five or six ex vivo stimulated adrenal glands from 
different naïve mice per group. * means p < 0.05.
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Figure 7. LQGV activates the ACTH-receptor on the murine adrenal cell line LHR-Y1.
LHR-Y1-cells were stimulated with either 300U recombinant hCG, 5, or 50 µg/ml LQGV in combination 
with either the cAMP-blocker (H-89), LH-receptor antagonist (LHR), or ACTH receptor antagonist (CIP). 
Subsequently, corticosterone levels in supernatant (A) and 11-β-hydroxylase mRNA expression levels (B) 
were determined in the cultured cells. Correlation analysis between 11-β-hydroxylase mRNA expression 
levels and corticosterone levels after 6 hours stimulation with either 300U recombinant hCG, 5µg/ml 
LQGV or 50 µg/ml LQGV in combination with either the cAMP-blocker (H-89), LH-receptor antagonist 
(LHR) or ACTH-receptor antagonist (CIP) (C) * means p < 0.05, ** means p < 0.01. Data depicted are 
from four single experiments * means p < 0.05.
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DISCuSSION
Endogenous glucocorticosteroid production and function are crucial in the control 
and resolution of inflammatory responses [22,25,33]. In this study we demonstrate for 
the first time that the hCG-related tetrapeptide LQGV, which reduces immune activation 
in response to hemorrhagic shock and resuscitation (HS/R), L. monocytogenes infection, 
and LPS injection [19-21], exerts anti-inflammatory effects through the induction of 
corticosterone production and secretion by the adrenal glands. In addition, we show 
that the LQGV-induced corticosterone production and secretion is mediated through 
ACTH-receptor activation and subsequent cAMP signaling.
Inflammation is a physiological reaction to infection and tissue injury [34]. However, 
an uncontrolled inflammatory response can culminate into SIRS and finally multiple 
organ dysfunction syndrome (MODS), which is a major cause of in hospital deaths 
worldwide [35]. LPS challenge of mice is an TLR-4 driven in vivo SIRS model that 
can result in MODS and eventually death [35]. In line with our previous study [19] we 
found that LQGV (50 mg/kg BW) can inhibit LPS-induced mortality in mice. This effect 
was completely reversed by mifepristone administration, demonstrating that LQGV 
(50 mg/kg BW) exerts its in vivo pro-survival effect through GR activation. Our 
observations are in line with those of others who have demonstrated that GR-signaling 
blockage increases the vulnerability of organisms to tissue injury and LPS-induced 
inflammation [23,36]. 
Glucocorticosteroids exert their immunosuppressive effect through binding to the 
cytoplasmic GR [22,33]. Upon ligand binding GR translocates into the nucleus, where it 
interacts with glucocorticoid responsive elements in the promoter region of target genes 
and regulates their expression [22]. The activated GR can also regulate gene expression 
through direct interaction with transcription factors, such as AP-1, NF-κB and signal 
transducers of activation and transcription (STATs) [37]. We found that splenocytes 
from LQGV-treated mice produced significantly less of the AP-1 and NF-κB controlled 
cytokines IL-6 and TNF-α when stimulated with HKLM in vitro, which was reversed 
when the GR-blocker mifepristone was co-administrated with LQGV to  the mice. Also 
in vitro blockage of GR activity reversed the inhibitory activity of plasma from LQGV-
treated mice with regard to HKLM induced IL-6 and TNF-α production by splenocytes. 
Furthermore, LQGV administration to mice resulted in increased corticosterone levels 
in plasma. Our study also shows that in vitro administration of LQGV to splenocyte 
cultures did not inhibit HKLM induced IL-6 and TNF-α production by itself. Together, 
these data indicate that LQGV renders cells less susceptible to multiple TLR activation 
through corticosterone-induced GR activity. We cannot exclude that other steroids, 
such as progesterone, are also produced  and secreted upon LQGV-induced ACTH-
receptor activation. However, corticosterone has a 5 to 10 times higher affinity for the 
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GR than progesterone [38,39]. Therefore, we believe that corticosterone is the major 
contributing anti-inflammatory glucocorticosteroid induced by high dose (50 mg/kg BW)
LQGV-treatment in our studies.
Glucocorticosteroid production is regulated by 11-β-hydroxylase within the 
zona fascilata of the adrenal cortex [40]. In rodents, 11-β-hydroxylase converts 
deoxycorticosterone to corticosterone, while in humans it converts deoxycortisol 
to cortisol [40]. The expression of 11-β-hydroxylase is dependent on ACTH-induced 
ACTH-receptor activation and subsequent cAMP-signaling [40-42]. LQGV increased 
11-β-hydroxylase mRNA expression levels and stimulated corticosterone production in 
ex vivo adrenal gland cultures. These effects were abolished when cAMP-signaling or 
ACTH-receptor activation were blocked. While LQGV is part of the amino acid sequence 
of loop 2 of β-hCG [13], it exerts its effects independent of the LH/βCG-receptor as is 
evident from our LH/βCG-receptor blocking studies in adrenal gland cultures and LHR-
Y1-cells. This notion is strengthened by our observation that LQGV did not directly 
inhibit the response of splenocytes to HKLM, despite the fact that immune cells can 
express the LH/βCG-receptor and do respond to recombinant hCG [8,9,43,44]. Thus 
LQGV actively stimulates the ACTH-receptor of adrenal cells, but more studies are 
needed to fully explain the mechanism by which LQGV activates the ACTH-receptor.
The in vivo corticosterone plasma levels were increased from at least one hour up 
to 24 hours following LQGV administration. These kinetics clearly differ from the in vivo 
stress-induced release of pre-existing corticosterone, which typically rises and declines 
again within 30-60 minutes [45]. Also, the ex vivo LQGV-induced 11-β-hydroxylase 
mRNA expression levels correlated positively with the corticosterone levels detected in 
adrenal gland culture supernatants. These data suggest that LQGV indeed stimulates 
corticosterone production and secretion by adrenal cells. Alternatively, the increase 
in plasma corticosterone level following LQGV administration could be due to an 
increased level of corticosteroid-binding globulin (CBG), which upon binding enhances 
the corticosterone half-life from 30-60 minutes to approximately 5 days [46]. We regard 
this unlikely as CBG is produced in the liver and therefore could not have influenced the 
increase in corticosterone levels detected in our adrenal gland culture supernatants [47]. 
Furthermore, glucocorticoids bound to CBG are biologically inactive [48], while we 
here show that LQGV stimulation results in the release of bioactive corticosterone, as 
reflected by the fact that mifepristone abolishes the LQGV effects. All together, these 
data indicate that LQGV can stimulate de novo corticosterone production and secretion 
by murine adrenal glands.
Previously, we demonstrated that LQGV reduced inflammation associated with 
hemorrhagic shock and resuscitation, and LPS-induced septic shock, while LQGV 
enhanced the susceptibility to L. monocytogenes infection [19-21]. GR blockage has 
been shown to increase disease severity during hemorrhagic shock and resuscitation 
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as well as LPS-induced septic shock [25,45,49], while synthetic glucocorticosteroids 
are protective in these models [50,51]. High corticosterone levels also render mice 
more susceptible to L. monocytogenes infection [45,52,53]. The effects of increased 
endogenous corticosterone levels on a L. monocytogenes infection was presented in 
a recent study [54]. These authors found that activation of the HPA axis by influenza 
virus leads to a prolonged increase of corticosterone levels that enhanced the 
susceptibility to L. monocytogenes infection [54]. We suggest that LQGV stimulated 
adrenal glucocorticosteroid production and subsequent GR activation contributed to the 
immunosuppressive effects that we found in our previous studies [14,19-21].
In conclusion, the data presented indicate that the hCG-related tetrapeptide LQGV 
can stimulate adrenal corticosterone production through activation of the ACTH-receptor, 
with consequent GR activation and immunosuppression in mice. This effect of LQGV 
may have therapeutic potential, for instance for treating severe inflammatory responses 
or in case of adrenal insufficiency as may occur after cranial irradiation. 
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ABSTRACT
Severe hemorrhagic shock (HS) followed by resuscitation induces a massive 
inflammatory response, which may culminate into systemic inflammatory response 
syndrome, multiple organ dysfunction syndrome and finally death. Treatments 
that effectively prevent this inflammation are limited so far. In a previous study, we 
demonstrated that synthetic oligopeptides related to the primary structure of human 
chorionic gonadotropin (hCG) can inhibit the inflammatory response and mortality 
that follow high-dose LPS-induced inflammation. Considering this powerful anti-
inflammatory effect, we investigated whether administration of similar synthetic hCG-
related oligopeptides (LQGV, AQGV, LAGV), during HS, were able to attenuate the 
inflammatory response associated with this condition. Hemorrhagic shock was induced 
in rats for 60 minutes by blood withdrawal until a MAP of 40 mmHg was reached. Rats 
received a single injection with one of the hCG-related oligopeptides (LQGV, AQGV or 
LAGV) or 0.9% NaCl solution as control 30 minutes after induction of HS. Treatment 
with LQGV, AQGV or LAGV prevented systemic release of TNF-α and IL-6 and was 
associated with reduced TNF-α, IL-6 and E-selectin mRNA transcript levels in the liver. 
LQGV treatment prevented neutrophil infiltration into the liver and was associated with 
reduced liver damage. Our data suggest that hCG-related oligopeptides, in particular 
LQGV, have therapeutic potential by attenuating the life threatening inflammation and 
organ damage that is associated with (trauma) hemorrhagic shock and resuscitation.
INTRODuCTION
Severe hemorrhagic shock (HS) is caused by massive blood loss that cannot be 
compensated for by the body without treatment. The primary treatment of HS is focused 
on controlling bleeding and restoring intravascular volume to improve tissue perfusion. 
Many patients with severe HS who are successfully resuscitated develop an inflammatory 
response, which may culminate into systemic inflammatory response syndrome (SIRS) 
and finally multiple organ dysfunction syndrome (MODS) [1]. In addition, approximately 
40% of patients with hemorrhagic shock develop sepsis as a result of increased gut 
permeability and development of compensatory anti-inflammatory syndrome [1-2]. 
Sepsis and MODS are the leading causes of death in critically ill patients on the intensive 
care unit all over the world with approximately 50% mortality [3].
The inflammatory response after HS and resuscitation is characterized by increased 
expression of adhesion molecules, such as E-selectin and intracellular adhesion 
molecule-1 (ICAM-1), on endothelial cells and hepatocytes [4]. Up-regulation of these 
adhesion molecules facilitates tissue infiltration by neutrophils, resulting in cell-mediated 
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organ injury [5]. Furthermore, increased levels of cytokines, such as TNF-α, IL-1β, IL-6 
and IL-10, are found systemically and locally in liver, lungs and intestine [6-8]. These 
cytokines, mainly produced by immune cells, affect organ integrity directly or indirectly 
through induction of secondary mediators, such as thromboxanes, leukotrienes, and 
complement [9-10].
The last decade, research has focused on reducing systemic and local inflammatory 
responses with therapeutic agents that neutralize cytokine activity or inhibit inflammatory 
mediator production. However, in the case of HS such treatments require initiation 
before the onset of shock to achieve an effect [11-13]. Clearly, this is impossible in most 
clinical settings. Therefore, therapies that efficiently inhibit the inflammatory response 
when initiated after hemorrhage-induced shock are more relevant. Studies on such 
treatments are limited [14], but are highly needed.
During pregnancy, the maternal immune system tolerates the fetus by reducing 
cell-mediated immune responses while retaining normal humoral immunity. In addition, 
clinical symptoms of cell-mediated autoimmune diseases regress in many patients 
during pregnancy [15]. Most likely a specific hormonal environment is responsible for 
modulating the immune system during pregnancy [15]. The hormone human chorionic 
gonadotropin (hCG) is secreted by placental syncytiotrophoblasts during human 
pregnancy. Human chorionic gonadotropin preparations exhibit not only endocrine 
effects, but also immunosuppressive activity [16]. We found that hCG preparations 
inhibited the onset of autoimmune type-I diabetes in nonobese diabetic mice [17]. 
This anti-diabetic/anti-inflammatory activity was not due to the heterodimeric hCG 
nor to its α- or β-subunits, but resided in a peptide fraction of 400-2000 Dalton, which 
likely originates from proteolytic cleavage of loop 2 of the hCG β-subunit [17-19]. 
Subsequently, we successfully demonstrated that synthetic oligopeptides, related to the 
primary sequence of loop 2 of the hCG β-subunit, inhibit inflammation, disease severity, 
and mortality in high-dose LPS-induced SIRS [18-19]. Considering this powerful effect 
of synthetic hCG-related oligopeptides on inflammation, we hypothesized that the 
administration of such oligopeptides after induction of HS could inhibit the inflammatory 
response associated with this condition. To this end, we used LQGV, which is part of 
the primary structure of loop 2 of the β-subunit of hCG, and two alanine replacement 
variants, namely AQGV and LAGV.
Using a rat model of (trauma) HS and resuscitation, we demonstrate that either 
LQGV, AQGV or LAGV, administered after the induction of HS, significantly prevented 
TNF-α and IL-6 release into the plasma and attenuated the increase in TNF-α, IL-6 and 
E-selectin mRNA transcript levels in the liver. In addition, LQGV treatment significantly 
prevented neutrophil accumulation in the liver, which correlated with decreased 
organ damage as reflected by reduced lactate dehydrogenase (LDH) and aspartate 
aminotransferase (AST) plasma levels.
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MATERIALS AND METHODS
Animals
Adult male specific pathogen-free Wistar rats (Harlan CPB, Zeist, The Netherlands), 
weighing 350–400g were used. Rats were housed under barrier conditions at 25°C 
with a twelve-hour light/dark cycle, and were allowed food and water ad libitum. The 
experimental protocol was approved by the Animal Experiments Committee under the 
Dutch Experiments on Animals Act and adhered to the rules laid down in this national 
law that serves the implementation of “Guidelines on the protection of experimental 
animals” by the Council of Europe (1986), Directive 86/609/EC. 
hCG-related synthetic oligopeptides
The hCG-related oligopeptides (LQGV, AQGV and LAGV) were synthesized by 
Ansynth Service B.V. (Roosendaal, The Netherlands) and dissolved in 0.9% NaCl at a 
concentration of 5 mg/ml.
Surgical procedures 
Rats were deprived of food overnight before the start of the experiment, but were 
allowed water ad libitum. Rats were anesthetized using a mixture of N2O/O2/isoflurane 
(Pharmachemie B.V., Haarlem, The Netherlands). Body temperature was continuously 
maintained at 37.5°C by placing the rats on a thermo controlled ‘half-pipe’ (UNO, 
Rotterdam, The Netherlands). Endotracheal intubation was performed, and rats were 
ventilated at 60 breaths per minute with a mixture of N2O/O2/isoflurane. Polyethylene 
tubes (PE-50, Becton Dickinson; St. Michielsgestel, The Netherlands) were flushed 
with heparin and placed via the right carotid artery in the aorta and in the right internal 
jugular vein. A 5 cm midline laparotomy was performed and a supra pubic catheter was 
inserted to monitor urine production. 
Experimental procedures
After an acclimatization period of 15 minutes, the rats were randomized into five 
different groups (eight rats per group): 1) sham, 2) HS, 3) HS with LQGV treatment (HS/
LQGV), 4) HS with AQGV treatment (HS/AQGV) and 5) HS with LAGV treatment (HS/
LAGV). Hemorrhagic shock was induced by blood withdrawal, reducing the circulating 
blood volume until a MAP of 40 mmHg was reached. This level of hypotension was 
maintained for 60 minutes. Rats received a single intravenous bolus injection of 5 mg/
kg body weight of either LQGV, AQGV, LAGV or 0.9% NaCl solution 30 minutes after 
the induction of HS. The peptides and dosage were based on previous studies, in 
which we performed dose-escalation experiments [38]. Sixty minutes after induction of 
hemorrhagic shock, rats were resuscitated by four times their shed blood volume over a 
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period of 30 minutes to normalize the MAP, and monitored for another 120 minutes after 
which they were sacrificed (Figure 1A). The rats received no heparin before or during the 
experiment. Sham animals underwent the same surgical procedure as the hemorrhagic 
shock animals, but without blood withdrawal and administration of oligopeptide. 
Measurements of mean arterial pressure
During the experiments, MAP was continuously measured using transducers 
(Becton Dickinson, Breda, The Netherlands) that were connected in line to an electronic 
recorder (Hewlett Packard, 78354-A, Cheshire, USA). 
Plasma collection and storage
Arterial blood was obtained 15 minutes before and 30, 60, 90, 120, 150 and 180 
minutes after onset of hemorrhage (Figure 1A). After blood withdrawal, leukocyte 
numbers were determined using a coulter counter (Beckman Coulter, Mijdrecht, 
The Netherlands) and corrected for the hematocryte. Approximately, 0.3 ml of blood was 
placed into mini collect tubes (Greiner, Bio-one, Alphen aan den Rijn, The Netherlands); 
plasma was obtained by centrifugation (1500 rpm; 5 min), immediately frozen, and 
stored at -80°C until assayed.
Tissue collection and storage
Liver, lungs, ileum and sigmoid were surgically removed at 180 minutes after 
hemorrhagic shock induction, snap-frozen, and stored at -80°C until assayed.
Evaluation of cytokines in plasma
TNF-α, IL-6 and IL-10 plasma levels were determined by enzyme-linked 
immunosorbent assay (R&D Systems, Abingdon, UK), according to the manufacturer’s 
instructions. 
Evaluation of mRNA levels by real-time quantitative (RQ)-PCR 
RNA was isolated using the Qiagen RNeasy kit (QIAGEN, Hilden, Germany), 
according to the manufacturer’s instructions. TNFA (encoding TNF-α), IL6 (encoding 
IL-6), IL10 (encoding IL-10), SELE (encoding E-selectin), and ICAM1 (encoding ICAM-1) 
gene expression levels were determined by RQ-PCR using an Applied Biosystems 7700 
polymerase chain reaction machine (Foster City, CA, USA). The expression levels of 
these genes were quantified by normalization against the mRNA levels of the household 
gene GAPDH. Primers and probes used are available upon request. 
Immunohistochemical analysis
Cryo-sections (6 µm) were fixed in acetone/0.05%H2O2 for five minutes and 
subsequently air dried for 10 minutes. Neutrophils were visualized by staining for 
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myeloperoxidase (MPO). Hereto, sections were incubated overnight at 4°C with a 
mouse-anti-rat MPO monoclonal antibody (Hbt, Uden, The Netherlands). Subsequently, 
sections were incubated for 60 minutes at room temperature with a goat-anti-mouse-
Horse Radish Peroxidase (HRP)-labeled monoclonal antibody (Dako B.V., Glostrup, 
Denmark). For visualization of HRP activity, 3-amino-9-ethylcarbazole substrate 
(Sigma Co., St Quentin Fallavier, France) dissolved in 50mM sodium acetate/0.02% 
hydroxyperoxide was used. Sections were embedded in Kaisers Gycerol/gelatin (Boom 
B.V., Meppel, The Netherlands). Numbers of MPO positive cells were counted per 
high power field (HPF) at a magnification of 200x. Per section a total of 15 HPF were 
Figure 1. 
(A) Schematic representation of the experimental design of induction of hemorrhagic shock in rats. 
(B) The measured blood pressure in mmHg was recalculated in percentages to standardize the 
experiment and to compensate for animal differences. 
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analyzed. Per organ a total of three consecutive sections, each separated 18µm from 
each other, were analyzed. 
Blood biochemical analysis
Plasma alanine aminotransferase (ALT), AST and LDH were determined at the 
Erasmus MC diagnostic facility according to standard procedures.
Statistical analysis 
Data are presented as the mean values ± standard deviation (SD) of the eight rats per 
group. Statistical analysis was performed using SPSS version 11 software (SPSS Inc., 
Chicago,Ill). Intergroup differences were analyzed with Kruskal-Wallis statistical test. 
If Kruskal-Wallis statistical testing resulted in a p < 0.05, a Dunn’s Multiple Comparison 
test was performed and a p < 0.05 was considered statistically significant. 
RESuLTS
Induction of HS
Rats were rapidly bled, within 10 minutes, to a MAP of 40 mmHg, which was 
successfully maintained for 60 minutes in all four experimental groups (Figure 1B). 
No change in MAP was observed in sham treated rats (Figure 1B). Sixty minutes 
after hemorrhagic shock, rats were resuscitated to induce organ reperfusion, which 
was associated with a normalization of urine production (data not shown). These 
data indicate that shock was induced equally in all four experimental groups and was 
followed by successful organ reperfusion. Heart rates in all four experimental groups 
increased immediately after induction of hemorrhagic shock and returned to normal 
after resuscitation. Over time, heart rate slowly increased in all four experimental HS 
groups (data not shown).
Oligopeptide treatment prevents the release of pro-inflammatory cytokines into 
plasma 
Before induction of hemorrhagic shock, TNF-α plasma levels were comparable in all 
five groups (~15-24 pg/ml; Figure 2). In the HS group, TNF-α levels started to increase 
30 minutes after induction of hemorrhagic shock. These levels were significantly 
increased after 60 minutes as compared to the sham group (331 pg/ml vs 29 pg/ml; 
p < 0.01). TNF-α levels reached a maximum of 384 pg/ml after 90 minutes in the HS group, 
after which levels declined again but continued to remain increased compared to the 
sham group (Figure 2). In contrast, none of the oligopeptide-treated HS groups showed 
an increase in TNF-α plasma levels during the experiment (Figure 2). In this model of 
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hemorrhagic shock, IL-6 levels are known to increase at a later time-point than TNF-α 
[20]. Therefore, we determined IL-6 levels in blood samples collected 120, 150 and 180 
minutes after the onset of hemorrhagic shock. In the HS group, IL-6 plasma levels were 
significantly increased as compared to the sham group at 120 minutes (2003 pg/ml vs 
331 pg/ml; p < 0.001), at 150 minutes (2444 pg/ml vs 333 pg/ml; p < 0.001) and at 180 
minutes (2940 pg/ml vs 343 pg/ml; p < 0.001) (Figure 3). Although, IL-6 levels tended 
to increase in the HS/oligopeptides-treated rats as compared to sham-treated rats, 
this never reached significance. Treatment with oligopeptides significantly diminished 
the release of IL-6 into plasma as compared to the non-treated hemorrhagic shock 
group (p < 0.05; Figure 3). IL-10 was undetectable in plasma of all groups throughout 
the experiment (data not shown). These data demonstrate that treatment with a single 
dose of either LQGV, AQGV or LAGV, after induction of hemorrhagic shock, significantly 
attenuated the increase in TNF-α and IL-6 into plasma.
Oligopeptide treatment is associated with a decrease in TNF-α and IL-6 mRNA 
transcript levels in the liver 
We also analyzed the TNF-α and IL-6 mRNA transcript levels in liver, lungs, ileum 
and sigmoid tissues at 180 minutes after the onset of hemorrhagic shock. In the liver, 
Figure 2. 
TNF-α plasma levels in different experimental groups determined at 15 minutes before and 30, 60, 90, 
120, 150 and 180 minutes after the onset of hemorrhagic shock. Data are presented as the mean of 
eight rats per group ± SD. * means p < 0.05, ** means p < 0.01, *** means p < 0.001.
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TNF-α transcript levels were significantly increased in the HS group as compared to the 
sham group (p < 0.001). Oligopeptide treatment was associated with reduced TNF-α 
transcript levels in the liver as compared to non-treated HS rats, with only HS/LQGV 
showing a significant reduction (p < 0.05; Figure 4A). In the HS group, IL-6 transcript 
levels in the liver were increased ~83 times as compared to the sham group (p < 0.001; 
Figure 4B). None of the oligopeptide treated groups showed a significant increase in 
IL-6 transcript levels as compared to the sham group. LQGV and AQGV treatment was 
associated with significantly lower IL-6 transcript levels as compared to the HS group 
(p < 0.05; Figure 4B). Although, IL-10 was undetectable in plasma, IL-10 transcript 
levels were increased in the livers of the HS group as compared to the sham group, 
which approached significance (p = 0.08). Although not significant, LQGV treatment 
was associated with decreased IL-10 transcript levels as compared to the non-treated 
HS group (data not shown). In lungs, ileum and sigmoid tissues no differences could 
be detected between the various groups for TNF-α, IL-6 and IL-10 transcript levels 
(data not shown). These data imply that oligopeptide treatment after shock induction 
significantly attenuated the increase in TNF-α and IL-6 transcript levels in the liver. 
Figure 3. 
IL-6 plasma levels in different experimental groups determined at 120, 150 and 180 minutes after 
the onset of hemorrhagic shock. Data are presented as the mean of eight rats per group ± SD. 
*** means p < 0.001.
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Oligopeptide treatment is associated with a decrease in E-selectin mRNA 
transcript levels in the liver 
In the HS group, the ICAM-1 transcript level was significantly increased in the liver as 
compared to the sham group (p < 0.001; Figure 5A). ICAM-1 transcript levels in the liver 
tended to decrease in the oligopeptide treated groups as compared to the non-treated 
HS group. The E-selectin transcript level in the liver of the HS group was significantly 
increased as compared to the sham group (p < 0.001). LQGV and AQGV treatment was 
associated with significantly lower E-selectin transcript levels in the livers as compared 
to the non-treated HS-group (p < 0.05; Figure 5B). These data demonstrate that 
LQGV and AQGV treatment after shock induction significantly attenuated the increase 
in E-selectin transcript levels in the liver, while ICAM-1 transcript levels were down-
regulated to a lesser extent. 
LQGV treatment prevents neutrophil accumulation in the liver 
In the HS group, the number of neutrophils in the liver was significantly increased as 
compared to the sham group (p < 0.05; Figure 6A). LQGV treatment significantly (p < 
0.05) prevented this neutrophil accumulation, while AQGV and LAGV treatment did not 
prevent neutrophil accumulation in the liver (p < 0.05; Figure 6). 
Figure 4. 
Relative expression of TNF-α (A) and IL-6 (B) mRNA transcripts in the liver, 180 minutes after the onset 
of hemorrhagic shock. Transcript levels are normalized to the expression level of GAPDH. Data are 
presented as the mean of eight rats per group ± SD. * means p < 0.05, *** means p < 0.001.
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LQGV treatment attenuates organ damage
Alanine aminotransferase, AST and LDH plasma levels were significantly increased 
in the HS group as compared to the sham group (ALT; p <0.01; Figure 7A), (AST; 
p < 0.01; Figure 7B) and (LDH; p < 0.01; Figure 7C), while LQGV treatment significantly 
(p < 0.05) attenuated this rise in AST and LDH. AQGV and LAGV treatment did not 
affect ALT, AST and LDH plasma levels as compared to the untreated HS group.
DISCuSSION
In this study we used a rat model of (trauma) hemorrhagic shock to test the 
therapeutic capacity of three synthetic hCG-related oligopeptides (LQGV, AQGV or 
LAGV). We demonstrate that a single administration of either LQGV, AQGV or LAGV, 30 
minutes after shock induction, markedly prevents TNF-α and IL-6 release into plasma 
and diminishes the increase of TNF-α, IL-6 and E-selectin mRNA transcript levels in the 
liver. In addition, LQGV treatment significantly prevented neutrophil accumulation into 
the liver, which coincided with lower AST and LDH plasma levels.
Hemorrhagic shock followed by resuscitation is characterized by a massive 
production of pro-inflammatory cytokines, such as TNF-α and IL-6, by immune cells 
[10]. Despite improvement in treatment strategies, (trauma) hemorrhage patients 
may still develop an inflammatory response that can lead to sepsis, MODS and finally 
Figure 5. 
Relative expression of ICAM-1 (A) and E-selectin (B) mRNA transcripts in the liver, 180 minutes after 
the onset of hemorrhagic shock. Transcript levels are normalized to the expression level of GAPDH. 
Data are presented as the mean of eight rats per group ± SD. * means p < 0.05, *** means p < 0.001.
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death. In our model of HS and resuscitation, we observed an inflammatory response, 
as reflected by significantly increased levels of TNF-α and IL-6 in plasma. TNF-α is a 
key mediator of the innate immune system that is crucial for the generation of a local 
protective immune response against infectious or non-infectious agents [21]. However, 
uncontrolled TNF-α production is lethal, as it induces tissue damage and promotes the 
production of secondary pro-inflammatory mediators, such as IL-6 [22]. 
Experimental treatment strategies aimed at neutralizing bioactive cytokines, 
especially monoclonal antibodies against TNF-α, have been successfully applied in 
several inflammatory disorders, including Crohn's disease and rheumatoid arthritis 
[23-24]. However, clinical studies using monoclonal antibodies against TNF-α showed 
Figure 6. 
(A) Number of neutrophils per High Power Field (HPF; magnification 200x) in the liver 180 minutes 
after the onset of hemorrhagic shock. Data are presented as the mean of eight rats per group ± SD.
Representative examples of livers from sham (B), HS (C) and HS/LQGV (D), 180 minutes after the onset 
of hemorrhagic shock. * means p < 0.05.
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no improvement in trauma-patients [25]. IL-6 is a highly pluripotent cytokine, which 
facilitates neutrophil infiltration into organs, thereby contributing to cell-mediated organ 
damage [26]. In our model of (trauma) HS and resuscitation, oligopeptide treatment was 
associated with significantly decreased levels of TNF-α and IL-6 in plasma. Reducing 
TNF-α and IL-6 plasma levels is of clinical importance, because high systemic levels 
of TNF-α and IL-6 correlate with poor outcome and decreased survival in patients with 
severe trauma and infection [27]. We found local TNF-α and IL-6 production in the 
liver after hemorrhagic shock and resuscitation, which was reduced upon oligopeptide 
treatment, in particular with LQGV. In lungs, ileum and sigmoid, we found no effect of HS 
on the transcript levels of TNF-α and IL-6. Trauma-hemorrhage has been recognized 
to induce acute lung injury/inflammation in humans and animals [28-29]. In our model 
we detected no increase of TNF-α, IL-6, E-selectin and ICAM-1 transcript levels in the 
lungs three hours after hemorrhagic shock, suggesting that a pulmonary inflammatory 
response was not (yet) evident. We have found that our oligopeptides efficiently inhibited 
SIRS and mortality that was induced upon LPS administration, which is an inflammatory 
model characterized by involvement of several organ systems, including the lungs [18-
19]. Therefore, although we cannot conclude it from the current study, we expect that 
our oligopeptides do prevent hemorrhagic shock-induced pulmonary inflammation.
IL-10 is an anti-inflammatory cytokine that reduces cell-mediated immune responses 
and pro-inflammatory cytokine production following hemorrhagic shock [8]. We were 
Figure 7. 
Plasma levels of ALT (A), AST (B) and LDH (C) 180 minutes after the onset of hemorrhagic shock. Data 
are presented as the mean of eight rats per group ± SD. * means p < 0.05, ** means p < 0.01.
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unable to detect IL-10 in plasma during the time frame of the experiments. However, 
local IL-10 production in the liver was detected, since IL-10 transcripts increased in 
the HS group. LQGV treatment was associated with decreased IL-10 mRNA levels 
as compared to the non-treated HS group. Although, this did not reach statistical 
significance, we propose that this may be of biological relevance since high IL-10 levels 
are associated with a high incidence of infection, MODS and increased mortality in 
(trauma) hemorrhage patients [30]. 
Neutrophils induce organ damage and enhance inflammation by the release of 
oxygen radicals, proteolytic enzymes and cytokines [31-32]. Neutrophil infiltration into 
organs is an early event of HS and resuscitation, and neutrophil depletion has been 
shown to prevent HS-induced inflammation and organ damage [5,33]. These data 
indicate a central role for neutrophils in the pathophysiology of HS and resuscitation. 
Leukocyte migration from blood into organs requires the consecutive events of rolling 
and sticking to activated endothelial cells, followed by diapedesis and chemotaxis 
[34]. Among these processes, selectin-mediated rolling is indispensable for initiation 
of leukocyte transmigration and inflammation [35]. In line with this, L- or E- selectin 
blockage, using monoclonal antibodies, reduced liver infiltration by neutrophils as well as 
inflammation and organ damage following hemorrhagic shock [36]. In our experiments, 
treatment with LQGV or AQGV significantly decreased E-selectin transcript levels in the 
liver. Furthermore, LQGV treatment prevented neutrophil accumulation in the liver and 
was associated with lower AST and LDH plasma levels after hemorrhagic shock and 
resuscitation. These data suggest that oligopeptide treatment, in particular LQGV, after 
hemorrhagic shock and resuscitation diminishes the expression of adhesion molecules, 
thereby inhibiting tissue infiltration by neutrophils and subsequent organ damage and 
systemic inflammation. 
In this model, LQGV, originating from the primary sequence of loop 2 of the β-subunit 
of hCG, was the most effective oligopeptide for every parameter determined. Alanine 
replacement in this sequence reduced the biological activity. We cannot exclude that the 
decreased TNF-α and IL-6 mRNA levels, upon oligopeptide treatment, that we observed 
in the liver are the result of a diminished cellular infiltrate. However, the decrease in 
E-selectin mRNA, which is only expressed by endothelial cells, indicates that the tested 
oligopeptides also interfere with mechanisms that regulate expression/activation of 
genes involved in inflammation and immunity. So far it is unclear what the underlying 
mechanism is by which these oligopeptides exert their effects. It is possible that they use 
yet unidentified receptors. However, we cannot exclude the possibility that, due to their 
small size and molecular weight, they penetrate the cell membrane [37] and exert their 
action either by interfering with signaling cascades or the transcriptional machinery. We 
do not exclude that different oligopeptides have different modes of action. Studies are 
in progress to reveal how these hCG-related oligopeptides exert their action.
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In summary, we demonstrated that administration of a synthetic hCG-related 
oligopeptide (LQGV, AQGV or LAGV) after the induction of severe hemorrhagic shock 
significantly attenuated the pro-inflammatory response both systemically and locally 
in the liver. Treatment with LQGV prevented neutrophil infiltration into the liver and 
subsequent liver damage. These data suggest that these oligopeptides, in particular 
LQGV, have therapeutic potential and may reduce the morbidity and mortality associated 
with hemorrhagic shock and resuscitation.
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ABSTRACT
Objective: Mortality in sepsis remains high and efforts to modulate the inflammatory 
response so far mostly failed to improve survival. The human chorionic gonadotropin 
(hCG) related tetrapeptide LQGV was recently shown to exert anti-inflammatory activity. 
The aim of this study was to assess the effect of LQGV on cecal ligation and puncture 
(CLP)-induced mortality and inflammation.
Design: Animal study.
Setting: University research laboratory.
Subjects: Male C57BL/6 mice.
Interventions: To examine the effect of LQGV by itself on CLP-induced mortality 
and inflammation C57BL/6 mice were exposed to a moderate CLP procedure (40% 
ligation and double puncture) with a mortality of ~80% within 5 days in control mice. 
In addition, to examine whether LQGV was of additive value to standard sepsis care 
(antibiotics and fluid resuscitation) a more severe CLP-procedure was used (80% 
ligation and double puncture), yielding ~100% mortality within 12 days in control mice. 
LQGV (5 mg/kg body weight), PBS (as control), or dexamethasone (2.5 mg/kg body 
weight) were administered perioperatively. Survival was monitored for 21 days and 
inflammatory markers were determined in plasma, peritoneal cavity, and lungs.
Measurements and main results: LQGV significantly improved survival from 
20% to 50% during the first 5 days following moderate CLP. This was associated with 
reduced cytokine and E-selectin levels in peritoneal lavage fluid, lungs and to a lesser 
extent in plasma. LQGV treatment also reduced pulmonary NF-κB activation and 
pulmonary damage. In the severe CLP-model, LQGV combined with fluid resuscitation 
and antibiotics resulted in significantly better survival (70%) than that observed with 
fluid resuscitation and antibiotics alone (30%).
Conclusions: LQGV improves survival following CLP. This is likely established by 
a modest reduction of the acute inflammatory response through a NF-κB dependent 
mechanism. Furthermore, LQGV may be a valuable additive next to the standard care 
in polymicrobial sepsis.
INTRODuCTION 
Sepsis and septic shock resulting in multiple organ dysfunction syndrome (MODS) 
are leading causes of morbidity and mortality [1-3]. Sepsis is characterized by an 
early Toll-like receptor (TLR) driven hyperinflammatory response, defined as systemic 
inflammatory response syndrome (SIRS). SIRS, induced by pathogen recognition 
through TLR, is characterized by leukocyte extravasation and release of cytokines (e.g. 
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interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α)) and chemokines (e.g. 
chemokine (C-C motif) ligand 2 (CCL2) and macrophage inflammatory protein-1α (MIP-
1α)) by inflammatory cells and endothelial cells [4]. This pro-inflammatory environment 
causes the release of secondary mediators, such as reactive oxygen species and nitric 
oxide that further augment the inflammatory reaction and subsequent organ damage 
[5]. The early hyperinflammatory response is followed by a state of immunosuppression 
characterized by abundant presence of anti-inflammatory cytokines (e.g. IL-10 and 
transforming growth factor-β (TGF-β)) as well as anergy and apoptosis of immune 
effector cells (e.g. B cells, T cells, and dendritic cells) [5-8]. Septic patients may die 
during the early hyperinflammatory phase of sepsis, but mostly succumb during the 
late immunosuppressive phase [7]. The fact that sepsis related morbidity and mortality 
still increases emphasizes the need for new therapeutics with immune regulatory 
properties [3].
During pregnancy the maternal immune system is regulated by a shift away from 
a type-1 (cellular) immune response toward a type-2 (humoral) immune response 
[9], a process in which downregulation of nuclear factor-κB (NF-κB) activity in type-1 
cells seems to be involved [10]. Consequently, clinical manifestations of auto-immune 
diseases, such as rheumatoid arthritis and multiple sclerosis, improve during pregnancy 
while symptoms of systemic lupus erythematosus, in which the principal pathology 
is auto-antibody driven, tend to flare up [11]. The pregnancy-associated hormonal 
environment is thought to contribute to maternal immune modulation. Human chorionic 
gonadotropin (hCG) is one of the first hormones formed during pregnancy and exerts 
immunomodulatory actions [12,13]. Degradation products of β-hCG are also present 
during pregnancy [14], and previously we have demonstrated that the peptides LQGV 
and VLPALP, which are present within the primary structure of loop 2 of β-hCG, have 
anti-inflammatory activities in models of auto-immune diabetes, hemorrhagic shock, 
and LPS-induced shock [15-17]. Moreover, in vivo administration of LQGV reduced the 
capacity of splenocytes to produce IL-6 and TNF-α upon lipopolysaccharide (LPS) and 
heat-killed Listeria monocytogenes stimulation in vitro, indicating that LQGV reduces 
TLR-driven cytokine production [18]. 
Several potent anti-inflammatory therapeutics, such as anti-TNF-α monoclonal 
antibodies, have been tested successfully in LPS models [19-21], however, appeared to 
be non-effective in both cecal ligation and puncture (CLP) induced polymicrobial sepsis 
in mice and clinical trials involving septic patients [21-24]. Recently, we described that 
LQGV effectively prevents LPS-induced shock and mortality in mice [17]. The CLP-
model, however, more adequately resembles the human immune reaction during sepsis 
than the acute and sterile LPS-induced shock model. Also CLP more closely mimics the 
clinical setting, as fluid resuscitation and antibiotics can be administered to evaluate the 
potential of new anti-inflammatory agents [25,26].
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In order to examine the potential of LQGV to reduce mortality and to modulate the 
inflammatory response during sepsis we first determined the effect of LQGV by itself 
in a polymicrobial murine sepsis model. Thereafter, in order to examine a potential 
additive value of LQGV to standard sepsis care, we determined the effect of LQGV 
in combination with fluid resuscitation and antibiotics. We demonstrate that LQGV 
improves survival after CLP, which is associated with reduced inflammation especially 
in the peritoneal cavity and the lungs. Furthermore, we demonstrate that combination 
treatment of LQGV with fluid resuscitation and antibiotics significantly improves survival 
as compared with fluid resuscitation and antibiotics alone. Our results demonstrate that 
the β-hCG related tetrapeptide LQGV acts as an anti-inflammatory agent and is a useful 
addition to the current standard treatment for sepsis
MATERIALS AND METHODS
Mice
Male C57BL/6 mice with an average weight of 25 g were purchased from Harlan 
(Horst, The Netherlands). The experimental protocol was approved by the local animal 
care and use committees.
Moderate CLP-induced polymicrobial sepsis
Moderate polymicrobial sepsis, defined as ~70 - 80% mortality during the acute 
phase of sepsis (first five days), was used to test potential effects of LQGV in sepsis. 
Hereto, mice underwent low-grade CLP as described [27,28]. Briefly, the cecum was 
located, exteriorized, and ligated 1 cm from its distal end without causing intestinal 
obstruction. Subsequently, the cecum was punctured twice with an 18-Gauge needle 
and manipulated to ensure extrusion of feces into the abdominal cavity. Postoperatively 
mice received a single subcutaneous (s.c.) injection of 0.5 ml of saline. Mice were 
monitored every 12 hours during the first 5 days (the acute hyperinflammatory phase 
of sepsis), followed by daily monitoring up to 21 days (the chronic immunosuppressive 
phase of sepsis).
Severe CLP-induced polymicrobial sepsis
Severe CLP-induced polymicrobial sepsis (defined as ~100% mortality when mice 
were postoperatively treated with fluid resuscitation only, and ~50% mortality when 
mice were postoperatively treated with fluid resuscitation and antibiotics) was used to 
test whether LQGV is of additive value to standard sepsis treatment. Hereto, the cecum 
was ligated just below the ileocecal valve without causing intestinal obstruction followed 
by double puncture with an 18-Gauge needle and manipulation to ensure extrusion 
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of feces [27]. To reach a mortality of ~50% during the chronic phase of sepsis mice 
received s.c. injections of Tienam (25 mg/kg body weight (BW); Merck Sharp & Dohme, 
Haarlem, The Netherlands,) dissolved in 1 ml 0.9% NaCl starting 2 hours after surgery 
followed by subsequent injections every 12 hours during the first 5 days. Control mice 
postoperatively received 1 ml 0.9% NaCl at the same time points. In survival experiments 
mice were monitored up to 21 days.
LQGV and dexamethasone treatment
LQGV (GL Biochem, Shanghai, China) was dissolved in phosphate buffered saline 
(PBS). In both CLP-models mice received an intravenous (i.v.) injection of LQGV (5 mg/
kg BW) or PBS (as control) 5 minutes before and 20 minutes after the CLP procedure. 
The time-points of administration and dosage were based on previous studies [16,29]. 
Furthermore, in the moderate CLP-model the effect of i.v. injection of dexamethasone 
(25 mg/kg BW; Sigma Aldrich, Zwijndrecht, The Netherlands, dissolved in PBS) [30] 
administered 20 minutes after the CLP procedure was examined. 
Blood
Blood was obtained at various time-points after CLP by cardiac puncture in tubes 
containing EDTA (Greiner, Bio-one, Alphen aan den Rijn, The Netherlands). Blood was 
centrifuged (1500 rpm; 5 minutes), and plasma was stored at -80ºC until assayed.
Peritoneal lavage
The peritoneal cavity was washed with 2 ml ice-cold PBS, followed by a second 
wash with 5 ml ice-cold PBS. Total cell counts were determined using a cell counter 
(Beckman Coulter B.V., Woerden, The Netherlands). The first 2 ml peritoneal wash 
was centrifuged (1500 rpm; 10 minutes), and supernatant was stored at -80ºC until 
assayed. Peritoneal cells from both washes were combined and resuspended (106 
cells/ml). Cytospin preparations were stained (Diff-Quick, Medion Diagnostics) and cell 
differentials were determined by counting 300 cells per cytospin.
Bacterial culture of peritoneal lavage fluid and blood
Bacterial counts were determined in blood and the first 2 ml peritoneal wash by 
plating serial dilutions onto blood agar plates (Columbia blood agar, BD Pharmingen, 
Breda, The Netherlands). Plates were incubated for 24 hours at 37ºC. CFU numbers 
were determined and expressed as log10 CFU per ml peritoneal fluid or blood.
In vitro culture of peritoneal cells
Peritoneal cells (106 cells/ml in RPMI 1640 containing 5% fetal calf serum and 
antibiotics) were cultured overnight and supernatants were collected for cytokine 
measurements.
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Cytokine determination
Cytokines in plasma were determined using a cytometric bead array (BD 
Biosciences, San Diego, CA, USA) [29]. Supernatant from the first 2 ml peritoneal wash 
and peritoneal cell-culture supernatants were analyzed for IL-6, TNF-α, chemokine 
(C-X-C motif) ligand 1 (CXCL1), and IL-10 by ELISA (R&D Systems Europe, Abingdon, 
UK). In experiments with dexamethasone, CCL2 and IL-6 levels were determined by 
ELISA (R&D systems).
Histologic analysis
Hematoxylin and eosin-stained lung sections, from 6 and 24 hours after CLP, were 
analyzed under a light microscope (Axioskop 2 plus, Zeiss).
RNA isolation and real-time quantitative PCR
RNA was isolated (RNeasy Micro Kit; Qiagen, Hilden, Germany) from lung tissue 
obtained 6 hours after CLP and reverse transcribed into cDNA [29]. IL-6, TNF-α, CXCL1, 
IL-10, and E-selectin mRNA levels were determined by real-time quantitative PCR (RQ-
PCR) using an AppliedBiosystems 7900 PCR machine (Foster City, CA, USA) and 
quantified by normalization against ABL [29].
Electrophoretic mobility shift assay (EMSA)
NF-κB activity was evaluated in nuclear extracts from lung tissue of mice sacrificed 
6 hours after CLP. Lung tissue was grinded and resuspended in ice-cold lysisbuffer 
containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol (DTT) and protease inhibitor cocktail (Roche, 
mini protease inhibitor, ethylenediaminetetraacetic acid (EDTA) free). After 20 minutes 
incubation on ice followed by centrifugation, nuclei were lysed in ice cold lysisbuffer 
containing 20 mM HEPES, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 
0.5 mM DTT and a protease inhibitor cocktail (Roche, mini protease inhibitor, EDTA 
free). EMSA was performed with 10 μg of nuclear extracts as described previously 
using double-stranded γ-adenosine triphosphate (ATP)-32P labeled oligonucleotide 
probes with specific recognition sequence for NF-κB or organic cation transporter-1 
(OCT-1) [31].
Statistical analysis
Data are presented as the mean values ± standard error of mean. Statistical 
analysis was performed using SPSS version 15 (SPSS Inc., Chicago, IL). Statistical 
significance was determined by log-rank survival analyses. Log-rank survival analyses 
was performed during both the acute phase of sepsis (until day 5) and the chronic 
phase of sepsis (until day 21) and corrected for population stratification of different 
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experiments. All cytokine and mRNA levels were log transformed in order to get normal 
distribution. The t-test was used to compare the mean cytokine and mRNA levels for 
the two subgroups. When data were evaluated over time a two-way analysis of variance 
was performed. Data shown in figures are geometric means with standard error, or 
indicated otherwise. A p-value <0.05 was considered as statistically significant.
RESuLTS
LQGV treatment improves survival following moderate CLP-induced sepsis
In PBS-treated mice, CLP resulted in 20% survival during the acute phase of sepsis, 
after which no further mortality was observed during the chronic phase (Figure 1). LQGV 
treatment significantly (p < 0.05) improved survival up to 50% during the acute phase of 
sepsis (Figure 1). In the chronic phase mortality increased in the LQGV-treated group 
to a comparable level as in the PBS-treated group due to deaths occurring during the 
last week of follow-up (Figure 1).
 
Figure 1. LQGV treatment improved survival.
LQGV was administered (5 mg/kg body weight) intravenously 5 minutes before and 20 minutes after 
low-grade cecal ligation and puncture (CLP). Survival was monitored for 21 days after CLP. LQGV 
treatment improved survival during the acute phase of sepsis (≤ day 5). Presented results were obtained 
in three identical independent experiments. Log-rank survival analyses were performed as described in 
Materials and methods. PBS, n = 25; LQGV n = 23. * p < 0.05.
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LQGV treatment moderately reduces the systemic inflammatory response 
following moderate CLP-induced sepsis
We next examined whether LQGV treatment affected the acute inflammatory 
response. Both in PBS and LQGV-treated mice IL-6, TNF-α, CCL2, and IL-10 plasma 
levels rapidly increased after CLP, peaking at 24 hours (Figure 2). In the LQGV-treated 
mice plasma levels were consistently lower, although this never reached significance, as 
ANOVA-analysis showed that the profiles of the mean cytokine levels did not significantly 
differ between treatment groups (Figure 2). Collectively, these data suggest that LQGV 
treatment reduces CLP-induced systemic cytokine levels and enhances the resolution 
of CLP-induced systemic inflammation, which is consistent with better survival.
Figure 2. LQGV treatment moderately reduced plasma cytokine levels.
LQGV was administered (5 mg/kg body weight) intravenously 5 minutes before and 20 minutes after 
low-grade cecal ligation and puncture (CLP). CLP induced an increase of plasma IL-6 (A), TNF-α (B), 
CCL2 (C), and IL-10 (D) in both PBS and LQGV-treated mice with maximum levels for all cytokines at 
24 hours post CLP. LQGV treatment was associated with lower IL-6, TNF-α, CCL2, and IL-10 levels at 
all time points. n = 5 mice/group at 0 hours post CLP. n = 17 mice/ group at 6 hours. n = 9 mice/group at 
24 hours. PBS, n = 7; LQGV, n = 10 at 48 hours. PBS, n = 7; LQGV, n = 8 at 72 hours.
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LQGV treatment is associated with reduced peritoneal inflammation following 
moderate CLP-induced sepsis
To examine the effect of LQGV treatment on CLP-induced local inflammation, 
peritoneal lavage fluid from 6 and 24 hours post CLP was analyzed for IL-6, TNF-α, 
CXCL1, and IL-10. This revealed a significant (p < 0.05) increase of these cytokines, 
peaking at 6 hours after CLP, in both groups (Figure 3). However, at 6 hours after CLP, 
IL-6 and IL-10 levels were significantly (p < 0.05) lower in LQGV-treated mice (Figure 3), 
whereas TNF-α levels were not affected (Figure 3B).
Next, we evaluated the effect of LQGV treatment on the production of IL-6, TNF-α, 
CXCL1, and IL-10 by cells obtained by peritoneal lavage at 6 hours and 24 hours 
following CLP. In both groups peritoneal cell numbers were significantly (p < 0.05) 
higher at 24 hours post CLP than 6 hours post CLP (Figure 4A). LQGV treatment did 
not affect the total number of peritoneal cells (Figure 4A), or the cellular composition 
Figure 3. LQGV treatment reduced peritoneal cytokine levels.
LQGV was administered (5 mg/kg body weight) intravenously 5 minutes before and 20 minutes after 
low-grade cecal ligation and puncture (CLP). Peritoneal washes were performed at 6 hours and 
24 hours after CLP and cytokine levels were determined. CLP induced an increase of IL-6 (A), TNF-α 
(B), CXCL1 (C), and IL-10 (D) levels. LQGV treatment was associated with reduced cytokine levels as 
compared with PBS-treated mice. n = 4 mice/group. * p < 0.05, ** p < 0.01.
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which mainly  consisted of neutrophils at 6 hours post CLP and at 24 hours post CLP 
(Table 1). In general, peritoneal cells from LQGV-treated mice produced less cytokines, 
being significant (p < 0.05) for IL-10 at 24 hours after CLP (Figure 4E). In PBS-treated 
mice, peritoneal cells obtained 24 hours after CLP produced significantly (p < 0.05) 
more IL-10 than cells obtained 6 hours post CLP (Figure 4E). No such increase in IL-10 
production was observed for peritoneal cells from LQGV-treated mice. In LQGV-treated 
mice, peritoneal cells obtained 24 hours after CLP produced significantly (p < 0.05) less 
CXCL1 than peritoneal cells obtained 6 hours after CLP. This decrease did not occur in 
PBS-treated mice (Figure 4D). 
LQGV treatment is associated with reduced pulmonary inflammation following 
moderate CLP-induced sepsis
Lung involvement is frequently observed during sepsis. Therefore, we examined 
whether LQGV treatment influenced pulmonary IL-6, TNF-α, CXCL1, IL-10, and 
Figure 4. LQGV treatment reduced cytokine production by peritoneal cells.
LQGV was administered (5 mg/kg body weight) intravenously 5 minutes before and 20 minutes after 
low-grade cecal ligation and puncture (CLP). Peritoneal wash was performed at 6 hours and 24 hours 
following CLP and cell numbers were determined. (A) CLP resulted in an increase of total cell numbers 
in both groups, which peaked at 24 hours. LQGV treatment did not influence the number of peritoneal 
cells retrieved by peritoneal lavage as compared with PBS treatment. Peritoneal cells were cultured 
overnight and levels of IL-6 (B), TNF-α (C), CXCL1 (D) and IL-10 (E) were determined. LQGV treatment 
was associated with slightly reduced IL-6 (B), TNF-α (C), and CXCL1 (D) production levels at 6 or 24 
hours. CXCL1 production levels (D) decreased significantly between 6 and 24 hours in the LQGV-treated 
mice, while this was not observed in the PBS-treated mice. IL-10 production (E) increased significantly 
between 6 and 24 hours post CLP in PBS-treated mice, while this did not occur in the LQGV-treated 
mice. The IL-10 level (E) was significantly lower in the LQGV-treated mice at 24 hours post CLP. n = 8 
mice/ group. * p < 0.05, ** p < 0.01.
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E-selectin mRNA levels at 6 hours after CLP. CLP resulted in a significant (p < 0.05) 
increase in mRNA expression of all examined cytokines and the adhesion molecule 
E-selectin in both experimental groups (Figure 5A). LQGV treatment significantly 
(p < 0.05) reduced IL-6, CXCL1, and E-selectin mRNA levels in the lungs (Figure 5A). 
Also IL-10 mRNA levels were reduced upon LQGV treatment, although not statistically 
significant (Figure 5A). LQGV treatment did not affect the increase of pulmonary TNF-α 
mRNA (Figure 5A).
The transcription factor NF-κB regulates the production of many cytokines and initial 
experiments demonstrated clear pulmonary NF-κB activity at 6 hours following CLP 
(data not shown). Therefore, we determined whether LQGV treatment affected the 
pulmonary NF-κB activity at 6 hours after CLP. Pulmonary NF-κB activation was lower 
in 75% of the LQGV-treated mice as compared with PBS-treated mice (Figure 5B). 
Because LQGV reduced pulmonary inflammation and NF-κB activation we next 
evaluated the effect of LQGV treatment on lung histology. Lungs obtained from PBS-
treated mice at 6 hours post CLP had thickened alveolar septa, mainly due to edema 
(Figure 5C). LQGV treatment reduced these histopathologic alterations (Figure 5C).
LQGV treatment does not affect bacterial load following moderate CLP-induced 
sepsis
To examine whether LQGV treatment interfered with bacterial dissemination in the 
peritoneal cavity and blood we determined bacterial loads. During the first 72 hours 
after CLP the number of CFU in blood and peritoneal lavage fluid did not differ between 
both groups (Figure 6).
Dexamethasone treatment reduces systemic, peritoneal, and pulmonary 
inflammation without improvement of survival following moderate CLP-induced 
sepsis
To compare the effect of LQGV with a commonly used anti-inflammatory agent we 
investigated the effect of dexamethasone on CLP-induced mortality and inflammation. 
Dexamethasone had no effect on survival in the moderate CLP-model when compared 
with PBS-treated mice (Figure 7A). Dexamethasone treatment did however significantly 
(p < 0.05) reduce plasma IL-6 and CCL2 levels as well as peritoneal IL-6 and CCL2 
Table 1. Effect of LQGV on peritoneal cell population. 
Time 6 hours post CLP 24 hours post CLP
Treatment PBS LQGV PBS LQGV
Peritoneal lavage
Granulocytes (%)a 83.2 [79.3 - 88.1] 84.0 [80.1 - 88.5] 75.7 [74.3 - 76.8] 74.3 [72.0 - 76.6]
Macrophages (%)a 16.8 [11.9 - 20.7] 16.0 [11.5 - 19.9] 24.3 [23.2 - 25.7] 25.7 [23.4 - 28.0]
a Mean [range]. n = 4 mice/group.
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levels at 6 hours after CLP (Figure 7B). Dexamethasone treatment also significantly 
(p < 0.05) reduced pulmonary IL-6 mRNA levels, while TNF-α remained unaffected 
(Figure 7B).
Figure 5. LQGV treatment reduced pulmonary inflammation.
LQGV was administered (5 mg/kg body weight) intravenously 5 minutes before and 20 minutes after 
low-grade cecal ligation and puncture (CLP). Lung tissue was obtained at 6 hours post CLP. (A) LQGV 
treatment was associated with reduced IL-6, CXCL1, and E-selectin mRNA expression levels. (B) 
Pulmonary NF-κB activity was reduced in nuclear extracts of LQGV treated mice. (C) Representative 
histological sections showed that LQGV treatment was associated with reduced alveolar septal 
thickening resulting from diminished edema. n = 4 mice/group, * means p < 0.05. Bars, 50 μm.
Chapter VI
118
    






) &%"!
'&#% $"!#%
*%
%
'$((



	
 




 
) &%"!

# 


		








# 

 
 


	 


$
&(
 
)
#$%
%"!
Figure 7. Dexamethasone treatment did not alter mortality and inflammation.
Dexamethasone was administered (2.5 mg/kg body weight) intravenously 5 minutes before and 20 
minutes after low-grade cecal ligation and puncture (CLP). (A) Survival was monitored for 21 days after 
CLP. Dexamethasone treatment did not affect mortality during the acute and chronic phases of sepsis. 
n = 8 mice/ group. (B) IL-6 and CCL2 levels were determined in plasma and peritoneal lavage at 6 hours 
post CLP. Relative IL-6 and TNF-α mRNA expression levels were determined in lung tissue obtained at 
6 hours post CLP. Dexamethasone reduced the IL-6 and CCL2 plasma levels as well as the peritoneal 
IL-6 and CCL2 level and the IL-6 mRNA expression level in the lung. n = 6 mice/group, * means 
p < 0.05, ** means p < 0.01.
Figure 6. LQGV treatment did not alter bacterial load.
LQGV was administered (5 mg/kg body weight) intravenously 5 minutes before and 20 minutes after 
low-grade cecal ligation and puncture (CLP) and bacterial load was determined in blood and peritoneal 
fluid obtained at different time points after CLP. LQGV treatment did not affect bacterial load in peritoneal 
fluid (A) and blood (B). Similar results were obtained in two identical independent experiments n = 8 – 10 
mice/group.
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LQGV as addition to standard sepsis treatment improves survival following 
severe CLP-induced sepsis
To determine a potential role of LQGV in the standard treatment of sepsis we 
evaluated the effect of LQGV in combination with fluid resuscitation and antibiotics, in a 
severe CLP-induced sepsis. In control mice that only received fluid resuscitation 100% 
mortality was observed (Figure 8). In this severe CLP-model treatment with LQGV plus 
postoperative fluid resuscitation alone did not improve survival (Figure 8). In control 
mice, treated with PBS followed by postoperative treatment with fluid resuscitation and 
antibiotics, survival increased to 30% (p < 0.01) after 21 days (Figure 8). However, when 
perioperative LQGV treatment was combined with postoperative fluid resuscitation and 
antibiotics, survival increased to 70% (p <0.05) compared with fluid resuscitation and 
antibiotics alone (Figure 8).
Figure 8. LQGV treatment in combination with standard care improved survival.
LQGV was administered (5 mg/kg body weight) intravenously 5 minutes before and 20 minutes after 
high-grade cecal ligation and puncture (CLP), followed by 5 day treatment with fluid resuscitation and 
antibiotics or fluid resuscitation alone. Survival was monitored for 21 days. PBS or LQGV treatment in 
combination with fluid resuscitation alone (LQGV) did not affect mortality. PBS treatment followed by 
postoperative treatment with fluid resuscitation and antibiotics (AB) was associated with improved survival. 
LQGV treatment in combination with fluid resuscitation and antibiotics (LQGV + AB) was associated 
with improved survival as compared with PBS-treated mice in combination with fluid resuscitation and 
antibiotics. Presented results were obtained in three identical independent experiments. Log-rank 
survival analyses were performed as described in Materials and methods. PBS, n = 12; LQGV, n = 6; 
AB, n = 18, LQGV + AB, n = 17. * p < 0.05, ** p < 0.01.
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DISCuSSION
Sepsis-related hospitalization and mortality still increase [3]. Although inflammation 
is a well recognized component contributing to the pathology of sepsis and septic shock 
most anti-inflammatory treatment strategies applied in sepsis gained disappointing results. 
Therefore, novel therapeutic interventions are required. CLP induces a polymicrobial 
peritoneal infection in the presence of necrotic gut tissue in the abdominal cavity, and 
is characterized by bacteremia, SIRS, septic shock, MODS, and eventually death and 
is considered to reflect the pathophysiology of human sepsis [25,27]. In line with other 
studies [30,32-34] we observed that most mice typically succumb from CLP-induced 
sepsis during the early acute hyperinflammatory septic phase (< 5 days following CLP). 
Here, we demonstrate for the first time that treatment with the β-hCG related tetrapeptide 
LQGV significantly improves survival during the early hyperinflammatory phase of CLP-
induced polymicrobial sepsis in mice. This was associated with a significant reduction 
of inflammation in the peritoneal cavity and lungs while only a modest reduction of 
systemic inflammation was observed. Furthermore, we demonstrate that LQGV has 
additive value to standard sepsis care with fluid resuscitation and antibiotics. 
In the present study LQGV improved survival in a moderate CLP-induced polymicrobial 
sepsis model. This survival benefit was associated with only a modest reduction of 
IL-6, TNF-α, IL-10, and CCL2 plasma levels. However, LQGV treatment was associated 
with enhanced resolution of plasma cytokine levels, suggesting decreased cellular 
activation upon LQGV treatment. Contrary to the systemic inflammatory response, 
LQGV treatment downregulated inflammation in the peritoneal cavity as reflected by 
significantly reduced IL-6 and IL-10 levels. This appeared not to be related to differences 
in total cell numbers recruited to the peritoneal cavity nor the cellular composition of the 
infiltrate. A consistent trend towards less cytokine production by these cells from LQGV-
treated animals was found, which was significant for IL-10. These data suggest that 
although these cells are recruited equally effective to the peritoneal cavity, their activity 
is altered by LQGV treatment. We cannot exclude that cells other than the recruited 
inflammatory cells contributed to peritoneal cytokine levels as well. Endothelial cells 
and mesothelial cells are well recognized producers of cytokines upon activation with 
LPS [35-37], and may therefore have been targeted by LQGV as well. CLP-induced 
sepsis is associated with NF-κB driven pulmonary inflammation and damage [38-
42]. LQGV treatment resulted in reduced pulmonary NF-κB activation in combination 
with a significant reduction of IL-6, CXCL1, and E-selectin mRNA levels and reduced 
histological pulmonary damage. LQGV treatment exerted a long-term beneficial effect 
on survival. However, small compounds such as LQGV, which has a molecular weight 
of 415 Dalton, are rapidly removed due to renal clearance [43]. This suggests that 
the protective effect of LQGV must be due to reduction of the early SIRS-response, 
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which is supported by our observation that LQGV reduces early immune activation 
following Listeria monocytogenes infection [18]. This implies that early interference with 
the SIRS-response can result in long-term beneficial effects on survival.
TLR activation by bacterial antigens or molecules released upon tissue damage 
activates transcription factors such as NF-κB which subsequently drive the production 
of cytokines. Therefore, TLR activation is considered as key event in the initiation 
of the inflammatory response during sepsis and tissue damage [44-47]. Our current 
study demonstrates that LQGV treatment reduces systemic and peritoneal cytokine 
responses as well as pulmonary NF-κB activation and cytokine and adhesion molecule 
production following CLP. Positive correlations between the intensity of the cytokine 
response and bacterial load have been described elsewhere [18,48]. Here, we observed 
no effect of LQGV on the bacterial load in blood and peritoneal cavity following CLP. 
Therefore, we consider it unlikely that the anti-inflammatory effect of LQGV following 
CLP is related to bacterial load. Previously, we found that LQGV administration to 
mice impaired the capability of splenocytes to produce IL-6 and TNF-α in response 
to LPS or Listeria monocytogenes antigens, indicating that LQGV interferes with TLR 
driven immune activation [18]. Recent data from our laboratory demonstrate that the 
effect of LQGV involves the induction of a secondary anti-inflammatory mediator that 
activates glucocorticoid receptor signaling (van der Zee, van den Berg et al., manuscript 
submitted). Overall, these data suggest that LQGV, at least partly, exerts its effect 
through activation of the glucocorticoid receptor and subsequent inhibition of TLR 
driven gene activation.
Dexamethasone is a well known anti-inflammatory agent that efficiently ameliorates 
the systemic inflammatory response following LPS injection [49,50]. Here, we found 
that dexamethasone significantly, and more effectively than LQGV, reduced the CLP-
induced inflammatory response. However, dexamethasone was not associated with 
survival improvement, which is in line with previous observations [49]. Therefore, our 
results suggest that extensive downregulation of the inflammatory response during 
polymicrobial sepsis (as established by dexamethasone) does not improve survival, 
while a relatively modest downregulation (as established by the LQGV treatment used 
in this study) does improve survival. This notion is supported by studies demonstrating 
that moderate IL-6 inhibition by neutralizing antibodies improves survival following CLP, 
while this survival benefit was not observed when a higher dosage of IL-6 neutralizing 
antibody was used [51] and point at an important physiological role of the inflammatory 
response following CLP. Overall, these data suggest that moderate downregulation 
of the inflammatory response, as observed after LQGV treatment, is a prerequisite to 
improve survival after CLP.
In the severe CLP-model, treatment with LQGV alone did not result in survival 
improvement. Bacterial dissemination can be expected to be higher in the severe 
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model as compared with the moderate model. The pathology and mortality in the severe 
CLP-model is likely due to a higher extent of bacterial dissemination and growth as 
well as a more severe inflammatory reaction. Inhibition of the inflammatory reaction 
by LQGV alone is apparently not sufficient to improve survival in this model. This is 
probably due to the inhibition of the antibacterial response as part of the inhibited 
inflammatory response [17]. However, at present fluid resuscitation and antibiotics are 
the cornerstones of sepsis treatment, and in line with previous studies [8,52], we found 
that this treatment combination improved long-term survival following CLP. Remarkably, 
the addition of LQGV to fluid resuscitation and antibiotics further improved long term 
survival as compared with fluid administration and antibiotics alone. This suggests that 
modest downregulation of the inflammatory response in combination with standard 
sepsis care might be a beneficial therapeutic approach.
CONCLuSIONS
Our data demonstrate that the β-hCG related tetrapeptide LQGV is able to improve 
survival during the acute hyperinflammatory phase following CLP-induced polymicrobial 
sepsis in mice. This beneficial effect is likely due to the moderate immunosuppressive 
effect of LQGV. Importantly, the immunosuppressive effect of LQGV is of additive value 
to antibiotics and fluid administration in improving survival following CLP-induced severe 
sepsis in mice. Therefore, LQGV might be a useful addition to the standard treatment 
of sepsis.
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ABSTRACT
Objective: A recent literature-based study suggested that low-dose corticosteroid 
treatment has a beneficial effect on mortality in septic patients, whereas high-dose 
corticosteroid treatment has not. This suggests that mild downregulation of the 
inflammatory response during early sepsis may be beneficial while extensive reduction 
of the inflammatory response is not. To investigate this hypothesis we examined the 
effect of dexamethasone (DEX) treatment in varying doses on cecal ligation and 
puncture (CLP)-induced inflammation and mortality.
Design: Animal study.
Setting: University research laboratory.
Subjects: Male C57BL/6 mice.
Interventions: Mice were subjected to CLP, DEX was administered intravenously at 
a dosage of 0.05 (L/DEX), 0.25 (M/DEX), or 2.5 (H/DEX) mg/kg body weight 20 minutes 
postoperatively. Mice receiving PBS served as controls. Survival was recorded up to 
21 days and inflammatory markers were determined in plasma, lung, liver, and kidney 
at 6 hours following CLP.
Measurements and main results: L/DEX treatment significantly improved survival 
compared with control mice whereas treatment with higher concentrations of DEX (M/
DEX and H/DEX) did not. Treatment with either M/DEX or H/DEX was associated with 
significantly (p < 0.05) reduced cytokine plasma levels as compared with controls at 
6 hours post-CLP. In addition, M/DEX or H/DEX powerfully reduced cytokine mRNA 
expression in the lung, liver, and kidney. In contrast, treatment with L/DEX was associated 
with a mild, but non-significant, reduction of cytokine plasma levels. In addition, L/DEX 
only moderately reduced cytokine mRNA expression in lung, liver, and kidney.
Conclusions: A mild downregulation of the early sepsis associated inflammatory 
response improves survival in a murine CLP model. Apparently, mild anti-inflammatory 
therapy allows the immune system to battle the invading pathogens sufficiently. We 
propose that the success of anti-inflammatory therapies in a septic setting fundamentally 
depends on finding a treatment balance that reduces the hyperinflammation-induced 
pathology but still allows adequate defense against pathogens.
INTRODuCTION 
Sepsis is a complex clinical syndrome resulting from a harmful host response to 
infection of which the incidence is still increasing [1]. Sepsis is characterized by an early 
hyperinflammatory response, defined as the systemic inflammatory response syndrome 
(SIRS) [2]. SIRS is represented by an excessive production of pro-inflammatory 
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cytokines relative to anti-inflammatory cytokines [3-5]. In time, SIRS will transit into a 
state of immunosuppression due to increased production of anti-inflammatory cytokines 
as well as anergy and apoptosis of immune cells [2,4,6-8]. The current treatment of 
septic patients mainly consists of administration of broad-spectrum antibiotics, fluid 
resuscitation, and ventilation. Treatment of sepsis patients has essentially remained 
unchanged during the last decades. Overall, the sepsis-related inflammatory response 
may develop into septic shock and multiple organ dysfunction syndrome (MODS), 
which are leading causes of morbidity and mortality in critically ill patients [9,10]. This 
emphasizes the need for therapeutic strategies with immunoregulatory properties.
During the last decades the application of general anti-inflammatory agents, such 
as corticosteroids, has been investigated in severe sepsis and septic shock. However, 
contradictory results have been obtained. Some studies demonstrated survival 
improvement after high-dose corticosteroid treatment [11] while others did not [12,13]. 
Other therapeutic interventions which aimed at blocking a single pro-inflammatory 
mediator, for instance with TNF-α specific monoclonal antibodies, have also been 
investigated. Although such studies showed a remarkable survival improvement in 
lipopolysaccharide (LPS)-induced shock in animals [14,15], no survival benefit was 
observed in the murine cecal ligation and puncture (CLP) polymicrobial sepsis model 
[16-18] nor in clinical trials involving septic patients [19-21]. Recently, an extensive 
literature review suggested that low-dose corticosteroid treatment has a beneficial 
effect on short-term mortality in patients with septic shock, in contrast to high-dose 
corticosteroid treatment [22]. This data illustrates the need for further studies to 
improve our understanding about the effectiveness of anti-inflammatory therapies on 
morbidity and mortality during sepsis and septic shock. The observations by Annane 
and colleagues [22] led us to hypothesize that mild immunosuppression is beneficial 
during a septic event whereas extensive immunosuppression is not.
In order to examine this hypothesis we investigated the effect of three different 
DEX dosages on acute inflammation and mortality induced by CLP in mice. Our study 
demonstrates that low-dose DEX treatment (0.05 mg/kg body weight (BW)) improves 
survival while it only moderately downregulates inflammatory parameters such as 
cytokine levels and adhesion molecules in plasma, lung, liver, and kidney. In contrast, 
treatment with a medium-dose DEX (0.25 mg/kg BW) or high-dose DEX (2.5 mg/kg 
BW) did significantly reduce the inflammatory response, but had no beneficial effect on 
survival. We propose that the success of anti-inflammatory therapies in a septic setting 
fundamentally depends on finding a treatment balance that is able to reduce SIRS-
induced pathology but still allows the immune system to raise an adequate host defense 
to the invading pathogens.
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MATERIALS AND METHODS
Mice
Male C57BL/6 mice with an average weight of 25 gram were purchased from Harlan 
(Horst, The Netherlands). All mice were maintained under standard conditions with a 
12 hour light/dark cycle and were allowed food and water ad libitum. Mice were used in 
the experiments at the age of 8 to 12 weeks. The experimental protocol was approved by 
the Animal Experiments Committee under the Dutch National Experiments on Animals 
Act and complied with the 1986 directive 86/609/EC of the Council of Europe.
Moderate CLP-induced polymicrobial sepsis model 
Moderate polymicrobial sepsis, defined as ~60% mortality during the acute phase 
of sepsis (first five days), was used to test the effect of different DEX dosages in a 
septic setting. Hereto, mice underwent CLP as described previously [23,24]. Briefly, 
the cecum was ligated 1 cm from its distal end followed by double puncture with an 
18-Gauge needle, and manipulated to ensure extrusion of feces into the abdominal 
cavity. Postoperatively all mice received a single subcutaneous injection of 0.5 ml of 
0.9% NaCl solution. Mice were monitored every 12 hours during the first 5 days, the 
acute hyperinflammatory phase of sepsis, followed by daily monitoring up to 21 days, 
the chronic immunosuppressive phase of sepsis. Sham mice underwent the same 
procedure but without ligation and puncture of the cecum.
Severe CLP-induced polymicrobial sepsis
Severe CLP-induced polymicrobial sepsis (defined as ~85% mortality when mice 
were postoperatively treated with fluid resuscitation only, and ~50% mortality when 
mice were postoperatively treated with fluid resuscitation and antibiotics) was used 
to test the effect of different dosages of DEX in combination with standard sepsis 
treatment. Hereto, the cecum was ligated just below the ileocecal valve followed by 
double puncture with an 18-Gauge needle and manipulated to ensure extrusion of feces 
[23,24]. To reach a mortality of ~50% during the chronic phase of sepsis (up to 21 
days) mice received subcutaneous injections of Tienam (25 mg/kg BW, Merck Sharp 
& Dohme, Haarlem, The Netherlands; dissolved in 1 ml 0.9% NaCl) starting 2 hours 
after surgery followed by subsequent injections every 12 hours during the first 5 days. 
Control mice postoperatively received 1 ml 0.9% NaCl at the same time points. Mice 
were monitored up to 21 days.
Dexamethasone treatment
Mice received a single intravenous injection of DEX (Sigma Aldrich, Zwijndrecht, 
The Netherlands; dissolved in PBS) 20 minutes after the CLP procedure. This time-
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point was based on previous studies [25]. Treatment groups were: low-dose DEX (L/
DEX; 0.05 mg/kg BW), medium-dose DEX (M/DEX; 0.25 mg/kg BW), or high-dose DEX 
(H/DEX; 2.5 mg/kg BW). Control mice received an injection with PBS. 
Blood
Blood was obtained 6 hours following CLP by retro-orbital plexus puncture and 
collected in ethylenediaminetetraacetic acid containing tubes (Greiner, Bio-one, Alphen 
aan den Rijn, The Netherlands). Plasma was obtained by centrifugation (1.500 rpm; 10 
minutes), immediately frozen, and stored at -80ºC until assayed.
Cytokine measurement
Plasma levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, the 
chemokines CCL2, CXCL1, CXCL2, and eotaxin, as well as the anti-inflammatory 
cytokines and soluble cytokine receptors IL-1Ra, IL-10, sTNF-R1, and sTNF-R2 were 
determined using a sequential enzyme-linked immunosorbent assay (ELISA) method 
as described previously [26]. Antibody pairs and recombinant proteins were obtained 
from R&D Systems Europe (Abingdon, UK).
RNA isolation and real-time quantitative polymerase chain reaction (PCR)
RNA was extracted from lung, liver, and kidney tissue obtained 6 hours after CLP 
using the RNeasy Micro Kit (Qiagen, Hilden, Germany) and reverse transcribed into 
cDNA as described previously [27,28]. CCL2, IL-6, TNF-α, E-selectin, and ICAM-1 
mRNA levels were determined by real-time quantitative PCR (RQ-PCR) using an Applied 
Biosystems 7900 PCR machine (Foster City, CA, USA) and quantified by normalization 
against the household gene ABL [28].
Statistical analysis
Data are presented as the mean values ± standard error of the mean. Statistical 
analysis was performed using GraphPad Prism 5.0 (GraphPad software, CA, USA) and 
SPSS version 15 (SPSS Inc., Chicago, IL). Statistical significance was determined by the 
non-parametric Mann-Whitney U test and log-rank survival analysis. Log–rank survival 
analyses were performed (until day 21) and corrected for population stratification of 
different experiments. A p-value <0.05 was considered as statistically significant.
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RESuLTS
The effect of DEX treatment on survival in a moderate CLP-induced sepsis 
model
In control mice, CLP resulted in an overall survival of 33% at day 21. Treatment with 
M/DEX or H/DEX DEX had no effect on survival; 39% and 33% survival, respectively. 
L/DEX treatment significantly improved survival up to 75% at day 21 (L/DEX vs. PBS 
p < 0.05; L/DEX vs. H/DEX p < 0.05) (Figure 1). L/DEX treatment also reduced the 
severity of clinical manifestations of sepsis, such as lethargy, body weight loss, and 
diarrhoea during the acute phase of sepsis. This was not observed for both higher DEX 
dosages (data not shown).
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Figure 1. Effect of dexamethasone treatment on survival.
Moderate polymicrobial sepsis was induced in C57BL/6 mice by ligation of the cecum 1 cm from the 
distal end followed by a double puncture with an 18-G needle. DEX was administered intravenously 
20 minutes following CLP. Survival was monitored for 21 days after CLP. L/DEX (0.05 mg/kg BW) 
treatment was associated with improved survival as compared with treatment with PBS, M/DEX 
(0.25 mg/kg BW), or H/DEX (2.5 mg/kg BW). Presented results were obtained in three identical 
independent experiments and corrected by stratification. n = 16 - 18 mice/group. * means p < 0.05.
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The effect of DEX treatment on plasma cytokine levels in a moderate CLP-induced 
sepsis model
We next examined the effect of the different DEX dosages on systemic cytokine 
levels. Plasma cytokine levels were determined 6 hours after CLP. In all experimental 
groups, CLP induced an increase of plasma CCL2, CXCL1, CXCL2, eotaxin, IL-1β, IL-
1ra, IL-6, IL-10, sTNF-R1, sTNF-R2, and TNF-α levels. In mice treated with M/DEX or 
H/DEX CCL2, CXCL1, CXCL2, eotaxin, IL-1ra, IL-6, sTNF-R1, and sTNF-R2 plasma 
levels were mostly significantly (p < 0.05) reduced compared with control mice (Figure 2). 
In the L/DEX treated mice plasma levels of CCL2, CXCL1, CXCL2, eotaxin, IL-1ra, IL-6, 
IL-10, sTNF-R1, and sTNF-R2 were consistently lower than in control mice, although 
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Figure 2. Effect of dexamethasone treatment on systemic inflammatory response.
Moderate polymicrobial sepsis was induced in C57BL/6 mice by ligation of the cecum 1 cm from the 
distal end followed by a double puncture with an 18-G needle. DEX was administered intravenously 
20 minutes following CLP. Plasma cytokine levels were determined at 6 hours following CLP. L/DEX 
(0.05 mg/kg BW) treatment was associated with reduced plasma levels of pro-inflammatory cytokines 
and anti-inflammatory cytokines. M/DEX (0.25 mg/kg BW) and H/DEX (2.5 mg/kg BW) treatment was 
associated with significantly reduced IL-6, CCL2, CXCL1, CXCL2, eotaxin, TNF-sr1, TNF-sr2, and IL-1ra 
levels as compared with PBS treated mice. n = 6 mice/group. * means p < 0.05, ** means p < 0.01.
 Sepsis treatment with dexamethasone 
133
this was never significant (Figure 2). The tested DEX concentrations did not affect the 
CLP-induced increase of plasma IL-1β and TNF-α (Figure 2).
The effect of DEX treatment on organ inflammation in a moderate CLP-induced 
sepsis
Since lungs, liver, and kidney are commonly affected during sepsis [29-31] we next 
examined the effect of the different DEX dosages on cytokine and adhesion molecule 
mRNA expression levels in these organs at 6 hours after CLP. In control mice, CLP 
strongly increased CCL2, IL-6, TNF-α, E-selectin, and ICAM-1 mRNA expression levels 
in lung, liver, and kidney tissue (Figure 3). DEX dose dependently reduced CCL2, IL-6, 
E-selectin, and ICAM-1 mRNA expression in all three organs, with the most powerful 
reductions in H/DEX treated mice (Figure 3). None of the tested DEX dosages affected 
the CLP-induced increase of TNF-α mRNA in any of the organs tested (Figure 3).
The effect of DEX treatment in addition to fluid resuscitation and antibiotics in a 
severe CLP-induced sepsis model
We further evaluated the effect of different dosages of DEX treatment in combination 
with the standard of sepsis care, consisting of fluid resuscitation and antibiotics, in a 
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Figure 3. Effect of dexamethasone treatment on pulmonary, hepatic, and renal inflammation.
Moderate polymicrobial sepsis was induced in C57BL/6 mice by ligation of the cecum 1 cm from the 
distal end followed by a double puncture with an 18-G needle. DEX was administered intravenously 
20 minutes following CLP. Lung, liver, and kidney tissue was obtained at 6 hours following CLP. 
Relative IL-6, CCL2, TNF-α, E-selectin, and ICAM-1 mRNA expression levels were determined in lung, 
liver, and kidney tissue. L/DEX (0.05 mg/kg BW), M/DEX (0.25 mg/kg BW), and H/DEX (2.5 mg/kg BW) 
treatment was associated with reduced IL-6, CCL2, E-selectin, and ICAM-1 mRNA expression levels 
compared with PBS treated mice. n = 3 mice/group.
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severe CLP-induced sepsis model. In control mice that only received fluid resuscitation 
the overall survival at day 21 was 17% (Figure 4). In mice that received treatment with 
fluid resuscitation and antibiotics, survival significantly increased to 50% (p < 0.05) 
at 21 days (Figure 4). In this severe sepsis model H/DEX treatment in combination 
with fluid resuscitation and antibiotics did not result in a better survival than with fluid 
resuscitation and antibiotics alone (Figure 4). L/DEX treatment in combination with 
fluid resuscitation and antibiotics increased survival up to 92%, which was significantly 
(p < 0.05) higher than with fluid resuscitation and antibiotics alone (Figure 4).
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Figure 4. Effect of dexamethasone treatment in combination with standard sepsis care  on 
survival.
Severe polymicrobial sepsis was induced in C57BL/6 mice by ligation of the cecum just below the 
ileocecal valve followed by a double puncture with an 18-G needle. DEX, or PBS as control, was 
administered intravenously 20 minutes after cecal ligation and puncture, followed by 5 day treatment 
with antibiotics and fluid resuscitation (AB) or fluid resuscitation alone (NaCl). Survival was monitored for 
21 days after cecal ligation and puncture. Control treatment in combination with fluid resuscitation alone 
did not affect mortality. Control treatment followed by postoperative treatment with antibiotics and fluid 
resuscitation was associated with improved survival. H/DEX (2.5 mg/kg BW) treatment in combination 
with antibiotics and fluid resuscitation did not affect survival compared with control treatment. L/DEX 
(0.05 mg/kg BW) treatment in combination with antibiotics and fluid resuscitation did improve survival 
compared with control treatment in combination with antibiotics and fluid resuscitation. Presented results 
were obtained in two identical independent experiments. Log-rank survival analyses were performed as 
described in Materials and methods. n = 12 mice/group. * means p < 0.05, ** means p < 0.01.
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DISCuSSION
Sepsis and septic shock are major causes of morbidity and mortality within intensive 
care units. The incidence of these conditions is still increasing [1]. A generalized pro-
inflammatory state is an early characteristic of sepsis and contributes to the severe 
pathology. This stresses the need for therapeutic approaches that modulate this pro-
inflammatory response. In the present study we show for the first time that treatment with 
L/DEX (0.05 mg/kg BW) significantly improves survival in CLP-induced polymicrobial 
sepsis in mice, while higher DEX dosages (M/DEX (0.25 mg/kg BW) and H/DEX 
(2.5 mg/kg BW)) showed no survival benefit. Remarkably, the pro-survival effect of 
L/DEX was associated with only a mild but consistent reduction of the inflammatory 
response, while both M/DEX and H/DEX were associated with significant downregulation 
of the inflammatory response. Our data demonstrates that the modest reduction of 
the inflammatory response by L/DEX is associated with a significant survival benefit. 
Importantly, this effect of L/DEX was of additive value to the standard sepsis treatment 
with fluid resuscitation and antibiotics.
Glucocorticosteroids are potent anti-inflammatory agents that upon binding to an 
intracellular glucocorticoid receptor prevent activation of a variety of inflammatory 
genes [32]. Glucocorticosteroid treatment has been show to improve survival in 
LPS models of septic shock, which was associated with a marked reduction of the 
inflammatory response [33-36]. However, in the CLP model, which more accurately 
reflects the pathophysiology of human sepsis, conflicting results have been obtained 
with corticosteroid treatment. Some studies described that high-dose corticosteroid 
treatment (30 mg/kg methylprednisolone) resulted in survival improvement [37], while 
others found no effect of high-dose corticosteroid treatment (e.g. dexamethasone ≥2.5 
mg/kg [35]). Here, we demonstrate that a single L/DEX administration 20 minutes after 
the CLP procedure improved survival while M/DEX and H/DEX did not. Remarkably, in 
septic patients it also appears that only low-dose corticosteroid treatment, defined as a 
total daily dosage of ≤ 300 mg hydrocortisone (or equivalent), has a beneficial effect on 
short-term mortality [22]. The human equivalent dose of the DEX concentrations used 
in our study are 0.20 mg/kg for H/DEX, 0.020 mg/kg for M/DEX, and 0.0041 mg/kg for 
L/DEX [38], which suggests that DEX dosages currently administered to septic patients 
[22] may be reduced to gain further survival improvement.
Pro-inflammatory cytokines and chemokines are crucially important in the 
activation of host defense mechanisms against invading pathogens [39], since they 
facilitate immune cell recruitment and activation [40,41]. Here, we found that L/DEX 
treatment was associated with a mild, non-significant, suppression of the sepsis-related 
inflammatory response, as reflected by mild reduction of cytokines, chemokines, and 
adhesion molecule levels in plasma, lung, liver, and kidney. In contrast, M/DEX and 
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H/DEX treatment resulted in significant reduction of the inflammatory response. This 
illustrates that mild downregulation of the pro-inflammatory response is associated with 
survival improvement while strong immunosuppression is not. In line with this, marked 
suppression of the innate immune system prior to infection favors excessive bacterial 
replication [42,43]. Deletion of signaling molecules, such as MyD88, that orchestrate 
cytokine responses upon a septic stimulus, also enhances vulnerability to infection [44]. 
Strong immunosuppressive therapy therefore likely abrogates the protective functions 
of the inflammatory response, such as activation of host defense mechanisms, while 
mild anti-inflammatory therapy blocks the detrimental effects of SIRS but preserves the 
protective inflammatory response. This is supported by the observation that, although 
IL-6 has been identified as a predictor of mortality in experimental sepsis [5] and in 
septic patients [45,46], high dosage of IL-6 neutralizing antibodies did not improve 
survival following CLP while a lower dosage did [47]. In addition, IL-6 knockout mice 
showed an enhanced mortality upon CLP [48,49]. This indicates that IL-6 is involved 
in the protective mechanisms upon a septic insult. Altogether, these data suggest the 
existence of a specific range in which the sepsis related inflammatory response can be 
pharmacologically reduced to obtain survival improvement.
In the present study L/DEX improved survival in a moderate CLP-induced polymicrobial 
sepsis model. However, as fluid resuscitation and antibiotics are the cornerstones of 
severe sepsis and septic shock treatment, we also investigated the effect of different 
DEX dosages in combination with fluid resuscitation and antibiotics in a severe CLP-
induced polymicrobial sepsis model. In line with previous observations [50], we found 
that fluid resuscitation and antibiotics improved long-term survival following CLP. When 
L/DEX was added to treatment with fluid resuscitation and antibiotics long term survival 
became significantly better than with fluid resuscitation and antibiotics alone. The 
highest DEX dosage tested in this study had no additive value to the treatment with 
fluid resuscitation and antibiotics alone. Therefore, mild reduction of the inflammatory 
response, as established by L/DEX, further improves the therapeutic potential of the 
current standard sepsis care.
We cannot exclude that other properties of DEX, such as its effect on the 
cardiovascular system, contributed to the survival benefit. Also, in our study the DEX 
treatment was given shortly (20 minutes) after induction of the septic insult, which we 
consider preventive rather than therapeutic. Nevertheless, our data clearly demonstrate 
that mild reduction of the inflammatory response during the early phase of sepsis is 
associated with long-term survival improvement, which warrants further studies to 
determine the range in which anti-inflammatory drugs can be of benefit in a septic 
setting.
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CONCLuSION
Our results demonstrate that L/DEX treatment can reduce mortality following CLP-
induced polymicrobial sepsis. This beneficial effect is associated with a mild (but non-
significant) suppression of the CLP-induced inflammatory response. We propose that 
the success of anti-inflammatory therapies in a septic setting fundamentally depends on 
finding the optimal level of immunosuppression that reduces SIRS-induced pathology 
but still allows an adequate host defense against invading pathogens. This implies the 
existence of a specific range in which reduction of the pro-inflammatory response will 
lead to survival benefit, while suppression beyond this range will not result in survival 
improvement (Figure 5). As the septic inflammatory response is complicated and differs 
among patients [29] insight into the immunological status of the individual patient will aid 
to maximize the chance of treatment success.
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Figure 5. Model explaining how anti-inflammatory therapy can be successfully applied in a septic 
setting.
The figure represents two pillars of the sepsis-related inflammatory response, i.e. intensity of the 
inflammation (upper left triangle) and host defense (upper right triangle). Success of anti-inflammatory 
therapies in a septic setting fundamentally depends on establishing a critical level of immunosuppression 
that prevents inflammation-induced pathology but still allows an adequate host defense against invading 
pathogens. Slight or no downregulation of the inflammatory response increases the risk of death. In 
addition, robust anti-inflammatory therapy inhibits the protective functions of the inflammatory response 
(left triangle) as reflected by diminished host defense mechanisms (right triangle), also increasing the 
risk of death. However, mild anti-inflammatory therapy ameliorates the detrimental effects of SIRS and 
preserves the protective effect of the inflammatory response, enhancing the chance of adequate host 
defense and subsequent survival. This suggests the existence of a specific range of anti-inflammatory 
treatment in which the sepsis-related inflammatory response can be modulated in such a way that 
survival improvement is obtained.
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CONCLuSIONS AND GENERAL DISCuSSION 
1. Main findings 
The research described in this thesis was initiated to increase the knowledge on 
the effects and the mechanistic aspects of hCG-related oligopeptides in experimental 
animal models that are associated with SIRS. In this context also different doses of 
dexamethasone were investigated.
Chapter II describes that high dose LQGV, VLPALP, and AQGV (50 mg/kg BW) 
enhance the susceptibility of mice to infection with L. monocytogenes. This is established 
by weakening innate immune activation through inhibition of early chemokine responses, 
impairing cellular recruitment and blunting the responsiveness of immune cells to 
L. monocytogenes antigens. 
Chapter III demonstrates that LQGV (50 mg/kg BW) stimulates neutrophil 
apoptosis and reduces O2
- activity. Possibly there is a relationship between these two 
observations. 
Chapter IV describes that LQGV (5 and 50 mg/kg BW) dose dependently activates 
the murine adrenal gland to produce and secrete the anti-inflammatory hormone 
corticosterone, and that activation of glucocorticoid receptor signaling is involved in the 
anti-inflammatory effects of high doses (50 mg/kg BW) of LQGV in LPS-induced SIRS.
Chapter V describes that a low dose of LQGV, AQGV and LAGV (5 mg/kg BW) 
attenuate the systemic and hepatic inflammatory response that follows hemorrhagic 
shock and fluid resuscitation. 
Chapter VI describes the application of the same low dose of LQGV (5 mg/kg BW) 
in a CLP model of sepsis in mice. This study shows that this dose of LQGV improves 
survival following CLP-induced sepsis and that this is associated with a modest reduction 
of the systemic, pulmonary and peritoneal inflammation. This dose of LQGV also acts 
as a useful addition to standard sepsis care with antibiotics and fluid resuscitation in a 
more severe CLP model.
Chapter VII describes that a low dose of the synthetic glucocorticoid dexamethasone 
(0.05 mg/kg BW) improves survival following CLP-induced sepsis in mice while higher 
doses of dexamethasone do not. This observation resulted in a model that states that 
survival improvement by anti-inflammatory therapy in a septic setting crucially depends 
on the level of immunosuppression. The optimum level of immunosuppression in a 
septic setting still allows appropriate activation of host defense mechanisms against the 
invading pathogen(s).
In this chapter the observations of chapters II - VII will be discussed in the context 
of literature dealing with inflammation, shock, glucocorticosteroids, and pregnancy. In 
addition, directions for future research will be discussed.
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2. Modulation of the inflammatory response during infectious and noninfectious 
insults
Inflammation is a response against an infectious or noninfectious insult with the 
aim to restore homeostasis [1]. PRR activation upon infection (PAMP and DAMP) 
or tissue damage (DAMP) activates transcription factors, such as NF-κB and AP-1, 
which subsequently drive the production of pro-inflammatory mediators, for instance 
chemokines and cytokines [2,3]. These mediators activate and orchestrate host 
defense mechanisms against the insult and contribute to repair mechanisms [1,4-6]. 
Mice that lack key chemokines, cytokines, their cytokine/chemokine receptors or 
downstream signaling proteins show a diminished inflammatory response upon an 
insult [7-11]. This leads to an increased susceptibility to infection, for instance with 
L. monocytogenes, and reduced pathology during a sterile inflammation, as may result 
from LPS injection or ischemia reperfusion injury [7-11]. 
In recent years, a lot of effort has been made to investigate the inflammatory response 
that is associated with sepsis by using LPS infusion into mice [12,13]. Although this 
model clearly provides a way to examine a hyper-inflammatory response that results 
from TLR-activation, it does neither represent a true bacterial septic condition nor a true 
septic inflammatory response [14,15]. One of the most important differences between 
LPS infusion and bacterial sepsis is that LPS is a bacterial product that is cleared 
from the body by immune defense mechanisms, while during sepsis multiplication of 
the invading pathogen occurs that increases the load of toxins and antigens derived 
from the pathogen. Also the cytokine response is more rapid and stronger upon LPS 
injection [16], while the clearance of systemic cytokines is delayed in a bacterial sepsis 
as compared to LPS infusion [17,18]. 
The SIRS-associated uncontrolled production of pro-inflammatory mediators can 
lead to MODS and death [19,20]. Therefore, attempts to control this response may limit 
organ damage and death. Inhibition of cytokine production or cytokine bioactivity, for 
instance with monoclonal antibodies directed against TNF-α or IL-6, as well as treatment 
with high doses of glucocorticosteroids, improves survival upon LPS infusion [15,21,22]. 
However, inhibiting TNF-α activity with neutralizing antibodies does not protect against 
CLP-induced septic shock [23]. This suggests that TNF-α alone is not an important 
cytokine in a septic condition, while TNF-α is important in sterile conditions, for instance 
after ischemia reperfusion injury and after LPS injection [24]. 
IL-6 is a cytokine that has a broad range of activities and is involved in maintaining 
the inflammatory response upon LPS and TNF-α injection [25]. In CLP mice, IL-6 plasma 
levels are considered as a predictor of death [26,27]. High doses of IL-6 neutralizing 
antibodies do not improve survival following CLP in mice, while a lower dose of IL-6 
neutralizing antibody does improve survival [28]. Also a complete lack of IL-6 does not 
improve survival following CLP in mice [29]. In contrast, a complete lack of IL-6 does 
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reduce pathology after renal ischemia reperfusion and LPS infusion [30,31]. These 
observations suggest that IL-6 exerts important physiological functions during sepsis 
that need to be maintained during therapeutic intervention in sepsis. 
In this thesis it was found that the success of an anti-inflammatory therapy with 
dexamethasone or LQGV, with regard to survival improvement in CLP-induced sepsis, 
most likely depends on finding an optimal level of immunosuppression. In line with this 
a recent literature based study suggested that low-dose corticosteroid treatment has 
a beneficial effect on short-term mortality in patients with septic shock, in contrast to 
high-dose corticosteroid treatment [32]. Therefore, it can be speculated that a specific 
level of immunosuppression that reduces SIRS-induced pathology, but still allows an 
adequate host defense against invading pathogens, is crucial to the success of anti-
inflammatory therapies. As the septic inflammatory response is complicated and differs 
among patients, insight into the immunological status (activated or suppressed) of 
the individual patient will aid to optimize immunosuppressive treatment and thus will 
influence therapy success [14].
Administration of LQGV and VLPALP two hours after LPS infusion improved survival 
in mice, while no survival benefit was observed when LQGV and VLPALP where 
administrated 24 hours after LPS injection [13,33]. However, administration of MTR, 
MTRV, VLPALPQ, and VVC did improve survival when administrated 24 hours after 
LPS infusion [33]. AQGV, the alanine replacement variant of LQGV, was effective when 
administrated either two or 24 hours after LPS injection in mice [33]. In a hemorrhagic 
shock and fluid resuscitation model in rats LQGV, AQGV and LAGV attenuated the 
inflammatory response when administrated shortly after bleeding (Chapter V). As both 
the LPS injection and the hemorrhagic shock/fluid resuscitation models represent a 
non-infectious SIRS, the beneficial effects on inflammation and survival cannot be 
simply translated to sepsis. Therefore, we investigated the anti-inflammatory effects of 
hCG-related oligopeptides in two different infection models: L. monocytogenes infection 
and CLP-induced sepsis in mice. 
In case of an L. monocytogenes infection in mice, a high dose of LQGV, AQGV 
or VLPALP (50 mg/kg BW) inhibited innate immune activation, leading to bacterial 
overgrowth (Chapter II). Mice that lack innate immune activators, such as TNF-α, IL-6, 
and IL-12, have an increased susceptibility to L. monocytogenes infection [34,35]. 
L. monocytogenes activates the extracellular receptor TLR-2, which results in the 
production of cytokines and chemokines [36]. LQGV treatment in vivo impaired the 
ability of splenocytes to produce TNF-α and IL-6 upon HKLM and LPS stimulation in 
vitro, but these responses were not completely blocked (Chapter II). In addition, LQGV 
reduced the initial chemokine response in vivo (Chapter II). These data suggest that 
LQGV administration to mice results in decreased PRR activation by bacterial antigens. 
In line with this, PRR gene mutations or polymorphisms in humans, for instance for 
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TLR, are linked to altered PAMP recognition and innate immune activation that have 
been linked to an increased susceptibility to severe infections [37]. Thus, PRR are 
key components in initiating the inflammatory response by microbes, and LQGV likely 
inhibits this activation.
In case of CLP-induced sepsis, we employed a lower dose of 5 mg/kg BW of 
LQGV. This dose did not completely reduce the cytokine response, but rather showed 
a minor to minimal reduction of the systemic, pulmonary and peritoneal inflammatory 
response, as compared to L. monocytogenes infection (Chapters II and VI). As hCG-
related oligopeptides were found to act in a dose dependent manner in experimental 
animal in vivo models, such as LPS infusion, renal ischemia reperfusion injury and 
transplantation of Lewis lung carcinoma [38,39], the differences observed between 
CLP- and L. monocytogenes-induced sepsis could be related to dose differences, as 
50 mg/kg BW was used during L. monocytogenes infection while only 5 mg/kg BW was 
used during CLP.
In summary, LQGV can exert anti-inflammatory activity upon infection and tissue 
injury. The successful use of LQGV as an anti-inflammatory therapeutic in an infectious 
condition most likely depends on finding the optimal level of immunosuppression that is 
needed for treatment success, just like in dexamethasone-induced immunosuppression 
(Chapter VII).
3. Mode of action of hCG-related oligopeptides
3.1 Adrenal gland activation
Addition of LQGV to cell cultures, for instance of splenocytes, did not reduce HKLM 
or LPS induced TNF-α and IL-6 production (Chapter IV). LQGV also did not reduce 
LPS and TNF-α induced E-selectin expression on endothelial cells in in vitro culture 
systems (unpublished data). These data suggest that LQGV by itself does not inhibit 
TLR-driven TNF-α, IL-6 and E-selectin production in these in vitro culture systems. 
However, the in vivo models clearly revealed that LQGV has anti-inflammatory activity, 
including suppression of TLR-driven TNF-α, IL-6 and E-selectin production. 
Glucocorticosteroid secretion by the adrenal gland is under the control of the HPA-
axis. Glucocorticosteroids are involved in maintaining homeostasis by regulating lipid 
and protein metabolism and in modulation of the cardiovascular system, the central 
nervous system and the immune system [40]. Synthetic glucocorticosteroids are widely 
and successfully applied for the treatment of pathological conditions associated with 
severe inflammation [40]. Almost all cells within the body express the cytoplasmic GR 
[40,41]. Upon ligand binding GR translocate into the nucleus, where they interact with 
glucocorticoid responsive elements in the promoter region of target genes and thereby 
regulate gene expression [40]. The activated GR can also regulate gene expression 
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through direct interaction with transcription factors, including AP-1 and NF-κB [42].
In this thesis we show that LQGV can inhibit innate immune activation in mice 
through activation of the GR (Chapter IV). As LQGV did not inhibit pro-inflammatory 
mediator production in vitro, it is unlikely that LQGV by itself activated GR signaling. 
This suggests that the immunosuppressive and anti-inflammatory effects of LQGV are 
established through an in vivo released secondary mediator that stimulates GR activity. 
The experiments described in Chapter IV demonstrate that in mice high dose (50 mg/
kg BW) LQGV-treatment can stimulate ACTH receptor driven adrenal gland activation, 
leading to a prolonged increase of corticosterone plasma levels. High endogenous and 
exogenous glucocorticosteroid levels impair the inflammatory response, which increases 
the susceptibility to L. monocytogenes [43-45]. An elegant example of the effects of 
increased endogenous corticosterone levels on an L. monocytogenes infection was 
presented in a recent study [46]. The authors found that activation of the HPA axis by 
influenza virus leads to a prolonged increase of corticosterone levels that enhance the 
susceptibility to L. monocytogenes infection [46]. In contrast, inflammatory responses 
that follow hemorrhagic shock/fluid resuscitation and LPS infusion were reduced by 
high endogenous and exogenous glucocorticosteroid levels, resulting in less organ 
damage [22,47]. Furthermore, blockage of GR signaling increases the vulnerability to 
LPS and hemorrhagic shock [48,49]. Therefore, it might be that the protective effect of 
LQGV on LPS and hemorrhagic shock also involves the stimulation of adrenal gland 
corticosterone production and subsequent GR activation. The role of the adrenal glands 
in the protective effect of LQGV in vivo is supported by the observation that LQGV had no 
protective effect against LPS-induced mortality in mice that underwent ADX (Figure 1). 
Also plasma from LQGV-treated ADX mice did not inhibit HKLM induced cytokine 
production by splenocytes from naive mice, while plasma from LQGV-treated control 
mice did inhibit this response (Chapter IV). 
Adrenal glucocorticoid secretion is linked to pituitary ACTH release [40]. However, 
nature tends to incorporate some redundancy into vitally important organ systems and 
ACTH-independent pathways for adrenal gland activation have been demonstrated as 
well [50]. This was illustrated for the first time in corticotropin-releasing hormone (CRH)-
knockout mice that do not secrete ACTH, but still produced high levels of corticosterone 
[51]. Also, the pentapeptide VPDPR that is derived from endogenous cleavage of pro-
colipase, exerts its anti-analgesic effect through adrenal gland activation and subsequent 
GR signaling in neurons [52]. 
Previously, it was shown that LQGV did not protect against renal ischemia reperfusion 
injury, while LQGV did reduce inflammation and organ damage during hemorrhagic 
shock and fluid resuscitation [39]. Although GR levels are equally expressed in liver 
and kidney the corticosterone binding capacity for GR is higher in the liver than in the 
kidneys under both normal and stress conditions [53,54]. This might explain why LQGV 
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was effective during hemorrhagic shock/fluid resuscitation, but not in renal ischemia 
reperfusion injury. 
In conclusion, adrenal gland activation is a natural mechanism that keeps the pro-
inflammatory response at bay. High dose (50 mg/kg BW) LQGV-treatment of mice can 
stimulate adrenal gland activation and account for a prolonged increase of corticosterone 
plasma levels with subsequent GR activation. May be next to this effect, LQGV can 
exert its anti-inflammatory effect also along other cellular and molecular processes. 
This would require further studies.
3.2 Neutrophil accumulation
Neutrophil extravasation is an early event of the inflammatory response [55]. 
The extravasation process requires a multistep cascade of adhesive and migratory 
events that are mediated by three classes of adhesion molecules, the selectins, integrins 
and adhesion receptors of the immunoglobulin superfamily, as well as chemokines. 
The extravasation process of neutrophils can be divided into five sequential stages: 
(a) selectin-mediated sticking to the endothelium; (b) integrin-mediated crawling over 
the endothelium; (c) firm arrest to the endothelium; (d) chemokine-induced activation; 
and finally (e) transendothelial migration [5,56]. Subsequently, through a chemokine 
gradient, neutrophils migrate to the inflamed loci, where they release their contents 
Figure 1. ADX abolishes the LQGV pro-survival effect after LPS infusion. 
Non-ADX and ADX C57BL/6 mice were treated with either 200 µl LQGV (50 mg/kg BW) or PBS. 
The next day, the mice were challenged with an LPS injection. Survival was scored every 12 hours. Data 
depicted are from 5 mice per group. 
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that affect local cell and tissue function [56-58]. Depending on the intensity of the 
inflammatory response, the tissue can be either completely shut down or attempts 
are made to restore homeostasis, during which some pathological changes can occur 
[59]. 
Neutrophil accumulation in tissues is an important contributor to tissue damage 
and tissue dysfunction that follows hemorrhagic shock and fluid resuscitation [60,61]. 
LQGV reduced hepatic neutrophil accumulation following hemorrhagic shock and 
fluid resuscitation, while AQGV and LAGV did not (Chapter V). Also following an 
L. monocytogenes infection LQGV reduced neutrophil accumulation. The reduced 
neutrophil accumulation in hemorrhagic shock was found to be associated with reduced 
mRNA expression of the endothelial specific adhesion molecule E-selectin (Chapter V), 
suggesting that in vivo LQGV can influence the E-selectin gene expression. E-selectin 
blockage has been found to protect against ischemia/fluid resuscitation and endotoxin-
induced damage [62,63]. Glucocorticosteroids can prevent the migration of immune 
cells from the circulation to an inflammatory site by reducing E-selectin and chemokine 
production upon injury [64-66]. LQGV treatment in vivo also reduced the production of the 
neutrophil attracting chemokines CXCL1/KC and CCL2/MCP1 upon an  L. monocytogenes 
infection (Chapter II). Although LQGV did reduce CCL2/MCP-1 plasma levels during 
an L. monocytogenes infection, no effect on monocyte recruitment/accumulation into 
L. monocytogenes infected organs was observed. The latter is in line with the observation 
that LQGV also did not reduce monocyte recruitment into the lungs and liver following 
hemorrhagic shock and fluid resuscitation (Figure 2). This may indicate that LQGV 
more or less specifically interferes with neutrophil recruitment. The mechanism behind 
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Figure 2. Monocyte infiltration into lung and liver. 
Number of ED1 positive cells (monocytes) per high power field (HPF) in the lungs and liver at 3 hours after 
the onset of hemorrhagic shock. Data are presented as the mean ± S.E.M. of eight rats per group. 
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this observation is unclear so far, but the possibility should be considered that specific 
induction of neutrophil apoptosis contributes to this observation (Chapter III). This 
would be in line with the observation that neutrophil depletion protects against LPS-
induced shock and hemorrhagic shock followed by fluid resuscitation, while neutrophil 
depletion enhances L. monocytogenes susceptibility [67,68]. 
3.3 ROS activity and neutrophil apoptosis 
Free radicals can be defined as molecules containing one or more unpaired 
electron(s) in atomic or molecular orbitals [69-71]. This unpaired electron usually gives a 
considerable degree of reactivity to the free radical. Molecular oxygen (dioxygen) has a 
unique electron configuration and is itself a radical [69-71]. The addition of one electron 
to dioxygen forms the superoxide anion radical (O2
-). Superoxide anion, arising either 
through metabolic processes or following oxygen activation by physical irradiation, is 
considered the primary reactive oxygen species (ROS) and can further interact with 
other molecules to generate secondary ROS [72]. The production of superoxide anion 
occurs mostly within the mitochondria of a cell. The mitochondrial electron transport 
chain is the main source of adenosine triphosphate (ATP) in the cell and thus essential 
for life [72,73].
ROS generation is relatively low during an ischemic event, however following fluid 
reperfusion a massive burst of ROS occurs that can induce tissue damage [74]. This burst 
is derived from several cell types but predominantly from neutrophils [58,75]. ROS activity 
can be neutralized by superoxide dismutase (SOD), which has been shown to reduce 
tissue damage and inflammation after hemorrhagic shock and fluid resuscitation [76,77]. 
Here we show hat LQGV as well as other hCG-related oligopeptides reduced superoxide 
anion activity (Figure 3) and that LQGV stimulated neutrophil apoptosis (Chapter III). 
Remarkably, SOD can also induce neutrophil apoptosis when excessively present [77]. 
Preliminary data using FITC-labeled LQGV revealed an uptake by phagocytic cells, 
mainly neutrophils and some monocytes, while lymphocytes remained FITC negative 
(unpublished data). This suggests that the uptake of LQGV-FITC by phagocytes is an 
active process, rather than the result of passive diffusion. Possibly, intracellular LQGV 
reduces O2
- activity thereby stimulating neutrophil apoptosis.
In conclusion, these studies show that adrenal glands can be involved in the LQGV-
induced immunosuppression. The neutralization of ROS by hCG-related oligopeptides 
and the transient apoptosis-induced neutrophil depletion may have contributed to the 
immunosuppressive effect observed in the tested in vivo models. These observations 
are visualized in a model that is depicted in Figure 4.
4. hCG-derived oligopeptides; implications for the biology of pregnancy? 
Pregnancy remains to some extent an immunological enigma as the fetus inherits 
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paternal antigens and yet coexists within the mother’s uterus in harmony throughout 
pregnancy. Characteristic for human pregnancy is the production of hCG, which is a 
member of the glycoprotein hormone family to which also luteinizing hormone (LH), 
follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH) belong 
[78]. Hormones from this family consist of similar heterodimeric structures sharing an 
identical α-subunit, but each of these hormones have a unique β-subunit that confers the 
hormonal biological specificity [79]. It has been demonstrated that hCG preparations, 
besides their endocrine functions, also influence the functionality of the immune system 
[80-83]. 
Besides the intact hCG hormone several other isoforms of hCG exist, especially 
during the second and third trimester of pregnancy [84]. In this phase of pregnancy 
loop 2 of β-hCG is extensively nicked by leukocyte elastase-like proteases, which 
generates hCG β-core and several nicked β-hCG forms [84]. These molecules can be 
detected in serum and urine in the second and third pregnancy trimester. Besides the 
generation of hCG β-core and nicked β-hCG, also small breakdown products of three to 
seven amino acids long, that originate from loop 2 of β-hCG, are likely generated [85]. 
It has been demonstrated that such small peptides can exert anti-inflammatory effects 
[13,38,83,85 and this thesis]. The hCG-related oligopeptides used in our studies have 
not been detected in pregnancy urine yet, but the relative amount of hCG β-core and 
Figure 3. Cytochrome C reduction activity. 
Adding hypoxanthine to a pH neutral cytochrome C, xanthine oxidase, and oligopeptide solution 
(1000 µg/ml) initiated the reduction of cytochrome C reaction. At the end of each experiment the level 
of cytochrome C reduction was calculated to percentage. Data are presented as the mean ± S.E.M. 
of three separate experiments, in which each of the tested oligopeptides was measured in sixfold. 
* p < 0.05; ** p < 0.01
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nicked β-hCG detected provide an estimate of the expected release of hCG-derived 
oligopeptides. 
During the second and third pregnancy trimester the HPA axis is activated, leading to 
enhanced glucocorticoid production [86]. Elevated glucocorticosteroid levels influence 
the maternal immune system as to facilitate fetal allograft maintaince [87]. Placental 
and hypothalamic derived CRH activate the anterior pituitary to produce ACTH, 
Adrenal steroid
production
Neutrophil
apoptosis
Immunosuppression
Sterile inammation:
• LPS-induced shock
• Hemorrhagic shock
  and resuscitation
Non-sterile inflammation:
• acute stage of moderate
  CLP-induced sepsis
Non-sterile inflammation: 
• L.monocytogenes infection
• Chronic stage of CLP-induced sepsis
• Severe CLP-induced sepsis
Benecial Detrimental
LQGV
• Cytokines
• Adhesion molecules ↓↓ Neutrophil numbers ↓
Figure 4. Proposed mode of action of LQGV. 
LQGV activates the adrenal gland to secrete glucocorticosteroids. Simultaneously LQGV induces a 
transient neutropenia. These two processes impaired the inflammatory response, which in a sterile 
condition prevents morbidity and mortality, while in case of infection this can increase the susceptibility 
to the pathogen. 
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which stimulates the adrenal cortex to produce glucocorticoids [40]. Adrenal steroid 
production may also be stimulated in a CRH/ACTH independent manner, however, 
the mechanisms involved herein are poorly understood so far [88]. Although, positive 
correlations between hCG and cortisol (the human analogue of rodent corticosterone) 
have been described [89,90], hCG administration to women does not result in cortisol 
production [91]. Because LQGV likely occurs in high amounts during the second and 
third pregnancy trimester (the moment at which cortisol levels rise as well [86]) and 
because of the observation that LQGV in mice stimulates corticosterone production, it 
can be hypothesized that LQGV and similar hCG-derived oligopeptides contribute to 
the pregnancy-associated adrenal glucocorticoid production. 
During pregnancy, neutrophil numbers in the peripheral blood steadily rise and 
may even lead to a neutrophilia [92]. Excessive increase in neutrophil numbers 
occurs during pre-eclampsia [92]. Besides the increase in numbers, neutrophils also 
increase their CD11b, CD14 and CD64 expression and intracellular ROS levels [93]. 
This activated phenotype is almost identical to the one seen in septic patients [93]. 
However, neutrophils at the maternal-fetal interface do not gain an activated phenotype 
[94]. This suggests that neutrophil activity is negatively regulated at this interface. The 
mechanism that prevents neutrophils at the maternal-fetal interface from gaining an 
activated phenotype is poorly understood, but a role for syncytiotrophoblasts herein has 
been suggested [95]. It could well be that hCG-derived oligopeptides, like LQGV, play 
a central role in this phenomenon.
To summarize, hCG-derived oligopeptides, in particular LQGV, may well be involved 
in the control of the maternal immune system to facilitate pregnancy success. This 
pregnancy-associated immune regulation possibly involves the stimulation of adrenal 
gland activation and inhibition of neutrophil activity at the maternal-fetal interface.
5. Future research directions
The studies described in this thesis demonstrate that the tested hCG-related 
oligopeptides exert anti-inflammatory activity in experimental animal models that are 
associated with SIRS. Although the picture of the mechanisms of action is largely 
incomplete for most hCG-related oligopeptides, some conclusions can be drawn, for 
instance about the dose response effect, the role of the adrenal glands and increased 
corticosterone levels, and the transient neutrophil depletion. Still these studies should 
be further expanded to provide a more detailed insight into the mechanisms of action. 
Approximately 40% of patients with hemorrhagic shock develop sepsis as a result 
of increased gut permeability and development of immune paralysis [16,96]. Therefore, 
it would be of clinical interest to evaluate the effects of hCG-related oligopeptides, in 
particular LQGV, in a double hit model of hemorrhagic shock/fluid resuscitation and 
subsequent CLP-induced septic shock. It is well known that the inflammatory response 
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that results from trauma and sepsis differs considerably between individuals. Therefore, 
the incorporation of genetic variability, as additional parameter, may be of clinical 
importance. This means that the use of outbred mouse models for future CLP-studies 
is of interest. 
The studies in this thesis showed that LQGV (5 mg/kg BW) or dexamethasone 
(0.05 mg/kg BW) administration before or around the CLP procedure reduced mortality. 
These administration schemes can be considered preventive rather than therapeutic. 
Thus studies should be performed to determine the therapeutic time-window of LQGV 
and low dose dexamethasone administration, as later anti-inflammatory treatment is of 
more interest for sepsis patients.
LQGV activates the ACTH receptor, however, the nature of the molecular interaction 
between LQGV and the ACTH-receptor is still unknown. Experiments with mutant cell 
lines that lack specific domains of the ACTH receptor can give more insight into the 
LQGV-ACTH receptor interaction. 
From an immunological point of view the existence of various oligopeptides in cells 
and tissues makes sense, considering that discriminating between self and non-self 
relies on MHC class I and II peptide presentation. It has been demonstrated that MHC 
class I presented peptides represent a comprehensive and balanced summary of the 
endogenous proteomic content of the cell [97]. Although peptides presented by MHC 
class I are typically 8-10 amino acids in size [98] it is likely that smaller peptides with 
regulatory activity are formed as well during the proteolytic processing. Therefore, 
screening peptide libraries for small oligopeptides with biological activities and 
originating from other proteins than hCG may be of interest. Many peptide components 
have been identified in tissues/organs and body fluids from different species, as well 
as in blood cells and tissue cultures [99]. The concept has emerged that tissue specific 
proteins are endogenously degraded by peptidases and thereby generate a large group 
of oligopeptides, ranging from 2 to 35 amino acids long. These peptides represent the 
tissue specific peptide pool defined as peptidome. This peptidome might present a 
new class of bioregulators that regulate important processes in life (inflammation and 
regeneration) [99]. Under pathological conditions, the tissue specific peptide pool will 
undergo dynamic changes that probably are involved in restoring tissue homeostasis. 
Also some of these oligopeptides provide a powerful tool for diagnostic purposes [99]. 
More research will possibly lead to the identification of many novel (endogenous) 
regulatory peptides that may originate from a wide variety of proteins. 
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Inflammation is the body’s way of informing itself of changes in homeostasis. 
Depending on the triggering event and anatomical location, the inflammatory response 
has different physiological purposes and pathological consequences. The production 
and secretion of inflammatory mediators can alter tissue functionality such that the tissue 
adapts to the harmful insult and restores tissue homeostasis with some pathological 
changes. 
The systemic inflammatory response syndrome (SIRS) is an excessive inflammatory 
response inflicted by a variety of clinical insults, such as severe hemorrhage, sepsis, and 
pancreatitis. Uncontrolled production of pro-inflammatory mediators can lead to multiple 
organ dysfunction syndrome (MODS) and death. Therefore, controlling the inflammatory 
response might limit tissue damage and death. However, despite improvement in our 
knowledge of the pathology of SIRS and the availability of novel drugs it appears to be 
difficult for controlling the inflammatory response during a severe infection.
The research described in this thesis was initiated to increase the knowledge on 
the effects and the mechanistic aspects of hCG-related oligopeptides in experimental 
animal models that are associated with SIRS. In this context also different doses of 
dexamethasone were investigated.
To explore the effects of hCG-related oligopeptides during infectious SIRS, we used 
two different models: (a) L. monocytogenes infection model in mice (Chapter II) and 
(b) CLP-induced sepsis model in mice (Chapter VI). These studies show that the hCG-
related oligopeptides LQGV, VLPALP and AQGV blunt innate immune activation. In case 
of L. monocytogenes infection this impairment increases the susceptibility of mice to the 
invading pathogen. In a CLP-induced sepsis model this impairment did not increase 
the susceptibility of mice, but rather decreased mortality. Furthermore, in combination 
with the standard sepsis care with antibiotics and fluid resuscitation, LQGV enhanced 
survival compared with antibiotics and fluid resuscitation treatment or LQGV treatment 
alone. As hCG-related oligopeptides were found to act in a dose dependent manner in 
experimental in vivo models, such as LPS infusion, renal ischemia reperfusion injury 
and transplantation of Lewis lung carcinoma, the differences observed between CLP- 
and L. monocytogenes-induced sepsis could be related to dose differences, as 50 mg/
kg BW was used during L. monocytogenes infection while only 5 mg/kg BW was used 
during CLP.
To examine the effects of LQGV, AQGV and LAGV during a non-infectious SIRS, we 
used a hypovolemic shock and resuscitation model in rats (Chapter V). This study also 
shows that the tested oligopeptides exert anti-inflammatory activity, as they attenuate 
the systemic and hepatic inflammatory responses that typically follow hemorrhagic 
shock and fluid resuscitation. 
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Mechanistic studies on the mode of action of high dose (50 mg/kg BW) LQGV- 
treatment revealed that this oligopeptide dose dependently stimulated ACTH receptor 
driven adrenal gland activation, leading to a prolonged increased plasma level 
of the anti-inflammatory hormone corticosterone, with subsequent GR activation 
(Chapter IV). High endogenous and exogenous glucocorticosteroid levels impair 
the inflammatory response and increase the susceptibility to L. monocytogenes. 
However, glucocorticosteroids reduce the inflammatory response pathology that follows 
hemorrhagic shock/fluid resuscitation and LPS infusion. This explains the effects 
observed in Chapters II and IV. Also it was found that LQGV reduced O2
- activity and 
stimulated neutrophil apoptosis (Chapter III). The latter may also have contributed to 
the reduced neutrophil accumulation observed in the different SIRS models. We do not 
exclude that LQGV and other hCG-related oligopeptides also have other effects that 
contribute to their anti-inflammatory effects.
During the last decades the treatment with synthetic glucocorticoids, such as 
dexamethasone, has been investigated in severe sepsis. However, contradictory 
results have been obtained. Some studies demonstrated survival improvement after 
high-dose corticosteroid treatment while others did not. Therefore, to investigate 
the effects of different dosages of dexamethasone during an infectious SIRS, we 
investigated the effects of high, median, and low dose dexamethasone treatment on 
mortality and inflammation in a murine CLP model in mice (Chapter VII). In this study 
it was demonstrated that an extreme low dose dexamethasone can reduce mortality 
following CLP-induced polymicrobial sepsis. This beneficial effect is associated with a 
mild (but non-significant) suppression of the CLP-induced inflammatory response. In 
this thesis we propose that the success of anti-inflammatory therapies in a septic setting 
fundamentally depends on finding the optimal level of immunosuppression that reduces 
SIRS-induced pathology but still allows an adequate host defense against the invading 
pathogens. This implies the existence of a specific range in which reduction of the pro-
inflammatory response will lead to survival benefit, while suppression beyond this range 
will not result in survival improvement
In conclusion, the studies described in this thesis show that (a) hCG-related 
oligopeptides can exert anti-inflammatory activity; (b) high dose LQGV-treatment can 
exert its anti-inflammatory effect by stimulating adrenal gland activation, leading to 
increased and prolonged corticosterone production and subsequent GR signaling; (c) 
hCG-related oligopeptides reduce O2
- activity and decrease blood neutrophil numbers, 
which may also contribute to the anti-inflammatory activity of the tested oligopeptides; 
(d) in a septic setting the survival improvement by dexamethasone and probably other 
anti-inflammatory therapeutics crucially depends on the level of immunosuppression 
that still allows appropriate activation of host defense mechanisms against the invading 
pathogen(s) but reduces SIRS-induced pathology. 
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Een ontsteking is een natuurlijke reaktie op een verandering in weefsel homeostase. 
Deze ontstekingsreactie is afhankelijk van de ontstekingsinitiator en de locatie in het 
weefsel. Een ontstekingsreactie kan verschillende pathologische gevolgen hebben. 
Een te krachtige locale ontstekingsreactie kan leiden tot een systemische 
ontstekingsreactie die vervolgens andere organen kan aantasten. In sommige gevallen 
kan de ongecontroleerde ontstekingsreactie organen uitschakelen; dit proces wordt 
orgaanfalen genoemd. In ziekenhuizen is orgaanfalen een groot medisch probleem, 
en verantwoordelijk voor een groot aantal sterfgevallen op de afdeling ‘Intensive Care’. 
Door de heftige ontstekingsreactie onder controle te brengen door behandeling met 
medicijnen, zou het aantal sterfgevallen mogelijk kunnen worden verminderd. In de 
laatste jaren is de medische kennis toegenomen met betrekking tot deze systemische 
ontstekingsreacties, maar men krijgt nog steeds geen grip op de behandeling van deze 
problematiek. In dit proefschrift is een aantal experimentele therapieën beschreven die 
mogelijk de systemische ontstekingsreactie onder controle kunnen brengen. Voor dit 
onderzoek zijn diermodellen gebruikt, zoals een hemorragische shock model in ratten en 
twee bacteriële infectiemodellen in muizen. De potentieel therapeutische stoffen die door 
ons zijn getest, zijn synthetische steroiden en oligopeptiden. De aminozuursequentie 
van deze oligopeptiden zijn gerelateerd aan het zwangerschapshormoon humaan 
choriogonadotropine (hCG).  
De hCG-gerelateerde oligopeptiden zijn getest in twee bacteriële infectiemodellen, 
namelijk een Listeria monocytogenes model (Hoofdstuk II) en een muizenmodel voor 
blindedarm ontsteking (CLP model) (Hoodfstuk VI). In deze studies is aangetoond 
dat de geteste hCG-gerelateerde oligopeptiden een remmende werking hebben op 
de ontstekingsreactie. Bij behandeling met een hoge dosis oligopeptide worden L. 
monocytogenes geïnfecteerde muizen gevoeliger voor de bacterie, terwijl bij een veel 
lagere dosis oligopeptide de CLP-geinduceerde sepsis muizen een overlevingsvoordeel 
hebben. Tevens hebben we een combinatietherapie bestudeerd van het hCG-
gerelateerde oligopeptide LQGV met antibiotica behandeling. Dit liet zien dat deze 
combinatietherapie een nog gunstiger effect heeft op de overleving van de muizen dan 
antibiotica en LQGV afzonderlijk.
De hCG-gerelateerde oligopeptiden LQGV, AQGV en LAGV zijn ook getest in 
steriele ontstekingsmodellen, zoals een hemorragische shock in ratten (hoofdstuk V). 
In dit model bleken lage doses (5 mg/kg BW) van de geteste oligopeptiden in staat de 
systemische ontstekingsreactie te remmen. Deze remming heeft mogelijk tevens een 
gunstig effect op de overleving van de ratten, maar dit is niet door ons getest.
Ons onderzoek naar het werkingsmechanisme van LQGV laat zien dat LQGV 
de bijnieren kan activeren via de adrenocorticotroop hormoon (ACTH) receptor. 
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Deze bijnier activiteit leidt vervolgens tot verhoogde corticosterone waarden in het bloed 
waardoor geactiveerde immuuncellen minder ontstekingsfactoren kunnen produceren 
(Hoofdstuk IV). Deze observatie is belangrijk omdat in het verleden is aangetoond 
dat door een verhoogde bijnieractiviteit de gevoeligheid voor een L. monocytogenes 
infectie toeneemt in muizen, maar ook bij vrouwen tijdens de zwangerschap. 
Tevens is aangetoond dat het hCG-gerelateerde oligopeptide LQGV de activiteit van 
zuurstofradicalen vermindert en celdood van neutrofielen induceert. Vermoedelijk gaan 
de neutrofielen dood omdat de vitaliteit van deze cellen afhankelijk is van de activiteit van 
zuurstofradicalen (Hoofdstuk III). De celdood van neutrofielen kan verklaren waarom 
er minder van deze cellen werden gevonden in de organen tijdens een systemische 
ontstekingsreactie. Mogelijk zijn er ook nog andere processen die worden beïnvloed 
door deze oligopeptiden, maar dit moet in de toekomst verder worden onderzocht.
Tot op heden lijkt de overleving van septische patiënten niet te verbeteren door 
behandeling met anti-inflammatoire therapieën. Echter, op basis van eerdere studies, 
waarin gebruik is gemaakt van IL-6 knock-out muizen en IL-6 neutraliserende antistoffen 
veronderstellen wij dat een matige remming van de systemische ontstekingsreactie, 
zoals deze optreedt in muizen na CLP geïnduceerde sepsis, resulteert in een verbeterde 
overleving, terwijl sterke downregulatie van de ontstekingsreactie geen gunstig effect 
heeft. In hoofdstuk VII wordt geïllustreerd dat slechts een matige remming van de 
met sepsis geassocieerde ontstekingsreactie door corticosteroïden resulteert in een 
verbeterende overleving van CLP-muizen. Dit impliceert dat er een range is waarbinnen 
de remming van de ontstekingsreactie een gunstig effect heeft. Voorwaarde is 
evenwel dat de capaciteit van het immuunsysteem om de sepsisgerelateerde micro-
organismen te bestrijden, gewaarborgd blijft. Deze balans van voldoende remming van 
de ontstekingsreactie met behoud van voldoende antimicrobiële afweer is mogelijk van 
cruciaal belang voor het slagen van anti-inflammatoire therapie bij patiënten met sepsis 
en septische shock.
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ABBREVIATIONS
AB antibiotics
ACTH adrenocorticotropin hormone 
ADX adrenalectomy  
ALT aminotransferase  
APC antigen presenting cells  
AST aspartate aminotransferase   
ATP adenosine triphosphate
BW body weight  
cAMP cyclic adenosin monophoshate    
CARS compensatory anti-inflammatory response syndrome 
CBG corticosteroid-binding globulin 
C/EBP-δ CCAAT/enhancer-binding protein-δ
CFU  colony forming units
CLP cecal ligation and puncture 
CpG cystine purine repeat     
CRH corticotropin-releasing hormone     
CRP C-reactive protein
CTL cytotoxic T lymphocytes      
DAMP danger-associated molecular patterns
DC dendritic cells
DEX dexamethasone  
ELISA enzyme-linked immunosorbent assay
FDC follicular dendritic cells   
FSH follicle stimulating hormone 
GR glucocorticoid receptor    
HBSS Hanks’ balanced salt solution
hCG human chorionic gonadotropin
HCMV human cytomegalovirus
H/DEX high-dose DEX (2.5 mg/kg BW dexamethasone)
HKLM heat killed listeria monocytogenes 
HPA hypothalamic pituitary adrenal   
HPF high power field      
HRP Horse Radish Peroxidase     
HS hemorrhagic shock
HSP heat shock protein     
ICAM-1 intracellular adhesion molecule-1    
ICE IL-1β-converting enzyme     
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ICU intensive care unit     
IFN interferon      
IL interleukin     
IP intraperitoneal      
IPAF IL-1β-converting enzyme (ICE)-protease activating factor 
IRF interferon-regulatory factor    
IV intravenous     
LBP LPS-binding protein    
LD lethal dose
L/DEX low-dose DEX (0.05 mg/kg BW dexamethasone)   
LDH lactate dehydrogenase    
LH luteinizing hormone    
LLO listeriolysin O     
LPS lipopolysaccharide     
MAL MyD88 adapter-like      
MAP mean arterial pressure    
MDA5 melanoma differentiation-associated gene 5
M/DEX medium-dose DEX (0.25 mg/kg BW dexamethasone)
MHC major histocompatibility complex
MODS   multiple organ dysfunction syndrome    
MPO myeloperoxidase      
MyD88 myeloid differentiation factor 88    
NAIP neuronal apoptosis inhibitor factors    
NALP NLR-domain leucine rich repeat and pyrin domain-like receptors
NF nuclear factor
NK natural killer      
NLR (NOD)-domain-like receptor    
NOD nonobese diabetic      
NOD nucleotide oligomerization-binding
ON overnight   
PAMP pathogen-associated molecular patterns   
PBS phosphate buffered saline solution 
PCR polymerase chain reaction  
PCT procalcitonin 
PG peptidoglycan
PMA phorbol 12-myristate 13-acetate     
PRR pattern recognition receptors     
RIG-1 retinoic acid inducible gene protein 1   
RLR RNA helicase family 
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RNI radical nitrogen intermediates
ROI radical oxygen intermediates    
ROS reactive oxygen species     
RQ-PCR real-time quantitative polymerase chain reaction
RUNX runt-related transcription factor    
SD standard deviation      
SEM standard error of the mean    
SIRS  systemic inflammatory response syndrome    
SOD superoxide dismutase 
SR soluble receptor     
TIRAP TIR domain-containing adaptor protein   
TLR Toll-like receptors     
TNF tumor necrosis factor     
TRIF TIR domain-containing adapter-inducing IFN-β  
TSH thyroid stimulating hormone
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DANKWOORD
En dan is het zover, het boekje is af! Gelukkig heb ik al het werk niet alleen 
hoeven doen; daarom hartelijk dank aan iedereen die een bijdrage heeft geleverd aan 
het tot stand komen van dit proefschrift. Ik wil graag een aantal mensen persoonlijk 
bedanken.
Als eerste wil ik natuurlijk Wim bedanken voor de directe begeleiding en ondersteuning 
tijdens mijn promotieonderzoek. Beste Wim, het is alweer een tijdje geleden dat jij 
werkgroepleider van de IRD groep werd, met als extra taak de “tijdelijke” begeleiding 
van het peptidenonderzoek. Ik wilde echter graag dat jij langer bij het peptidenonderzoek 
betrokken zou blijven. Om die reden heb ik je gelijk in jouw eerste week als werkgroepleider 
gevraagd of jij mijn copromotor wilde worden. Als ik nu door dit boekje blader, zie ik dat 
dit zijn vruchten heeft afgeworpen. Tijdens mijn promotieonderzoek heb jij mij ALTIJD 
met raad en daad ter zijde gestaan. Jouw gedachten en gedrevenheid hebben een 
belangrijke bijdrage geleverd aan mijn wetenschappelijke ontwikkeling.
Beste professor Benner, beste Rob, jij was als mijn promotor en één van de initiators 
van het peptidenonderzoek op de afdeling enorm betrokken bij dit onderzoek. Na mijn 
eerste sollicitatiegesprek zag jij het zitten om met mij in zee te gaan. Ik wil je graag 
bedanken voor je begeleiding en voor de nuttige discussies die wij over het onderzoek 
hebben gehad.
Natuurlijk wil ik mijn collega’s van de IRD-groep bedanken voor de plezierige tijd 
op het lab. Ook al bestaat de groep uit een wetenschappelijke en een diagnostische 
tak, toch hebben wij met elkaar veel plezier gehad. Alle borrels en etentjes zal ik niet 
vergeten. Marion, Marja, Nicole, Benjamin, Jeroen en Conny, jullie zijn de drijvende 
kracht van de IRD groep, ga zo door! Beste Conny, jou wil ik graag nog apart noemen: 
bedankt voor alle experimenten die jij voor mij hebt gedaan. Ik kan me voorstellen 
dat het soms iets te veel was, maar toch had jij altijd alles onder controle. De meeste 
resultaten van jouw experimenten zijn in dit boekje terechtgekomen. En dat is nog niet 
alles: straks, als ik mijn boekje sta te verdedigen, sta jij als paranimf naast mij om mij 
te helpen.
De fibroblast is een belangrijke cel voor de inductie en controle van een 
immuunrespons, althans dat hoor ik de laatste twee jaar van Leendert. Beste Leendert, 
succes met het afronden van je promotieonderzoek en met je verdere opleiding tot 
chirurg (of toch oogarts ).
Beste Kim, halverwege jouw promotieonderzoek kwam jij in onze werkgroep terecht 
en dat is succesvol geweest. Op dit moment ben jij druk bezig met het afronden van 
jouw onderzoek. Ik wens je veel succes daarmee. Ik heb enorm genoten van de TREC 
verhalen, al kan ik ze niet meer navertellen. 
Jan Willem, mijn medepromovendus in het sepsis- en ontstekingsonderzoek. 
Samen op congres gaan was altijd een feest, ik bedoel een wetenschappelijke ervaring. 
Dankwoord
172
In Keulen moesten wij voor het eerst ons onderzoek presenteren tijdens een 
internationaal congres; wat waren wij zenuwachtig! Achteraf was dit erg leerzaam en 
leuk. Onze overige congresbezoeken zal ik ook nooit vergeten en misschien komen er 
tijdens mijn feestje wel enkele foto’s voorbij die wij niet (of toch wel) snel zullen vergeten. 
Ook jij staat straks naast mij om mij te helpen bij de verdediging van dit boekje.
Beste Pieter, de schakel tussen Rotterdam en Oklahoma. Zonder jou was de Listeria 
studie niet mogelijk geweest. 
Tessa, Gemma, Petra, Tim, Ivar, Rogier, Ron en Nisar, jullie ook bedankt voor de 
plezierige samenwerking!
Iedereen op de afdeling Immunologie wil ik bedanken voor de gezellige labuitjes 
en feestjes op de afdeling. Tijdens mijn promotieonderzoek heb ik enorm veel geleerd 
van een ieder van jullie. Geertje, Wendy, Erna, Marcia en Daniëlle, bedankt voor de 
ondersteuning en voor het verzorgen van de lay-out van mijn proefschrift.
Tijdens mijn promotieonderzoek heb ik de mogelijkheid gekregen om meerdere 
werkbezoeken af te leggen aan het lab van prof.dr. D.A. Drevets aan de Oklahoma 
University in Oklahoma City. Dear Doug, thank you for the visits to your lab. These visits 
to Oklahoma were important for my personal development as a scientist. With pleasure, 
I think back on the time that was spend in the O’Donoghue Research Building (ORB). 
The experiments were enormous, but in the end we have an excellent publication in the 
Journal of Infectious Diseases. Marylin, thank you for your assistance with the infections; 
without your help I would probably have spent more time at the ORB and hardly have 
any time left to visit the Oklahoma attractions. You made this possible, thank you. Dear 
Jennifer, although your name is not on the listeria paper, you still had an important 
contribution to this work. Your assistance with preparing the lab at the ORB helped a lot 
and I really appreciate it. Prof.dr. Brackett, dear Dan, thank you for offering lab space 
to us to perform all the experiments. We enjoyed our time in the ORB, especially the 
thanksgiving lunches; thanks everybody! 
Na werktijd blijft het onderzoek door je hoofd spoken. Ik kan me voorstellen dat dit 
tot frustraties heeft geleid bij mijn familie. Lieve memke en Klaas, ik wil jullie bedanken 
voor de steun die jullie mij hebben gegeven tijdens mijn promotieonderzoek. 
De laatste alinea is voor jou Yolanda. Lieve Yolanda, promoveren is al bijzonder, 
maar samen vijf jaar lang een promotietraject doorgaan is héél bijzonder. Wij hebben 
elkaar gesteund en door moeilijke tijden geholpen. Ook zijn wij samen naar Oklahoma 
geweest en hebben wij daar onderzoek gedaan. De experimenten in het ORB en dan 
ook nog de nachtelijke testen van het tornadowaarschuwingssysteem in het gebouw 
maakte ons leven toch nog een beetje avontuurlijk. Ik houd van jou.
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1. PhD training
Year Workload
(Hours/ECTS)
General courses
Academic writing in English for PhD-students - 
(EUR)
2008 4 weeks
NOW talentendag: Onderhandelen en - 
subsidieaanvragen
2006 8 hours
Management course for PhD students (NIBI)- 2008 2 days
Data analysis ESP03 (NIHES)- 2006 1 week
Biomedical research techniques (Molmed)- 2005 1 week
Small nuclear polymorphisms and human - 
diseases (Molmed)
2005 1 week
Basic and translational oncology (Molmed)- 2005 1 week
In vivo imaging (Molmed)- 2005 1 week
In-depth courses
Classical methods for data-analysis  (NIHES)- 2008 5.7 ECTS
Molecular immunology- 2006 7 days
Seminars and workshops
Weekly Monday morning department meetings- 2005-2010
Monthly department seminars- 2005-2010
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Oral presentations
Small oligopeptides liberated from human - 
chorionic gonadotropin (hCG) have potent anti-
inflammatory activity - Queen Mary University, 
London, UK
2010
The synthetic hCG-related oligopeptide LQGV - 
impair early innate responses to Listeria 
monocytogenes in mice through activation of 
the adrenal glands - Jaarcongres NVVI 2009, 
Noordwijkerhout, The Netherlands
2009
Synthetic hCG-related oligopeptides impair early - 
innate responses to Listeria monocytogenes in 
mice - European Shock Society Meeting 2009, 
Lisbon, Portugal
2009
Tetrapeptide LQGV inhibits inflammation and - 
organ damage after hemorrhagic shock and 
resuscitation - Department of Surgery, Oklahoma 
University, Oklahoma City, Oklahoma, USA
2008
Small oligopeptides liberated from human - 
chorionic gonadotropin (hCG) have potent anti-
inflammatory activity - Department of Surgery, 
Oklahoma University, Oklahoma City, Oklahoma, 
USA
2007
Posters
Synthetic hCG-related oligopeptides impair early - 
innate responses to Listeria monocytogenes in 
mice - Molecular Medicine Day, Rotterdam, The 
Netherlands
2010
Synthetic oligopeptides related to the β-subunit of - 
hCG attenuate inflammation and liver damage after 
(trauma-) hemorrhagic shock and resuscitation - 
Molecular Medicine Day, Rotterdam, The 
Netherlands
2008
Synthetic oligopeptides related to the β-subunit - 
of hCG attenuate inflammation and liver 
damage after (trauma-) hemorrhagic shock 
and resuscitation - Jaarcongres NVVI 2007, 
Noordwijkerhout, The Netherlands
2007
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(Inter)national conferences
Trauma, Shock, Inflammation, and Sepsis, 8- th 
World Congress, Münich, Germany
2010 5 days
Molecular Medicine Day, Rotterdam, The - 
Netherlands
2010 1 day
European Shock Society Meeting, Lisbon, - 
Portugal
2009 3 days
Annual meeting NVVI, Noordwijkerhout, The - 
Netherlands
2009 2 days
International Shock Meeting, Cologne, Germany- 2008 5 days
Annual meeting NVVI, Lunteren, The Netherlands- 2008 2 days
Annual meeting NVVI, Noordwijkerhout, The - 
Netherlands
2007 2 days
Basic transcriptional and translational biology, - 
Cold Spring Harbor, New York, USA
2007 2 days
Molecular Medicine Day, Rotterdam, The - 
Netherlands
2007 1 day
Annual meeting NVVI, Noordwijkerhout, The - 
Netherlands
2006 2 days
Annual meeting NVVI, Lunteren, The Netherlands- 2006 2 days
Molecular Medicine Day, Rotterdam, The - 
Netherlands
2006 1 day
Nieuwe ontwikkelingen in de immunologie, - 
Rotterdam, The Netherlands
2005 1 day
Working visits
Oklahoma University Health Science Center, - 
Oklahoma City, USA
2008 
2007 
2006
6 weeks
6 weeks
4 weeks
Didactic skils
Basic training didactics ‘ Teach the teacher’- 2008 16 hours
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2. Teaching
Year Workload 
(Hours/ECTS)
Supervising practicals and excursions, tutoring
Immunology practicals for medical students- 2005-2010
Supervising bachelor theses
Ivar Noordstra: Effecten van hCG-gerelateerde - 
oligopeptiden op celmigratie in vitro
2009 5 months
Tim Lage Venterink: De effecten van hCG - 
gerelateerde oligopeptiden op LPS en TNF-α  
geactiveerde endotheelcellen
2007 5 months
3. Grants
TRUST fund Erasmus University: travel grant- 2010
European Shock Society Meeting 2009 in Lisbon: - 
travel grant
2009
TRUST fund Erasmus University: travel grant- 2008
NVVI: travel grant for PhD-students- 2007
